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Despite over one hundred years of research, Tuberculosis (TB) disease, caused by the 
bacteria Mycobacterium tuberculosis (Mtb), continues to be the leading cause of death by an 
infectious disease worldwide. This is attributed to socioeconomic factors, slow drug development 
pipelines and discovery, poor treatment compliance, increasing drug resistance, and the lack of 
an effective vaccine— predominantly due to our incomplete understanding of an effective immune 
response against Mtb infection. Novel TB treatment regimens and an advanced understanding of 
the underlying factors that contribute to TB pathogenesis and host resistance are not only 
warranted, but essential for the eradication of this disease.  
Host-directed therapies, or therapies which target host mediated responses rather than 
the infectious agent itself, are becoming a novel approach to both treat disease and gain insights 
into the pathogenesis of many chronic illnesses. In our studies, we sought to evaluate the use of 
the anti-diabetic drug metformin for these purposes, which was based off its high safety profile, 
existing approval by the food and drug administration (FDA), and its demonstrated reduction of 
clinical manifestations associated with other chronic inflammatory illnesses. Moreover, its multi-
targeted effects on both systemic and cellular metabolism make it a unique tool to study the role 
that metabolism plays in disease pathogenesis. In this dissertation, we evaluated the influence 
of metformin treatment on TB disease outcome and characterized the phenotypic and functional 
implications of metformin on the T cell response to infection.    
Aim 1. Evaluate metformin as a host-directed therapy against Mycobacterium 
tuberculosis infection. In our first, aim we evaluated whether metformin, by normalizing 
systemic glucose metabolism, could improve clinical TB disease outcome of Mtb infected guinea 
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pigs. Interest in this study arose from the observation that in both human and animal 
models, increased systemic blood glucose concentrations highly correspond with TB disease 
progression and severity. Hyperglycemia, or high blood glucose, and insulin resistance are known 
risk factors for TB and occur as a consequence of Mtb infection. Patients with underlying 
metabolic disorders that take metformin display slower disease progression and improved clinical 
disease outcome, suggesting a role for systemic metabolism 
in TB disease pathogenesis. Immune cell metabolism, which directly controls cellular fate and 
function, has also recently been implicated to have profound influences on the outcome of various 
diseases and is likely to be affected by Mtb infection and metformin treatment alike. Therefore, in 
addition to evaluating the systemic metabolic implications of metformin treatment on TB disease 
pathogenesis, our studies also aimed to understand immune cell metabolism in the context of 
disease and as a mechanism of metformin mediated protection. 
In this study, guinea pigs were treated with metformin two weeks prior to or concurrent 
with aerosol Mtb aerosol infection, which continued throughout the course of infection. During 
chronic stages of disease, Mtb infected animals displayed significantly reduced Mtb colony 
forming units and lesion burden in the lungs compared to untreated animals. Improved disease 
outcome was associated with restored insulin sensitivity, but glucose tolerance was unchanged 
between groups, suggesting an alternative mechanism of host-mediated 
protection. Metabolic characterization of PBMC derived T cells by extracellular flux 
analysis demonstrated that in response to Mtb infection, utilization of the glucose processing 
pathways, glycolysis and oxidative phosphorylation were both significantly upregulated 
compared to uninfected animals; treatment with metformin, however, maintained 
homeostatic metabolic rates. Significant differences in mitochondrial membrane potential and 
superoxide production, both metabolic indicators of altered cellular function, were also 
observed between CD4+ T cells from metformin treated and untreated animals. Furthermore, 
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metformin treatment corresponded to decreased levels of pro-inflammatory cytokines in the 
lungs.   
These data demonstrate that metformin is an effective host-directed therapy 
against Mtb infection when initiated prior to infection, but this was not due to the maintenance of 
systemic metabolism. Instead, we provide evidence that metformin elicits protection by directly 
modulating immune cell metabolism and thus, altering the immune response to Mtb infection. The 
early treatment timeline required for metformin-induced protection and differences in T cell 
metabolism further suggest that T cells are directly targeted by metformin and likely play a critical 
role in enhanced protection against disease. 
Aim 2. Characterize T cell differentiation and metabolism in response to metformin 
treatment. The results obtained from aim 1 align with findings from the literature, which show that 
T cells with decreased metabolic flux and mitochondrial membrane potential correspond to a 
memory T cell phenotype. We, therefore, hypothesized that by regulating T cell metabolism, 
metformin enhances the generation of memory T cells that display decreased pro-inflammatory 
potential and tissue destruction and promote increased protection against chronic Mtb infection.   
To test this hypothesis, we characterized the phenotypic, functional, and metabolic 
profiles of CD4+ T cells that were differentiated using an in vitro model of effector like T 
cell (TEL) generation, in the presence or absence of metformin. Memory like T cells (TML) were 
also generated and the metabolic and functional properties of these cells were characterized and 
used to define a decreased state of T cell differentiation. Using this model, we found that memory 
T cell formation was not enhanced by metformin, as originally hypothesized; however, dramatic 
changes in surface marker expression were observed between cells that did or did not receive 
metformin. Significant increases in the levels of the cellular migration and tissue adhesion 
markers CD44 and CD69 and decreased IL-2Rα, or CD25, expression were associated with 
metformin treated compared to untreated CD4+ T cells. Expression of the terminal differentiation 
marker KLRG1 and transcription factor BIimp-1 were also significantly decreased by metformin 
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treatment while the memory associated transcription factor BCL-6 was significantly increased— 
suggesting that although metformin does not increase memory T cell generation, it does 
dramatically influence T cell phenotypic development by preventing terminal differentiation. 
Furthermore, mitochondrial membrane potential and the production of multiple pro-inflammatory 
cytokines were significantly reduced by metformin treatment, which is consistent with data from 
our in vivo studies in aim 1 and further supports the notion that T cells become less differentiated 
when treated with metformin.  
Metabolic characterization showed that metformin significantly reduced mitochondrial 
function and increased TEL reliance on glycolytic metabolism, which was in parallel with increased 
glucose uptake and the maintenance of cellular energy demands as measured by ADP: ATP 
ratios. These results were unique in comparison to memory T cells and less differentiated subsets, 
which demonstrate very little reliance on glycolysis for energy. Notably, however, spare 
respiratory capacity (SRC), a hallmark of memory T cell metabolism, was significantly increased 
in metformin treated TELs compared to untreated cells. Most importantly, we show that the 
generation of non-terminally differentiated CD4+ T cells by metformin resulted in significantly 
improved cell survival and enhanced proliferation and IL-2 production following secondary antigen 
challenge.  
Together, these data indicate that reduced T cell differentiation by metformin results in a 
long-lived CD4+ T cell subset that has enhanced survival and superior capacity to respond to 
antigen re-challenge. Whether or not these cells are responsible for increased protection against 
Mtb infection is the goal of aim 3 in this dissertation. 
Aim 3. Determine whether metformin treated CD4+ T cells confer increased 
protection against Mtb infection, in vivo. In aims 1 and 2 we found that metformin altered T 
cell metabolism both in vivo and in vitro, and in in aim 2, we demonstrated that this corresponded 
to the differentiation of non-terminally differentiated effector CD4+ T cells that have an increased 
capacity to respond to secondary antigen challenge. The goal of aim 3 was to then determine 
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whether metformin treated non-terminally differentiated T cells displayed enhanced protection 
against Mtb challenge in vivo. Mtb antigen specific-Ag85b TCR Tg (p25) T cells were either 
maintained in their naïve state or differentiated in vitro, as in aim 2, under TEL or TML conditions, 
with or without metformin. Differentiated T cells were then transferred into wild type C57Bl/6 mice, 
which were exposed to Mtb aerosol infection one day following transfer. On days 15 and 30, 
disease severity was assessed by quantifying lung Mtb colony forming units (CFUs) and lesion 
burden. No significant differences were observed between groups at either timepoint. Migratory 
capacity of adoptively transferred T cells was assessed by quantifying the total number of p25 
cells in the vasculature versus lung parenchyma, based on previous studies which describe the 
dysfunctional migration of terminally differentiated T cells from the blood into tissues where they 
elicit a protective response. Surprisingly, no differences in the proportion of adoptively transferred 
CD4+ T cells were observed between metformin treated and untreated subsets. Surface marker 
expression of molecules known to be associated with differentiation, migration, cell survival, and 
phenotype were also assessed on adoptively transferred CD4+ T cells 30 days following infection. 
Interestingly, despite major differences at the time of transfer, only subtle variances were found 
between TEL, TML, and naïve (TN) phenotypes. Furthermore, no significant differences were 
observed between metformin treated and untreated TEL or TML cells.  
Based on the lack of protection conferred by adoptively transferred T cells in this study, 
we conclude that pre-differentiated TEL or TML cells transferred prior to infection do not provide 
immunological protection against early Mtb infection and acute TB disease. Retrospective 
evaluation of our study design, however, lead us to believe that under different conditions 
alternative results will be obtained. Future studies will take into consideration the timing of the cell 
transfer with respect to infection and other design features, including the use of immunodeficient 
recipient mice, that may have a large impact on the interpretation of these findings.  
Conclusions. In this dissertation we have shown that metformin treatment improves the outcome 
of TB disease and directly modulates T cell differentiation through metabolic rewiring. Although 
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the outcome of aim 3 in this study did not turn out as expected, our results shed light on the 
mechanisms by which metformin impacts T cell differentiation in the general context of disease. 
These data will be useful for both the application of metformin as a treatment for other 
diseases and in helping understand the underlying pathogenesis of illnesses for which 
metformin has proven beneficial. Moreover, further investigation into whether metformin treated 
T cells provide protection against TB disease when administered during different stages of 
infection may have implications for the design of vaccines and expand our current understanding 
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1.1 Tuberculosis: Epidemiology, Transmission, Diagnosis, and Treatments 
Epidemiology of Tuberculosis. 
In 1882 microbiologist Robert Koch discovered the causative agent of tuberculosis (TB) 
disease, the bacterium Mycobacterium tuberculosis (Mtb) 1.  Attributable to his discovery, we have 
since gained considerable insights into the pathogenesis of TB disease, leading to the 
development of therapeutic interventions, strategies for disease prevention, and ultimately, an 
overall reduction in global TB cases. Despite this progress, however, recent modeling strategies 
suggest that approximately 23% of the global population is infected with Mtb and have what is 
referred to as latent tuberculosis 2. In 2018 alone, the World Health Organization (WHO) estimates 
that around 10 million people fell ill with TB disease while ~1.45 million individuals died from TB-
associated illness 3. To address the TB global health crisis, the WHO developed the “End TB 
Strategy”, which aims to decrease the incidence of TB deaths by 95% and reduce new cases by 
90% between 2015 and 2030 4. To meet these targets, a 4-5% reduction in incidence by 2020 
and a 10% decline by 2025 must be achieved by adopting the three fundamental pillars for 
success, which includes 1. integrated patient-centered TB care and prevention, 2. bold policies 
and supportive systems, and 3. intensified research and innovation 4. Current reports show that 
between 2015 and 2018 global TB incidence was reduced by 6.3% and TB deaths decreased by 
11%, a step in the right direction, but ultimately failing to meet the desired decreases of 20% and 
35% by 2020, respectively 3. 
Among the 10 million new cases reported in 2018, South-East Asia accounted for 44%, 
Africa 24%, and the Western Pacific 18% of all cases 3. Socioeconomic disparities observed 
between developed Western civilizations and those areas with high disease burden are 
undeniably and largely accountable for these high numbers 5, 6, 7. Studies show that social factors 
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including living and working conditions, overcrowding, malnutrition, and social habits including 
smoking and high alcohol consumption are tied to the incidence of TB disease 7, 8, 9, 10. Decreased 
access to health care and treatment is also a determinant of disease progression and mortality 
within these settings, however, studies suggest that even with ample treatment available, 
countries that rank low on the socioeconomic scale continue to suffer more greatly from TB 
morbidities 7. In one epidemiological study, the transmission of TB to children <5 years old was 
monitored in Cape Town, London, and New York between 1912 and 2012. Despite the 
introduction of chemotherapy and similar control strategies in the mid-1950’s, rates of TB 
transmission were unequally reduced in Cape Town compared to New York and London 6. These 
results suggest the large impact that socioeconomic factors play on TB disease transmission, 
regardless of treatment availability 6.  
Among socioeconomic factors, disease comorbidities, including HIV and diabetes mellitus 
(DM) significantly increase the susceptibility of TB disease and mortality. Infection with HIV is 
known to be the single greatest risk factor attributed to the development of active TB, increasing 
the risk of disease by 20-fold 11, 12. Although the relationship between HIV and Mtb co-infection is 
complex, impairment and depletion of the CD4 T cells during HIV infection weakens immune 
control against Mtb, ultimately leading to increased susceptibility and progression of TB disease  
13. In support of this, HIV-positive patients with diminished CD4 T cell counts are at increased risk 
for the development of active TB while patients on anti-retroviral therapy (ART), which promotes 
restoration of the immune response and CD4 T cell numbers, are at significantly decreased risk 
of succumbing to advanced disease compared to patients not receiving ART 14, 15. In addition to 
the effects that HIV has on the advancement of TB disease, Mtb infection increases HIV viral 
replication, thereby contributing to enhanced viral burden and to the acceleration of AIDS 
progression 16, 17. Among people living with HIV/AIDS, TB is currently the leading cause of death 
and in 2018, HIV/TB co-morbidity accounted for 251,000 deaths 3. Moreover, 0.8 million TB cases 
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were attributable to HIV infection, yet it is estimated that nearly 60% of global HIV-related TB 
cases are not diagnosed or reported 11. In the TB endemic area of sub-Saharan Africa, an 
estimated 25 million individuals are infected with HIV, highlighting the importance of controlling 
both HIV and TB incidence and transmission. To reduce the incidence of TB/HIV co-morbidities 
a strategy called the “3 I’s” has been implemented in high risk regions and includes 1. intensified 
TB case finding through enhanced screening for TB among HIV-positive persons, 2. isoniazid 
preventative therapy, and 3. infection control 18. Moreover, enhancement of TB testing among 
HIV-positive patients is also performed but poses a challenge due to the decreased presence of 
bacilli in sputum associated with HIV infection 19. 
Persons with uncontrolled diabetes and diabetic complications are also pre-disposed to 
co-morbidity with TB. Studies that have assessed the association of TB disease in diabetic 
patients found that diabetes mellitus (DM) increases the risk of developing active TB disease by 
1.5 to 4-fold 20, 21, 22, 23. A systematic review that evaluated the prevalence of latent TB in persons 
with DM also found a 4.4-fold increased incidence of LTBI 24. In 2018, it was estimated that DM 
accounted for 0.4 million cases of TB and that the global prevention of DM could avoid up to 4.1% 
of all TB cases 20. Current projections of the impact of DM however, are concerning and estimate 
that 578 million people will be living with DM by 2030, highlighting the need for increased TB 
testing and preventative measures among the largely at-risk DM population 25.  
Like other risk factors, the relationship between TB and DM is complex and not fully 
understood. Infection with Mtb alone causes a transient state of elevated blood glucose similar to 
diabetes (fasting glucose >6.9mmol/L or random glucose >11.1mmol/L), making it difficult to 
discern whether Mtb-infected individuals possessed undiagnosed underlying DM  or if the 
metabolic alterations are solely due to Mtb infection itself 26. A meta-analysis published in 2018 
showed that after excluding all studies that did not establish DM diagnosis prior to developing TB, 
DM patients had a 1.5-fold risk of developing active TB compared to non-diabetic counterparts 21. 
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A dose-like response of disease progression is also observed in patients with poor glycemic 
control, which have a 2-fold increased risk of developing active TB compared to non-DM persons, 
while there is no significant difference of disease progression between DM patients with good 
glycemic control and those without DM 20, 27.   
In addition to underlying DM, the influence that TB-associated hyperglycemia has on the 
pathogenesis and progression of TB is even less clear and is one of the main objectives of our 
research studies highlighted in this dissertation work. Epidemiological studies in humans as well 
as studies in guinea pigs show that following successful anti-microbial TB treatment and disease 
resolution, blood glucose levels return to a normal state 28, 29. Although more studies are needed 
to better understand this phenomenon, the transient relationship between TB and hyperglycemia 
is in accordance with stress hyperglycemia, a condition that has been described in hospital-
associated illnesses and occurs due to the intertwined relationship between inflammatory cytokine 
production and hormones on metabolic regulation 26. At our current state, a better understanding 
of the relationship between non-TB associated hyperglycemia and TB-associated hyperglycemia 
is desperately needed to gain better access and control over testing and treatment of DM patients.    
The increasing prevalence of drug resistant Mtb also serves as a key hurdle in controlling 
the global incidence of TB. Infection with drug-resistant strains currently accounts for about 
200,000 deaths each year and are on track to becoming the world’s most deadly pathogens 30. 
By 2050, estimates predict that approximately a quarter of all TB infections will be drug resistant 
30. Bedaqualine is the newest class of antibiotic approved for use against multidrug-resistant TB 
and was the first anti-TB drug to be approved in over 40 years, shedding light on the arms race 
between antibiotic discovery and the evolution of the pathogen 31. In their most modest forms, 
strains of antibiotic resistant Mtb carry genes that render them resistant to the front-line TB drugs 
rifampicin (Rif) or isoniazid (INH). More resistant strains, however, are capable of resisting both 
Rif and INH, multidrug-resistant TB (MDR-TB), or a combination of both frontline drugs, a second-
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line injectable (SLID, kanamycin, amikacin, or capreomycin) and any fluoroquinolone, also known 
as extensively drug-resistant strains (XDR-TB)  31.  
 Studies show that the primary reason for the rising incidence of drug resistant TB is not 
currently due to transmission of drug resistant bacilli, but rather, inappropriate management 
practices including inadequate treatment regimens and high rates of non-compliance by patients 
31. In India, which accounts for the highest number of patients with drug-resistant TB in the world, 
infection models suggest that if current TB management practices remain unchanged there will 
be a 275% increased risk of infection with MDR-TB over the next 20 years 32. Moreover, these 
models predict that there will be a shift in the main method of MDR-TB acquisition, which will be 
predominantly caused by transmission rather than poor TB treatment management 32, 33. 
Standardized empirical medical treatment without performing susceptibility testing is associated 
with increased treatment failure, relapse, and the development of multidrug resistance in patients 
with INH-resistant Mtb infection 34. These data, therefore, support a need for modified treatment 
practices and susceptibility screening in order to combat the further spread of drug-resistant TB. 
Transmission of Mtb. 
Typically, infection with Mtb causes disease in the lungs, or pulmonary TB. In 
approximately 15-20% of cases however, the bacteria localize to and infect other tissues of the 
body causing extrapulmonary TB; although, this generally occurs due to bacterial escape and 
dissemination from infected cells in the lungs 32. Infection with Mtb occurs via human-to-human 
transmission through airborne respiratory droplets caused by coughing, sneezing, singing, 
shouting or performing other forceful gestures causing respiratory excretion 32. Of the 1.7 billion 
people thought to be harboring Mtb, only a subset of these individuals with active pulmonary 
disease are infectious 2, 32. An epidemiological study performed on household contacts in Lima, 
Peru demonstrated that persons with the highest level of infectivity had bacteria that could be 
positively identified in their sputum (smear) and by culture while those that tested smear negative 
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and culture positive had decreased risk of infectivity and smear negative culture negative 
individuals had nearly no risk of transmitting infection 35. In addition, a recent study assessed the 
percent of viable bacteria present in respiratory droplets from smear positive culture positive 
patients and reported that only 43% of respiratory droplets contained viable bacilli. Moreover, only 
25% of these had CFU counts greater than 10 bacilli 36.  
Diagnosis of Tuberculosis. 
Among the quarter of the population that is infected with Mtb, the majority of individuals 
carry the bacteria in a subclinical latent state, while only 3-5% will develop active disease 2. There 
is currently no good way of predicting who will and will not progress to active TB, however, 
underlying risk factors, such as those previously discussed, are strongly correlated to advanced 
disease. Identifying infected individuals, as well as their disease state, is important for initiating 
the appropriate treatment regimen and reducing the transmission of disease. Clinical guidelines 
have been developed by the WHO for the identification of latent and active TB, however, adoption 
of these methods varies by region and is largely dependent on the availability of resources. 
Currently, there is no single, simple, all-inclusive, and widely available test that is used for 
the diagnosis of TB 32. Individuals with symptoms that correspond to TB disease as the suspected 
diagnosis are typically evaluated for pulmonary lesions by chest x-ray and the presence of 
bacteria in the sputum by microscopic examination of a sputum smear 37, 38. Using these methods 
has led to the identification of millions of cases worldwide, however, the availability of high-quality 
radiography is often limited and sputum smears lack sensitivity 36, 37. Limitations with these 
techniques is especially amplified in high-TB burden areas where money and resources for testing 
equipment are limited and there is a high incidence of HIV, which is associated with reduced 
bacteria in the sputum 19. In one study it was shown that sputum smear microscopy was 
associated with a sensitivity ranging from 35-80% in HIV-negative patients and only 20% in HIV-
positive patients 39. As an alternative, sputum culturing, which is considered the gold standard for 
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Mtb identification, may be performed; yet, bacterial culturing and identification can take up to 42 
days and requires lab facilities and personnel and so is often not a favorable option 40. 
Due to the limitations associated with these testing strategies, research has focused on 
identifying alternative methods that have higher sensitivity and specificity, require less resources 
and clinical expertise and are less costly. The identification of biomarkers in the blood or urine of 
patients has been an attractive strategy that has generated a large amount of interest for the 
development of new diagnostics 40. Lipoarabinomannan (LAM) is a mycobacterial glycolipid that 
is shed from the bacteria during replication in the host and has recently been identified as being 
detectable in the urine and blood of infected patients 39. A diagnostic test for the identification of 
LAM is currently available and is recommended to assist in the diagnosis of TB in HIV-positive 
patients where bacteria are not readily identified in the sputum 41. In addition, LAM detection is 
useful for the identification and diagnosis of extrapulmonary TB, which cannot be done using 
traditional methods 42. Although this test provides promise, studies show that LAM tests have 
varied sensitivities of between 13-51%, and although LAM is suggested to be specific for Mtb, 
LAM-like glycolipids have been identified in other species of bacteria, which may interfere with 
testing specificity 39. Therefore, this testing method is not largely used to diagnose TB in its current 
state but is a useful alternative resource for TB diagnosis in difficult cases. 
On a more positive note, a rapid molecular diagnostic test that detects Mtb-specific amino 
acid sequences, called the Xpert MTB/RIF Ultra assay was recently developed and approved for 
TB diagnosis. In 2018, the WHO released an updated compendium of guidelines for the treatment 
and care of TB recommending the Xpert MTB/RIF Ultra assay as the first line of diagnosis for TB 
in patients that are capable of producing sputum 4. The assay is performed in a small cartridge, 
can be read in 2 hours, and is demonstrated to have an overall sensitivity of 87.5%, including 
sensitivity of 78.9% on smear-negative samples, and a specificity of 98.7% 43. When compared 
to smear microscopy methods, Xpert is estimated to increase TB detection by 23% 44. Moreover, 
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in addition to Mtb diagnosis the Xpert assay also identifies the presence of rifampin resistance 
genes that are responsible for 95% of Mtb RIF resistance 43 . The ease of use and added benefit 
of resistance identification makes this test a powerful advancement in TB diagnosis and is 
expected to become a standard TB diagnostic method. However, the high price of manufacturing 
is a hurdle that will need to be overcome before it is fully adopted by countries around the world.  
In addition to active disease testing and diagnosis, testing for LTBI can be performed by 
tuberculin skin test (TST) or an interferon-gamma release assay (IGRA), though neither of these 
tests differentiates between active or latent infection. Both tests are immunologically based and 
depend on re-activation of the cell-mediated immune response following secondary exposure to 
Mtb antigens 45, 46. Widespread testing for LTBI is not routinely performed in endemic areas but is 
rather restricted to persons who are at high risk of developing active TB disease and could benefit 
from prophylactic treatment 45. And although immunological tests are beneficial for identifying 
LTBI in some populations, false positives can occur in persons that have been recently vaccinated 
with BCG, have been exposed to non-tuberculosis mycobacteria (NTMs), or have previously been 
infected with and cleared Mtb 47. Therefore, to minimize the risk of unnecessarily treating people 
with harsh anti-TB drug regimens that may otherwise cause more harm than good as a result of 
toxic side effects, only a small population of individuals at high risk of developing disease are 
routinely tested 48. The WHO currently recommends systematic LTBI testing for adults, 
adolescents, and children living with HIV, HIV-negative household contacts, and other at-risk 
groups including patients initiating anti-TNF treatment, patients receiving dialysis, or patients 
preparing for organ transplants 48. WHO does not currently recommend that persons from other 
high-risk categories including those with diabetes, tobacco smokers, excessive alcohol users, or 
underweight individuals are systematically tested unless they are included in one of the other 
recommendations 48.  
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Treatment of TB Disease. 
 The treatment of TB is complex and depends on a variety of factors including disease 
state, Mtb drug susceptibility, and underlying risk factors associated with TB disease progression. 
Drug regimens are long and often include multiple antibiotics that are associated with harsh side 
effects including hepatotoxicity, gastrointestinal issues, influenza-like syndrome, dizziness 
fatigue, and hearing loss 49, 50. Consequently, poor treatment compliance is common among TB 
patients and is associated with increased Mtb transmission and the emergence of drug resistance.  
In accordance with WHO guidelines, drug regimens have been developed based on 
disease state for the treatment of LTBI, drug-susceptible TB, and drug-resistant TB. In addition, 
TST negative individuals with an increased risk of TB disease, such as those living with HIV or 
household contacts of infected persons, are encouraged to take isoniazid preventative treatment 
(IPT) 32. Despite adverse events associated with antibiotic treatment, data shows that preventative 
treatment for TB reduces the overall risk of active disease by 33% and by 64% in TST-positive 
individuals 51. Therefore, the benefit of providing prophylactic treatment is considered to outweigh 
the risk of side effects and non-compliance. 
Table 1. Mtb antibiotic treatment regimens 4, 48. 
Treatment Category Treatment Regimen 
Preventive Therapy 
• Infants <12 months with HIV that are living in contact with a 
person with TB should receive 6 months of INH preventive 
treatment. 
 
• In areas with a high TB prevalence, children 12 years or 
older living with HIV and who do not have contact with a TB 
infected individual and are considered unlikely to have TB 
disease should receive IPT for 6 months. 
 
 
• In settings with high TB incidence, adults and adolescents 
living with HIV who have unknown or positive TST and are 




• HIV-negative children <5 years old who are household 
contact with TB confirmed patients and do not have active 
TB should be given TB preventive treatment. 
 
• In countries with high TB incidence, children older than 5, 
adolescents, and adults who are household contacts of TB 
infected individuals and do not have active TB should be 
given preventive treatment. 
 
• In countries with low TB incidence, adults, adolescents, and 
children who are household contacts of TB-infected 
individuals should be systematically tested and treated for 
LTBI. 
Treatment of LTBI 
• INH monotherapy is recommended for both adults and 
children in countries with high and low TB incidence. 
 
• Rifampicin plus INH daily for 3 months should be offered as 
an alternative to 6 months of INH monotherapy for children 
and adolescents aged <15 years in countries with high TB 
incidence. 
 
• Rifapentine and INH weekly for 3 months may be offered as 
an alternative to 6 months of INH monotherapy as 
preventative treatment for both adults and children in 
countries with a high TB incidence. 
 
 
• In countries with low TB incidence, alternatives to 6 months 
of INH therapy include: 9 months of INH, or a 3-month 
regimen of a weekly rifapentine plus INH, or 3-4 months of 
INH plus rifampicin, or 3-4 months of rifampicin alone. 
Treatment of  
Drug Susceptible TB 
• The first phase of treatment includes daily dosing for two 
months with INH, rifampicin, pyrazinamide, and ethambutol 
followed by four months of daily treatment with INH and 
rifampicin.  
Treatment of  
Drug Resistant TB 
• Rifampicin-susceptible, INH-resistant TB should receive a 
six-month combination treatment with rifampicin, 
ethambutol, pyrazinamide, and levofloxacin, with or without 
INH. 
 
• Patients with rifampicin-resistant (RR-TB) or MDR-TB who 






In 1921, after 11 years of propagating a virulent strain of Mycobacterium bovis through 
bile, glycerin, and potato medium, scientists Calmette and Gúerin discovered a resulting 
attenuated strain that provided protection against TB disease 1. The live attenuated bacilli quickly 
became the widely administered vaccine, Bacille Calmette-Gúerin (BCG). Today, BCG remains 
the only approved vaccine for the prevention of TB and is the most widely used vaccine in the 
world 52. In TB endemic regions, BCG is administered to infants at birth due to its high protective 
efficacy against severe forms of disease in infants and children, including meningeal and miliary 
forms of TB disease. The overall protection by BCG, however, is estimated to be only 50%, 
resulting in high infection rates in endemic areas despite high vaccine coverage 53. BCG’s efficacy 
is even more variable in adults (0-80%) and provides poor protection against pulmonary TB, the 
most common form of disease 54, 55. It is poorly understood why protection is so variable among 
individuals, though multiple hypotheses have been proposed. 
The original strain of BCG M. bovis’ loss of virulence is characterized by the deletion of 
the RD1 locus, which encodes the key virulence factors as well as strong T cell antigens, secretory 
antigen target 6 (ESAT-6)  and culture filtrate protein 10 (CFP-10) 56. Over the past 100 years, 
however, BCG has been continuously passaged leading to over 20 genetically distinct substrains 
57, 58 There is currently no evidence, however, that the strain of BCG used is associated with 
increased or decreased protection. The most likely explanation for variable protection is, rather, 
thought to be due to immune sensitization caused by environmental exposure of NTMs. This 
hypothesis is supported by data showing that individuals without prior infection to Mtb 55.  
To better understand the variable efficacy conferred by BCG, as well as develop novel 
vaccines with enhanced protection, the identification of correlates of protection is critical. 
Currently, our understanding of what constitutes vaccine-mediated protection is limited and 
biomarkers indicative of protection are lacking 59. Though based on conflicting evidence, there is 
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a general consensus that IFN-γ-generating CD4 (Th1) and, to a lesser extent, CD8 T cells are 
central for protection against TB 60, 61, 62. In animal models of Mtb infection, the depletion of either 
CD4 or CD8 T cells led to increased pathology and Mtb bacterial burden 15, 63. Additionally, the 
lack of IFN-γ production during infection is associated with an inability to restrict Mtb growth and 
progression to fatal disease 64, 65. Vaccination with BCG follows the Th1 generating paradigm and 
is demonstrated to generate effector memory T cells in the lung that produce IFN-γ and other 
cytokines, including TNF-α and IL-2, which are considered important pro-inflammatory mediators 
in the response against Mtb 66. The variable protection provided by BCG alone, however, 
demonstrates the lack of a fully effective immune response against TB 67, 68.  
New vaccines against TB are often  designed to amplify the BCG response, either by 
creating recombinant BCG strains or boosting existing immune populations from previous 
vaccination 56. The MVA85A vaccine, a recombinant strain of the Vaccinia Ankara virus 
expressing the immunodominant Mtb protein antigen 85A, is an example of the prime-boost 
strategy. In animals, MVA85A was shown to induce a strong antigen specific Th1 response which 
corresponded to significant protection from Mtb challenge 69, 70, 71. The results from a clinical trial 
that included 2,797 infants in South Africa and took nearly two years to complete however, 
showed no increase in protection following vaccination 72. The disappointing findings from this 
study emphasize the importance of identifying correlates of vaccine protection, which can be 
translated from animal models into humans.  Other non-clinical studies also raise caution against 
relying on the magnitude of the Th1 response as a predictor of protection, and show that the 
amount of IFN-γ produced by CD4 T cells positively reflects bacterial load and is associated with 
increased pathology rather than clinical improvement 73. Other studies demonstrate that IFN-γ 
production is critical for the early control of Mtb infection, but an ongoing pro-inflammatory 
response results in pathological damage and dissemination of bacteria to other tissues 59, 74. 
Based on these studies it is highly likely that the overall implications of Th1-mediated immunity 
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depend on a multitude of factors that can either result in benefit or detriment, including the kinetics 
of this response throughout Mtb infection. The fine tuning of T cell activation, differentiation, and 
cytokine production during various disease stages must, therefore, be recognized when designing 
TB vaccines. 
Recent studies suggest that rather than cytokine potency, the primary goal of TB 
vaccination should be the generation of central memory T cells that are long-lived and maintain 
self-renewal 75, 76. Models of alternative routes of BCG vaccination, which correlate to enhanced 
efficacy, demonstrate that the greatest levels of protection are positively correlated with the 
presence of central memory T cells 73, 77, 78. These cells not only have the ability to rapidly expand 
and produce cytokines, but also replenish pools of cells that have undergone convalescence in 
response to chronic infection. Adoptive transfer studies support the important role that these less 
differentiated cells play in mediating protection against TB disease. In comparison to Th1 
differentiated IFN-γ-producing T cells, less differentiated non-IFN-γ producing cells showed 
superior protection following Mtb challenge due to their persistence and superior proliferative 
capacity 79. Additionally, cells that expressed the checkpoint inhibitor PD-1, which limits T cell 
effector function, displayed superior proliferation, cytokine production, and protection following 
cell transfer in comparison to IFN-γ and TNF-α secreting effector cells 80. These results suggest 
that a successful vaccine against TB must generate T cells that maintain plasticity and the ability 
to replenish and respond to infection during chronic stages of disease.  
1.2 Immunopathogenesis of Tuberculosis. 
Innate Immunity. 
The innate branch of the immune system plays multiple important roles in the response 
against Mtb infection. It serves as the first line of defense upon pathogen recognition, initiates the 
development of the antigen-specific adaptive response, and maintains bacteria in an organized 
structure to prevent the spread of infection. Mtb is transmitted by the inhalation of respiratory 
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droplets containing viable bacilli that travel from the upper respiratory tract into the lower airways 
where it establishes infection in the alveoli 81. On the journey to the alveoli, bacteria traverse 
through mucus lined airways composed of tightly organized alveolar epithelial cells (AECs), which 
serve as the first line of defense against Mtb infection 82. AECs provide physical barriers of 
protection by blocking bacterial entry into the body and producing a secretory substance called 
airway surface liquid (ASL). This thin layer of mucus contains various antimicrobial elements 
including enzymes, reactive oxygen and nitrogen species, and immunoglobulins, which provide 
immediate defense following pathogen entry 81, 82, 83. In addition, AECs initiate cell-mediated 
effector responses following antigen recognition. They express various pattern recognition 
receptors (PRRs) on their surface that recognize Mtb molecules and initiate phagocytosis and the 
production of cytokines and chemokines 82, 84. AECs role in pathogen clearance through 
phagocytosis is shown to be limited, however, their corresponding recruitment of professional 
immune cells to the site of infection is an important aspect of the early immune response to Mtb 
infection 82, 85. 
Alveolar resident macrophages are considered the most important innate immune cell 
involved in Mtb infection 86. They play a dual role in both protection and pathogenesis by providing 
cell-mediated bacterial killing while also serving as the predominant host cell for Mtb survival and 
replication 81, 87, 88. The determination of whether macrophages successfully kill the bacteria upon 
initial recognition or whether Mtb virulence mechanisms allow the bacteria to persist, ultimately 
dictates progression to infection 89, 90. Like AECs, macrophages contain a variety of PRRs on their 
surface. As a general response to bacterial infection, macrophages phagocytose and 
compartmentalize the bacteria into vacuoles called phagosomes that undergo a series of events 
leading to phagosome maturation, or the result of phagosome-lysosome fusion. This process 
ultimately yields acidification of the vacuole, a pre-requisite to produce digestive enzymes and 
reactive oxygen and nitrogen molecules that are used to degrade intracellular antigens 89, 91. 
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Bacterial survival strategies of Mtb have evolved to circumvent this process by inhibiting 
phagosome-lysosome fusion to maintain their residence within macrophages 92, 93. Additionally, 
Mtb has developed multiple other virulence mechanisms in order to persist, replicate, and 
disseminate. These include escape from the phagosome into the cytosol, modulation of controlled 
cell death pathways, interruption of cytokine production and effector function, and acquisition of 
nutrients from the host 87, 94.  
Granulocytic cells, or neutrophils, are also implicated to play important roles in innate 
immune defense against Mtb, yet their exact role is less clear. Neutrophils have a biphasic 
response to Mtb, where they appear in large numbers immediately following infection, disappear, 
and then influx again at around days 8-15 until the end of infection 95. In one study, the depletion 
of neutrophils was associated with decreased iNOS expression during early stages of infection, 
which is required for nitric oxide production involved in macrophage-mediated bacterial killing 91, 
95. Evaluation of neutrophil numbers in the blood of humans has also been shown to correspond 
to the risk of becoming infected with Mtb, while those with higher neutrophil counts are shown to 
have a decreased risk of infection, suggesting their importance in controlling early infection 86. 
Like macrophages, neutrophils are phagocytic cells that can ingest and kill bacteria internally, 
though their traditional role is to release toxic substances into their surroundings resulting on non-
specific microbial and cellular destruction. Interestingly, although they have phagocytic capacity 
and aggregate in the lungs in high numbers during early infection, neutrophils are not found to be 
associated with bacilli, discounting their role in Mtb killing through phagocytosis or direct 
mechanisms 95. Rather, these findings suggest that neutrophils elicit their antimicrobial effects 
through indirect processes, such as enhancing macrophage-induced Mtb death 96. In support of 
this, when neutrophilic material is added to Mtb-infected macrophage cultures, there is an 
observed increase in macrophage antimycobacterial activity in comparison to cultures without the 
material 96. Additionally, entrapment of bacteria within neutrophil NETs, or neutrophil extracellular 
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traps composed of DNA and antimicrobial proteins, is shown to increase bacterial phagocytosis 
and enhance killing by macrophages 97, 98. Importantly, although neutrophils play an important 
role during the early course of infection by mediating bacterial killing, their aggregation within 
granulomas during later course of infection is also associated with necrosis, inflammation, and 
bacterial dissemination 86, 99, 100. In further support of disease promotion by neutrophils, our lab 
has also shown that lysed neutrophils provide an extracellular matrix composed of 
macromolecules and extracellular DNA that facilitate the growth of complex Mtb communities 101. 
It is therefore important to recognize both the immune-mediated benefits and dangers of 
neutrophilic involvement at specific timepoints during infection. 
While initial attempts to ward off bacteria with the innate response can be effective, the 
generation of the adaptive immune response significantly enhances cell-mediated bacterial killing 
and is critical for preventing the development of active disease. At the interface between the innate 
and adaptive immune response, professional antigen presenting cells called dendritic cells are 
responsible for mediating the development of antigen-specific cells 102. In the early stages of 
infection monocyte derived inflammatory DCs in the lung internalize bacteria and migrate to 
nearby draining lymph nodes in response to a CCL19/CCL21 chemokine gradient 103, 104. Once in 
the lymph node, these cells facilitate antigen presentation and the maturation of antigen-specific 
lymphocytes that make up the adaptive immune response 105.  
Adaptive Immunity. 
The importance of T cell-mediated immunity to Mtb infection has been demonstrated in 
both animal models and in human diseases that possess aberrations to a conventional T cell 
response 106. This central role for T cells in protection against active TB is highly recognized in 
HIV-infected persons, which have a dramatically increased risk of developing disease 107. 
Importantly, the risk of disease is reduced following restoration of CD4 T cell counts following 
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ART 108. In addition, animal models of TB show similar findings, where CD4 or CD8 T cell depletion 
leads to enhanced disease progression and death compared to immunocompetent hosts 60, 74.  
A defining characteristic of the adaptive response against Mtb is the delayed accumulation 
of antigen-specific T cells within the lungs of infected individuals, which doesn’t occur until days 
14-19 following infection 109. This delayed recruitment is thought to contribute to the early 
establishment of infection, allowing for continuous recruitment, apoptosis, and reinfection of 
macrophages, ultimately allowing the bacterial multiplication and propagation 102. Preceding the 
development of antigen-specific effector lymphocytes and their migration into the lungs, T cells 
must be appropriately activated through MHC antigen presentation, co-stimulatory signals, and 
cytokines in the lymphoid tissues. Relative to the delayed activation and migration of T cells, DCs 
experience delayed recruitment into the lymph nodes, which directly corresponds to becoming 
infected with Mtb 109. Furthermore, once in the lymph node, only selective subsets of DCs are 
shown to be effective at facilitating T cell activation. While monocyte-derived pro-inflammatory 
DCs are responsible for trafficking antigen to the lung, only classical lymph node residing DCs 
are capable of presenting antigen to and activating T cells. Studies show that the transfer of 
soluble antigen within the lymph nodes to cDCs occurs in order to facilitate T cell activation 110, 
111.  
Once activated, effector CD4 and CD8 T cells leave the lymph nodes and migrate to the 
early granuloma in response to cytokines produced by endothelial and epithelial cells as well as 
macrophages within the local microenvironment. Increased production of chemokines CCL19 and 
CCL21 are induced in the lung to attract antigen-specific T cells to the site of infection while 
enhanced CXCL13 enables their localization within lymphoid follicles where they come into 
maximal contact with Mtb infected macrophages and mediate killing of infected cells 112, 113. Early 
studies identified IFN-γ as the central component of T cell-mediated protection through its 
induction of macrophage apoptotic cell death and intracellular induced bacterial killing 65, 91. In 
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support of this, mice that lack IFN-γ display an inability to produce reactive nitrogen species, 
which are required for macrophage-mediated bacterial clearance, and in-turn, results in 
uncontrolled bacterial growth and a rapid progression to TB disease 65, 114.  
The primary production of IFN-γ has been attributed to CD4 T cells of the Th1 lineage, 
which traditionally protect the host against intracellular pathogens by initiating cell death through 
macrophage induced bacterial killing. Following transfer of CD4 Th1, Th2, or Th17 lineage 
differentiated cells into Mtb infected mice, Th1 cells indeed displayed superior protection against 
TB disease compared to the other cellular subsets 115. Interestingly, however, in both mouse and 
non-human primate models lacking CD4 T cells, IFN-γ levels are maintained following chronic 
Mtb infection 63, 74, 107. Rather, CD8 T cells compensated for the loss of CD4-derived IFN-γ. In non-
human primates, IFN-γ levels were even increased in CD4-depleted animals in response to Mtb 
in comparison to those with intact lymphocyte populations. Despite the sustained levels of IFN-γ, 
however, CD4-depletion was associated with increased disease progression and reduced 
survival in comparison to animals with CD4 T cells, inferring that IFN-γ levels alone is not 
predictive of protection 63, 74. In further support of this, a cell transfer experiment with Th1 cells 
that lacked the transcriptional regulator Tbet, which controls IFN-γ production, showed that Tbet 
knockout cells provided the same level of protection as wild type Th1s 115. Therefore, other 
mechanisms must exist for Th1-induced protection. 
More recently, it has been suggested that the production of multiple cytokines through a 
coordinated response is more closely associated with bacterial clearance and protection against 
TB disease progression 116. Evaluation of immune environments within individual granulomas 
from Mtb infected non-human primates shows an inverse correlation between bacterial burden 
and the presence of both Th1 and Th17 cytokines, including IFN-γ, IL-2, TNF-α, and IL-17 117. 
Additionally, T cell deficient mice displayed significant protection when administered either Th1 
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or Th17 differentiated CD4 T cells, indicating an important role for the generation of Th17 
mediated immunity 118. In response to Mtb infection, the predominant Th17 cytokine, IL-17, has 
been shown to be required for T cell localization within lymphoid follicles, which is necessary for 
maximal macrophage activation 112. Furthermore, IL-17 has been demonstrated to be critical for 
neutrophil recruitment early during infection and mice that lack the IL-17 receptor succumb to 
increased bacterial burden and have decreased lengths of survival following infection 119.  
In addition, TNF-α production is also implicated as an indispensable T cell-generated 
cytokine that mediates lymphocyte recruitment to the site of infection and is required for the 
formation and maintenance of the granuloma 120, 121. Following chronic Mtb infection in non-human 
primates, TNF-α neutralization resulted in disorganization of the granuloma and enhanced 
disease progression 122. Interestingly, TNF-α production during chronic disease has also been 
associated with increased expression of anti-inflammatory molecules and is hypothesized to help 
sustain a balance between pro- and anti-inflammatory mediator, which are required to maintain 
stability of the granuloma 122. Evidence suggesting the benefit of this balance is demonstrated in 
sterilized granulomas, which possess a higher proportion of IL-10 producing T cells to IL-2, TNF-
α, and IL-17 generating effector cells 117.  
In addition to generating the cytokines necessary for promoting bacterial clearance and 
preventing tissue destruction, the temporal and kinetic qualities of the T cell response to Mtb 
infection are also critically important. Macrophage activation in the lung must be facilitated by T 
lymphocytes that have traversed from the draining lymph node in an activated state and 
extravasated across the endothelium into the interstitial space. Conclusions from multiple studies 
characterizing the T cell response to Mtb in the lung have been drawn on the assumption that the 
cells being evaluated reflect that of the local lung immune environment. To discriminate between 
lung and vascular resident lymphocytes, recent studies demonstrate that the injection of 
fluorescently labeled antibodies into the vasculature prior to euthanasia results in the identification 
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of these two unique populations. Using this technique, findings reveal that the majority of cells 
evaluated from single cell isolates following tissue digestion reside in the vasculature rather than 
lung tissue 123. Interestingly, recent studies using intravascular (iv) staining show that antigen-
primed T cells in the vasculature can be discriminated from those in the parenchyma through their 
expression of the terminal differentiation marker KLRG1 124, 125, 126. In comparison to tissue-homing 
antigen-specific T cells, KLRG1+ cells from the vasculature produce higher levels of IFN-γ but 
provide significantly reduced levels of protection in the lung, suggesting that  T cell-mediated 
protection corresponds more with the level of T cell differentiation and lung homing capability than 
their capacity to produce IFN-γ 125, 127.  
In further support of these findings, T cell effector populations are shown to delineate into 
either KLRG1+ or PD-1+ lineages following Mtb infection in mice 80. In contrast to KLRG-1, PD-1 
is a checkpoint inhibitor associated with reduced T cell effector functions and is often associated 
with T cell exhaustion— though it is more recently recognized as a critical regulator of immune 
function rather than an indicator of dysfunction. Consistent with previous findings, transfer of 
KLRG1+ cells into Mtb infected mice resulted in cytokine production, but the cells were short lived 
and unable to provide long lasting protection against Mtb infection 80. Alternatively, PD-1+ T cells 
were highly proliferative and upon transfer and following antigen encounter converted into a 
KLRG1 cytokine-secreting phenotype capable of restoring functional immune populations with 
provided protection against Mtb infection 80, 128. Data from human studies further support the 
importance of the level of T cell differentiation in response to Mtb infection, where accumulation 
of highly differentiated T cells in the blood are found to correspond with increased tissue 
destruction in the lung 129. 
Furthermore, the influence of T cell differentiation on the capacity to elicit a protective 
immune response against Mtb has also been demonstrated following vaccination 130. The waning 
of BCG-induced protection corresponds to the accumulation of terminally differentiated T cells in 
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the lung 131, 132. Also, in comparison to T cells primed by a subunit vaccine, Mtb- and BCG-primed 
T cells expressed KLRG-1 and had decreased lung-homing capacity, which corresponded to 
decreased protection 133. Moreover, persistent expression of the immunodominant Mtb protein 
ESAT-6 is found to coincide with KLRG1 expression during Mtb infection and with ineffective 
immune control 134. Taken together, these studies provide robust evidence that in addition to 
cytokine production, the level of T cell differentiation in response to infection is a critical indicator 
of whether T cells will possess the survival and homing capacity required to adequately respond 
to Mtb infection. 
The development of functional exhaustion has also been proposed to contribute to the 
inadequate T cell response against Mtb infection. Exhaustion is characterized by the up-regulation 
of check-point molecules, including PD-1, TIM-3, and CTLA-4, to name a few, which are 
associated with the reduced capacity of T cells to secrete effector molecules 135, 136. Consistent 
with the exhaustion phenotype, T cells from mice chronically infected with Mtb display reduced 
levels of pro-inflammatory cytokines, including IL-2 and TNF-α, increase their production of the 
anti-inflammatory cytokine IL-10, and are demonstrated to express the exhaustion markers TIM3 
and PD-1 137, 138. To mediate improved T cell function in other chronic inflammatory diseases—
predominantly cancer—antibody-mediated blockade of checkpoint signaling has been exploited 
as a successful immunotherapeutic strategy. Surprisingly, in the context of Mtb infection, loss of 
PD-1 signaling is associated with exacerbated disease progression 139, 140, 141. Evidence of this is 
demonstrated in PD-1 knockout mice, which display uncontrolled bacterial growth and advanced 
necrosis that is associated with infiltration of neutrophils and increased expression of pro-
inflammatory cytokines 140. Likewise, blockade of PD-1 signaling in a 3-dimmensional cell culture 
model of human tuberculosis resulted in increased Mtb growth and pro-inflammatory cytokine 
secretion 139. In humans, treatment with anti PD-1/PDL1 therapy is associated with an increased 
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risk of developing active TB disease, suggesting the importance of immune regulation during Mtb 
infection 142.  
Furthermore, there is a large body of evidence that suggests that while pro-inflammatory 
cytokines are necessary for controlling infection, they are equally as important in contributing to 
disease pathogenesis 86, 117. For example, IFN-γ levels in bronchoalveolar lavage (BAL) fluid from 
humans have been shown to correspond to disease severity while increasing IFN-γ production in 
mice directly leads to exacerbated lung infection and early death 138. Furthermore, although TNF-
α is implicated to play an important role in maintaining the granuloma, its overproduction leads to 
increased bacterial replication 139. Thus, despite their roles in protection, the levels of pro-
inflammatory cytokines must be intricately balanced to avoid bacterial growth, tissue destruction, 
and ensuing disease. 
 Taken together, the T cell response to Mtb infection is highly complex and depends on a 
multitude of factors to provide appropriate immune protection. While CD8 T cells contribute to 
IFN-γ production and play important roles in limiting disease, the majority of protection is still 
considered to be associated with the generation of a successful CD4 antigen-specific response. 
The coordinated production of multiple cytokines is one important element of protection, but more 
recent findings suggest that the degree of T cell differentiation is critically important for enhancing 
migration to infection and in maintaining a pool of self-renewing cells that provide prolonged 
protection against chronic infection. Moreover, maintaining the balance between pro and anti-
inflammatory mediators during different stages of infection is critical for maintaining bacterial 
control and limiting disease pathogenesis. There are obvious contradictory findings that convolute 
our understanding of the acquired response to TB. However, by focusing on components of the 
immune response that are not solely dependent on cytokine production, such as localization and 
timing of the response, a better understanding of T cell immunity is being attained.  
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The Granuloma. 
As a consequence of persistent immune stimulation by Mtb infection, aggregates of cells 
form into organized structures known as granulomas. Granulomas are composed of multiple cell 
types including macrophages, neutrophils, DCs, B and T cells, NK cells, and fibroblasts and are 
thought to be formed as an immune defense mechanism to prevent bacterial dissemination 143. 
Considering only a small proportion of Mtb infected individuals develop active progressive 
disease, one can argue that the granuloma is a relatively effective immune-mediated defense 
strategy. On the contrary, granulomas provide an ideal niche for Mtb replication and survival within 
macrophages and, therefore, their formation is also seen as an immune evasion strategy that 
favors Mtb persistence within the host. 
Early following infection, Mtb induces a pro-inflammatory response that initiates the 
migration of macrophages across the lung epithelium into the interstitium 144. This process is, in 
part, mediated by the production of metalloproteinase 9 (MMP9) by epithelial cells 143. Once inside 
the lung tissue, persistent macrophage stimulation induces the production of pro-inflammatory 
intermediates, further propagating the recruitment of macrophages to the site of infection. Newly 
arriving macrophages phagocytose Mtb-containing apoptotic compartments, which subsequently 
becoming infected and aggregate, resulting in the development of the early granuloma. Following 
the generation of the adaptive immune response, the infected core of macrophages becomes 
surrounded by multiple cell types including mononuclear phagocytes, foamy macrophages, and 
lymphocytes. Progressive development of the lesion is characterized by the formation of a fibrous 
capsule surrounding the macrophage core, which ultimately prevents ensuing macrophage killing 
through lymphocyte-mediated mechanisms 143.  
Subsequent with mature granuloma formation, local immune cells switch from a pro- to an 
anti-inflammatory state and display increased production of the regulatory cytokine IL-10. This 
altered phenotype is thought to stabilize the granuloma by limiting inflammation and tissue 
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destruction  88, 145. In addition, despite low antigen availability, surveillance of the granuloma is 
ensued throughout infection by CD11c+ DCs, demonstrated by their continuous migration to lung 
draining lymph nodes and the priming and activation of naïve CD4 T cells 86, 146. This phenomenon 
can be observed through the waxing and waning of activated cells in the blood of infected 
individuals and corresponds to a cyclical pattern of inflammation 147. In most cases, this immune-
mediated structure remains stable and successfully prevents the progression to active disease. 
However, and for reasons not well understood, in a small percentage of infected individuals the 
granuloma collapses and necrosis of infected cells leads to bacterial escape and dissemination 
to other regions of the lung and other organs throughout the body 148. 
1.3 T Cell Differentiation.  
Preceding their development into naïve T cells, double negative (CD4-/CD8-) 
hematopoietic lymphoid precursors that originate in the bone marrow migrate to the thymus where 
they undergo a series of maturation events. A small portion of these cells (~5%) will develop into 
a population of γ:δ T cells, while the majority will take on an α:β phenotype, distinguished by 
differences in T cell receptor (TCR) chain composition 149. Following their entry into the thymus, 
T cells are distributed between the thymic cortex and medulla, where they undergo TCR 
rearrangement and positive and negative selection. Within the cortex, the TCR is formed as a 
result of rearrangement of the alpha and beta chains and the concurrent up-regulation of both 
CD4 and CD8 molecules. Double-positive cells then move into the medulla where they undergo 
positive and negative selection. These processes eliminate cells based on their inability to 
recognize self MHC molecules and those that respond to self-antigens, respectively. Additionally, 
these cells lose either CD4 or CD8 surface marker expression and identify as single-positive 
lymphocytes 149. This process occurs most efficiently in young children, as thymic output is 
observed to decline over time 150. Interestingly, of the immature progenitors that enter the thymus 
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for maturation, only approximately 2% survive maturation and comprise the circulating T-cell 
repertoire, which is estimated to comprise at least 10^8 different T cell antigen specificities 151. 
Following their maturation in the thymus, naïve antigen-inexperienced T lymphocytes 
circulate between the blood and secondary lymphoid organs in search of their cognate antigen. 
This migration pattern of continuous surveillance is enabled by their expression of lymphoid 
homing receptors CCR7 and CD62L 152. These molecules interact with ligands lining blood 
vessels that directly lead to lymph node entry, known as high endothelial venules, by facilitating 
rolling and extravasation through the vessel walls 152. Inside the lymphoid tissues, T cells 
aggregate into specialized T cell zones, which permits their interaction with antigen presenting 
cells to ensue activation and differentiation 153. Successful T cell activation is accomplished by 
the participation of three processes including: 1. recognition of cognate antigen presented on 
MHC complexes, 2. co-stimulatory signaling, and 3. cytokine production 154. Upon receiving these 
three signals, T lymphocytes differentiate into CD8 cytotoxic or CD4 T helper subsets that are 
distinguished by their transcriptional programs and cytokine producing capabilities 155. Typically, 
lineage-differentiated CD4 cells are classified into Th1, Th2, Th17, T follicular helper (Tfh), or 
induced regulatory T cell (iTreg) subsets, though the identification of new subsets is continuously 
increasing in complexity 127, 156, 157. Cytokine availability within the local activation environment 
ultimately dictates T helper cell lineage differentiation by inducing the expression of various 
transcription factors. Th1 cells, which respond to intracellular bacterial and viral infections by 
promoting cell-death of infected cells through IFN-γ production, up-regulate the transcription 
factor Tbet in response to IL-12 158. Th2 cells, which are required for the humoral immune 
response and the clearance of extracellular pathogens, are induced through IL-4 production and 
are distinguished by the transcriptional regulator GATA3 159. Th17 cells, which play an important 
role in mediating extracellular pathogen clearance, are induced by a combination of TGF-β with 
IL-6, IL-21, and IL-23 and require the transcription factor RORγt 160. Tfh cells, which are important 
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for the generation of antibody production by B cells, become induced by IL-21 and are dependent 
on BCL6 for their transcriptional regulation 161. And finally, iTregs, which regulate the pro-
inflammatory effector response through their production of the anti-inflammatory cytokine IL-10, 
are induced by TGF-β and are characterized by the transcription factor FOXP3 162. Together, 
these individual cell types comprise a multi-faceted response against numerous pathogens but 
intriguingly, evidence is building to show that there is also a fair amount of plasticity among them 
following their initial lineage commitment 155, 163. 
In addition to their lineage differentiation, CD4 T cells are classified into different clusters 
based on their effector functions, migratory capacity, maintenance of stemness and self-renewal 
and susceptibility to activation-induced cell death 164. Based on these characteristics, cells are 
classified into stem cell memory (Tscm), central memory (Tcm), effector memory (Tem), effector (Tef), 
or end stage terminally differentiated subsets (Temra), where the former are associated with a less 
differentiated phenotype capable of self-renewal and persistence and the latter possess high 
effector functions but succumb to rapid cell death following activation 165, 166. The least 
differentiated of these subsets, Tscms, are a newly classified subset of memory cells that display 
a naïve-like phenotype, with the exception of activation markers CD95 and IL-2β 167, 168. These 
cells have become a target for vaccination due to their stem-cell like characteristics including 
maintained self-renewal, robust proliferation following antigen re-challenge, a high level of 
plasticity, and long-lasting survival after primary infection 168, 169, 170. There is evidence that 
following secondary challenge, Tscms differentiate into both effector and memory T cell subsets, 
enabling the generation of cells that can both rapidly respond to infection and maintain a memory 
pool 167. 
Following Tscms along the differentiation gradient are the more well characterized central 
and effector memory T cells subsets 171. Unlike Tscm, these cells effectively up-regulate expression 
of the activation marker CD44 following antigen encounter, which gives them the capacity to 
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migrate from the vasculature into peripheral tissues 172, 173. These cells are found to persist 
following the resolution of infection and can proliferate and differentiate into responsive, cytokine-
secreting effector cells following secondary challenge 171. The long-term maintenance of antigen-
specific memory T cells is facilitated by their interactions with cytokines IL-15 and IL-7, in an 
MHCII independent manner 174. Tcm and Tem subsets are unique from one another based on their 
homing capacities and differential effector functions. Central memory T cells are the least 
differentiated of the two and are identified by their retained expression of the lymphoid homing 
molecules CCR7 and CD62L 171. Like naïve T cells, Tcms follow a migratory route through the 
blood and into secondary lymphoid organs where they can interact with DCs that carry antigen 
from peripheral sites of infection 154. Following their primary activation and differentiation, these 
cells produces low levels of inflammatory cytokines required for effector functions, but high 
amounts of IL-2 needed for proliferation 175. In response to secondary challenge, Tcms display 
extensive capacity to proliferate and produce effector cytokines 176. Conversely, effector memory 
T cells lose their expression of CCR7 and CD62L and inherit cytotoxic effector functions following 
primary antigen challenge, yet they are shown to persist within the blood many years after antigen 
clearance 154. Following antigen-specific re-challenge in the peripheral organs, these cells rapidly 
proliferate and increase production of inflammatory cytokines required for antigen clearance. 
Unlike Tcms however, these cells are committed effector T cell progenitors that succumb to cell 
death after a limited number of cell divisions. Therefore, Tems are unable to replenish the memory 
pool, and over time, repeated antigen recognition contributes to a decline in the availability of this 
protective memory population 177. 
In contrast to long-lived memory populations, the most highly differentiated cells are those 
that attain full-blown effector functions and subsequently die during the convalescence stage of 
the T cell response. These cells are identified as effector and terminally differentiated end stage 
effector subsets 166. In response to antigen stimulation, effector cells up-regulate their expression 
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of activation markers including CD44, CD69, and CD25. These markers facilitate migration 
(CD44) and retention (CD69) in peripheral tissues as well as responsiveness to IL-2 induced 
proliferation (CD25) 177. Effector cells are responsible for mediating initial antigen clearance at 
sites of infection by producing large amounts cytokines to mediate cell-induced microbial killing 
by macrophages and granulocytes (Th1/Th17) or antibody production by B cells (Th2) 177. 
Following a limited number of cell divisions, effector cells become terminally differentiated and 
are characterized by altered transcriptional profiles and are identified by their surface expression 
of KLRG1. These cells maintain high levels of effector functions but lose proliferative and self-
renewal potential and have a relatively shortened life spans 178. In various disease models, 
including TB, terminally differentiated T cells have been shown to provide limited protection 
against Mtb due to their inability to migrate, survive long-term, and produce adequate cytokines 
following secondary challenge and/or chronic infection 125, 126, 141. 
To determine the extent of T cell differentiation, the levels of expression between the 
antagonistic transcriptional regulators Blimp-1 and BCL6 can be measured. High Blimp-1 
expression is associated with high secretory and low proliferative capacity, the inability to self-
renew, and decreased survival 166, 179, 180. Mice that lack Blimp-1 expression fail to activate and 
mount a cytotoxic response, demonstrating its importance in effector T cell development 181, 182. 
Furthermore, Blimp-1 depletion is associated with increased cell longevity and decreased IFN-γ 
production in effector T cells as well as the inability to form short-lived KLRG1+ effector cells 178.  
Interestingly, in contrast to the importance of Blimp-1 in promoting an effector T cell phenotype, 
studies suggest that the development of terminal differentiation is important for the maintenance 
of T cell homeostasis and regulation 183. For example, Blimp-1-induced cell elimination has been 
described in a subset of lymphomas, where those that highly express the transcriptional regulator 
undergo pre-mature differentiation and cell death compared to those with no expression, which 
undergo persistent proliferation and contribute to aggressive disease progression184. Presumably, 
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this is a consequence of their increased survival in the absence of Blimp-1 expression 178. BCL6 
on the other hand, is directly associated with longevity and is highly expressed in memory T cells 
179, 185, 186. The predominant role of BCL6 in CD4 lymphocytes is to regulate the development of 
follicular T helper cells and promote antibody affinity maturation and activation of the humoral 
response within germinal centers 187. The sustained interactions of CD4 T cells with B cells, 
however, simultaneously blocks the development of T helper cells by repressing the expression 
of effector associated transcription factors Blimp-1 and Tbet and promoting memory T cell 
development 128, 186, 187, 188. Together, the graded levels of expression between Blimp-1 and BCL6 
can be used to evaluate the extent of T cell differentiation, which may not be fully captured by 
surface marker expression. 
The usefulness of identifying and characterizing the extent of T cell differentiation and 
survival following activation is critical for the development of effective vaccines and immune-
based therapies.   This has recently been highlighted in the effectiveness of adoptive cell transfer 
therapies for the treatment of cancer. Traditionally, the goal of many T cell-based immune 
therapies has been to generate a robust effector-like phenotype that produces potent cytokines 
and initiates tumor killing in vitro. However, an in vivo comparison between highly differentiated T 
cells that display superior anti-tumor activity in vitro with their less-differentiated counterparts, 
showed that there was an inverse relationship in in vitro and in vivo killing capacity.Therefore, 
while the less differentiated cells were unable to promote tumor killing in vitro, they provided 
superior protection in vivo due to their homing, proliferative, and survival capacity 165. Similar 
results have been summarized in other studies showing that the adoptive transfer of early effector 
and even naïve cells induce increased tumor eradication in comparison to more-differentiated 
effector cells 189. Furthermore, recent studies are finding that following vaccination, less 
differentiated cells have increased proliferative and cytokine responses following secondary 
challenge and persist in the body for many years and can provide long-lasting protection 175. 
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Different levels of T cell differentiation are achieved by modifying the strength and duration 
of the primary activating signals 177, 189, 190. Generation of more terminally differentiated effector T 
cells is attained following strong TCR engagement and an increase in cytokine availability 191. 
Multiple studies have demonstrated that by modulating either the concentration of anti-CD3, which 
binds the TCR co-receptor complex CD3 and induces activation signals, or the amount of 
activating cytokine, graded levels of transcription factor expression and functional “effectorness” 
are achieved 187, 192, 193, 194. For example, the amount of IL-12 present in cell culture during T cell 
priming directly influenced the level of Tbet expression, which increasingly corresponded to the 
upregulation of KLRG1 and short-term survival following activation 193. In vivo, T cells that are 
activated in the lymph nodes at later points during T cell priming and have reduced interactions 
with DCs  display a surface phenotype indicative of reduced stimulation and show decreased 
levels of proliferation, consistent with a less differentiated but non-memory phenotype 195. 
Moreover, high dose infection with cytomegalovirus coincides with more highly differentiated cells 
in comparison to low-dose infection, suggesting that increased antigen availability promotes 
increased differentiation 196. Consistent with increased antigen availability, the continuous 
availability and interaction with the immunodominant Mtb antigen, ESAT-6, induces terminally 
differentiated cells while Ag85b, which is only acutely present, generates cells with a less-
differentiated memory-like phenotype 134. 
Lastly, an important consideration for the generation of different T cell subsets is the 
evolutionary path of development. As previously described, signal strength and duration are 
important for generating more- or less-differentiated T cell phenotypes. What is less well 
understood regarding T cell differentiation is whether cells undergo a progressive path of 
differentiation following antigen encounter or if they become committed to one cell type. Various 
developmental models have been proposed for the generation of effector and memory T cell 
subsets, including the linear, progressive, and divergent differentiation models. The linear model 
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is the most traditional view of differentiation and is based off the idea that following activation, T 
cells undergo rapid proliferation and develop into cytotoxic effector T cell subsets 197. Following 
their response to infection, most of these cells undergo contraction, or cell death, while a small 
proportion revert to a less differentiated memory phenotype that persist and respond to secondary 
challenge 177. Evidence of this model is supported by the observation that Th1 or Th2 conditioned 
cells with effector properties maintain a small population after antigen clearance that remain viable 
and provide an anamnestic response to re-challenge 197, 198. Alternatively, oppositions to this 
model suggest that memory is generated independent of the need to differentiate into an effector 
T cell phenotype, citing that in comparison to memory T cells, effector T cells have reduced 
telomerase activity and telomere length, indicating their high replication history that is not 
apparent in memory subsets 199. Rather, it is hypothesized that memory and effector cells go 
through progressive differentiation, in which they sequentially gain effector functions depending 
on the strength of the activating signal. This is observed in memory cells responding to infection 
that acquire a KLRG1+ effector phenotype following subsequent antigen challenge and the 
generation of central memory T cells from naïve cells 200. Recent evidence supporting this 
hypothesis is the use of new technologies that allow single cell, epigenetic modifications and 
transcriptional profiles associated with cell differentiation to be tracked from naïve T cells into 
more differentiated phenotypes 201, 202. The last model of differentiation, the divergent model, 
suggests that during proliferation, proteins that determine the generation of memory or effector T 
cells are unevenly distributed, yielding two phenotypically distinct daughter cells 203, 204. Evidence 
of this phenomenon is observed in the unequal partitioning of Tbet and other proteins involved in 
cellular functions such as the metabolic coordinator, mTORC1 203, 205.  
In conclusion, the activation and differentiation of T lymphocytes is a complex process that 
results in the generation of many different subsets with specialized responses to disease. 
Regardless of the cell type however, T cell subsets appear to exist on a differentiation continuum 
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that corresponds with their ability to either persist through self-renewal or provide a robust, but 
deadly, effector response.  
1.4 T Cell Metabolism. 
 Historically, immune cell metabolism was commonly regarded for its role in producing 
adenosine triphosphate (ATP) to fill basic cellular energy demands. More recently, however, the 
discovery that many aspects of cellular metabolism directly influence immune cell fate and 
function, termed immunometabolism, has garnered interest to understand it on a deeper level. T 
cell metabolism, has gained considerable attention as a therapeutic target to functionally enhance 
the T cell response against chronic illnesses including cancer, autoimmune disorders, and 
infectious diseases. The basic understanding of how T cells modulate their metabolism in 
accordance with their function and, in turn, how this is affected by individual diseases has been 
an area of recent and rapid investigation.   
The two major pathways of energy metabolism are oxidative phosphorylation (OXPHOS), 
also referred to as mitochondrial metabolism due to its mitochondrial localization, and glycolysis. 
OXPHOS is the most efficient method of energy production, yielding ~32 ATP molecules per mole 
of glucose and serves as the predominate energy source for quiescent T cells 206. Alternatively, 
glycolysis, which results from glucose fermentation into lactate, yields only 2 ATP per glucose 
and is engaged by activated T cells experiencing rapid expansion 207. Generally, glycolysis 
predominates under oxygen replete conditions in which OXPHOS cannot function efficiently. T 
cell dependence on this pathway, however, is independent of oxygen availability (aerobic 
glycolysis) and commences even when oxygen is available and can support more efficient modes 
of energy production. Utilization of aerobic glycolysis is not unique to T cells but was first 
discovered by the scientist Otto Warburg in the 1920’s, who noticed that cancer cells consumed 
glucose at a rapid rate under aerobic conditions relative to normal cells in surrounding tissues. 
This phenomenon was termed the Warburg Effect and was postulated to occur because of 
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dysfunctional mitochondria. More recent evidence show that the Warburg Effect is intentionally 
regulated by cells and is required for cell growth and proliferation through the generation of 
biosynthetic intermediates 208.  
Glycolysis 
Increased glycolytic programming in T cells has been well characterized following T cell 
activation. More specifically, TCR and CD28 co-ligation mediate the upregulation of glycolysis by 
activating the AKT/mTOR pathway. The important role of mTOR in the immunometabolic 
phenotype of activated T cells has been shown using the specific mTOR inhibitor rapamycin. T 
cells that are stimulated in the presence of rapamycin are characterized by dramatically reduced 
glycolytic activity and loss of effector differentiation and function compared to untreated cells 209, 
210, 211. Repression of this pathway is also achieved under natural conditions by the 
phosphorylation of adenosine monophosphate-activated protein kinase (AMPK), which senses 
energy levels through AMP:ATP ratios to either inhibit or promote mTOR activation 212.  mTOR 
activation induces the expression of transcription factors that regulate the production of glycolytic 
enzymes, T cell cytotoxic molecules, and epigenetic modifications that promote an effector T cell 
response, including c-Myc, HIF1α, and ERRα 213, 214, 215, 216, 217, 218, 219. One of the earliest events 
observed following T cell receptor co-ligation is increased expression of the glucose transporter, 
Glut1, on cell surfaces, which coincides with dramatically increased glucose transport that is in 
excess of what is required to maintain cellular energy demands 217, 220. In the absence of glucose, 
T cells fail to gain full effector functions, even in the presence of alternative substrates that fuel 
OXPHOS for energy generation 221. Additionally, the inhibition of glycolytic metabolism with the 
inhibitor 2-deoxyglucose (2-DG) suppresses the development of effector functions and redirects 
cellular differentiation towards a non-inflammatory phenotype, demonstrating the essential role 
that glycolysis plays in the development of effector T cells 216, 222.  
34 
The substantial increase in glycolysis following T cell activation is primarily attributed to 
increased demand for biosynthetic precursors required for cell growth and proliferation. For 
example, the generation of glucose-6-phosphate (G6P) from glucose feeds into the pentose 
phosphate pathway (PPP), which is required for nucleotide synthesis and is responsible for 
maintaining cellular redox status through the generation of NADPH 207. Additionally, 3-
phosphoglycerate, which is generated during the seventh step of glycolysis, is shuttled into the 
serine biosynthesis pathway to generate the amino acid serine. Additionally, glycolytic generation 
of pyruvate not only contributes to mitochondrial ATP production through tricarboxylic acid cycle 
(TCA)-generated reducing intermediates but is also used to synthesize fatty acids through its 
conversion to citrate in the TCA cycle. Fatty acids can then by synthesized into triglycerides for 
storage or immediately utilized for membrane biogenesis in actively dividing cells 223. Inhibition of 
cellular proliferation, but not survival, by 2-DG following T cell activation further demonstrates the 
critical contribution glycolysis plays in generating metabolic intermediates needed for the 
expansion of activated T cells. 
Interestingly, despite the role that glycolysis plays in the generation of biosynthetic 
molecules, only a small proportion of glucose consumed during activation is attributed to the 
building of these intermediates. Rather, the majority of glucose taken up by cells is converted into 
lactate by lactate dehydrogenase (LDHA) and is ultimately secreted into the extracellular 
environment 212, 213. Notably, lactate, which is traditionally regarded as a biproduct of glycolysis, 
has recently been found to serve as an energy source, gluconeogenic precursor, and signaling 
molecule through cellular uptake by lactate shuttles 224. In T cells, the expression of these lactate 
transporters, monocarboxylate lactate transporters MCT1 and MCT4, are shown to be 
upregulated in response to activation, and inhibition of MCT1 during T cell activation resulted in 
the inhibition of cell division supporting a role for lactate in T cell function 225. In contrast however, 
environments with exceedingly high concentrations of extracellular lactate, such as the tumor 
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microenvironment, have shown that lactate also inhibits T cell proliferation and cytokine 
production by blocking lactate export 226. These studies highlight the need to better understand 
the influence that lactate has on T cell function within the context of various diseases.  
Nonetheless, lactate production through glycolysis and LDHA activity is an important 
component of T cell function. Deletion of LDHA results in a significant reduction in glucose uptake 
which corresponds with the loss of effector functions, suggesting that glucose fermentation is also 
an important component of the glycolytic switch. One explanation for the engagement of LDHA is 
to prevent lactate buildup within the cell and maintain cellular redox and glycolytic flux by recycling 
NAD from NADH 207, 212, 227. Because NAD is required for constant cycling through glycolysis, 
maintaining an NAD pool enables the continuous shunting of substrates into anabolic pathways 
to promote cell growth. Regulation of NAD:NADH ratios by LDHA can also be used as a cell 
signaling mechanism or to induce epigenetic modifications that influence cellular function 228. 
Additionally, high utilization of glycolysis may be employed as a primary means to generate ATP 
in order to free up TCA cycle intermediates and mitochondrial function.  
Independent from the role in biosynthesis, glycolysis also directly influences cytokine 
production. Deletion of LDHA results in T cells with diminished IFN-γ production that are unable 
to develop into potent effector T cells with anti-tumor activity 217, 229, 230. Under quiescent 
conditions, the glycolytic enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
allosterically binds to mRNA encoding IFN-γ, thus preventing translation. Following up-regulation 
of glycolysis, however, GAPDH is reassigned to perform its metabolic functions, resulting in 
dissociation from mRNA and the subsequent translation of IFN-γ 231. Due to the role that metabolic 
substrates have on epigenetic manipulation, there are likely many other similar processes that 
occur in response to glycolysis that impact the production of cytotoxic intermediates required for 
effector function that have not yet been identified 232.  
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Mitochondrial Metabolism. 
 Though not as well recognized, enhanced utilization of OXPHOS must also occur following 
T cell receptor engagement for the induction of cellular activation and proliferation 231. The 
mitochondria are major producers of cellular ATP and engage in important cell signaling events, 
both of which are required to maintain cell survival and facilitate T cell activation. Glucose is a 
major mitochondrial substrate that must be broken down through a series of chemical reactions 
in order to drive ATP production by OXPHOS. First, glucose is converted to pyruvate by glycolysis 
in the cytoplasm and then pyruvate subsequently enters the mitochondria and is converted into 
acetyl-CoA by the enzyme pyruvate dehydrogenase. Acetyl-CoA then undergoes an aldol 
condensation reaction with oxaloacetate to form citrate and proceeds through a series of chemical 
reactions to generate reduction intermediates (NADH and FADH2) that feed into the ETC 207. 
Under quiescent conditions glucose can efficiently be used to fuel this process, however, under 
highly glycolytic conditions in which glucose is diverted to generate biosynthetic molecules, other 
fuel sources can also enter the TCA cycle to produce NADH and FADH2. 
  The amino acid glutamine fuels mitochondrial respiration following conversion into α-
ketoglutarate 207. The metabolic intermediate α-ketoglutarate is produced through a process 
called glutaminolysis and enters the TCA cycle and progresses through the normal series of 
reactions that produce NADH and FADH2. Following T cell stimulation, glutamine is an 
indispensable nutrient for cell proliferation and effector functions, which has been demonstrated 
by the inability of activated cells to proliferate or produce cytokines in the  absence of glutamine 
233, 234. In response to TCR engagement, increased expression of amino acid transporters, such 
as SLC7A5 and SLC1A5, and intracellular glutamine levels as well as enhanced rates of 
glutaminolysis are detected in T cells 212. Under highly glycolytic conditions, glutamine serves as 
an alternative source of fuel for OXPHOS-mediated energy production, which then allows the 
carbons derived from glucose to be used for the synthesis of other biosynthetic intermediates 235. 
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Additionally, intracellular amino acid levels have the capacity to regulate anabolic growth by 
mediating mTOR activation 210.  
Fatty acids are also an energy rich fuel source that give rise to electron donors through 
the TCA cycle 236. They can either be taken up from the extracellular environment by the fatty acid 
transporter CD36, or in some cases by passive diffusion, or endogenously created from the TCA 
cycle intermediate citrate. Before entry into the TCA cycle, fatty acids must be transported into 
the mitochondria then broken down into Acetyl-CoA through a process called β-oxidation. A 
carnitine shuttle system is used to transport long-chain fatty acids into the mitochondria by 
converting the fatty acid into acylcarnitine through a series of chemical reactions and transport by 
the mitochondrial membrane protein CPT1A and the inner membrane shuttles 
carnitine/acylcarnitine translocase (CACT) 237. Once inside of the mitochondria, fatty acids are 
converted into acyl-CoA and broken down into acetyl-CoA through β-oxidation. Depending on the 
length of the fatty acid, β-oxidation yields different numbers of acetyl-CoA molecules by 
undergoing multiple cycles. Each cycle consists of a series of four reactions which require the 
removal of two-carbon units to produce acetyl-CoA 237. This makes fatty acids an extremely 
efficient fuel source; for example, a single palmitate containing 16 carbons yields 8 acetylCoA 
and a final yield of approximately 106 ATP molecules.  
Due to increased efficiency in generating ATP, fatty acids are predominantly oxidized by 
cells that survive for long periods of time under quiescent conditions. In contrast, in response to 
TCR engagement, T cells upregulate de novo synthesis of fatty acids for their incorporation into 
cell membranes and use as posttranslational protein modifiers 238. In addition, synthesized fatty 
acids can be stored as triglycerides for future metabolic retrieval 238. Studies in T cells show that 
inhibition of de novo fatty acid production does not compromise effector differentiation, but instead 
results in reduced proliferation and subsequent death of antigen-specific T cells 239, 240. Studies in 
cancer, which represent a proliferation and survival dynamic like T cells, also show decreased 
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proliferation and survival after blocking fatty acid synthesis 238, 241. These results indicate that in 
addition to providing macromolecules required for cell growth, fatty acid generation is also a 
critical component of maintaining cell survival. 
 Quiescent T cell subsets including naïve, regulatory, and memory T cells are metabolically 
characterized by predominate dependence on mitochondrial metabolism 242. These cells rely both 
on glucose and fatty acids to maintain energy demands through OXPHOS, though relative 
reliance on one or the other is more accurately attributed to the distinct cell type. Naïve T cells, 
for example, harness most of the energy from glucose metabolism while memory and regulatory 
T cells are characterized metabolically by increased utilization of fatty acid oxidation. Because 
quiescent T cells do not have internal glycogen stores, these cells are highly dependent on 
glucose import to maintain metabolic and energy demands 213. Survival promoting signals by 
growth factors such as IL-7 and IL-15 are shown to keep cells alive by maintaining metabolic 
function, while cells that lack growth factors display a decreased metabolic rate that is associated 
with loss of Glut1 expression and cell death 243 216.  
 The reliance on mitochondrial metabolism by Treg and memory T cell subsets is so 
important for their phenotypic development that pharmacologic inhibition of glycolysis and thus, 
promotion of OXPHOS can be exploited to generate the respective phenotypes. Studies have 
demonstrated that the deletion of mTOR in mice results in the formation of regulatory T cells 
following TCR-activation instead of effector T cell subsets. In addition, inhibition of mTOR in mice 
that are predisposed to develop autoimmune diseases increases the Treg:Th17 T cell ratio, 
resulting in decreased inflammation and improved disease outcome 244, 245, 246. Furthermore, 
memory T cell generation is also enhanced following mTOR inactivation. This has been 
demonstrated in infection and in vaccination models comparing vaccination alone or in 
combination with rapamycin or metformin, both of which are mTOR inhibitors 247. In these studies, 
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mice receiving the combined treatment plus vaccination had increased development of antigen-
specific memory T cells that corresponded to improved disease outcome.  
Complementary to reliance on OXPHOS, more detailed characterization of Treg and 
memory T cell metabolism has revealed the critical importance of β-oxidation in directing subset 
development and maintenance of cell survival. Regulatory T cells continuously import 
extracellular fatty acids, which then undergo oxidation in the mitochondria. This is a result of 
expression of LKB1, a central regulator that promotes mitochondrial metabolism, and 
simultaneously, de novo fatty acid synthesis. Diverting glycolytic flux following activation therefore 
is critical for promoting regulatory over effector T cells by preventing biogenesis and cell growth. 
Like Tregs, memory T cells are also highly reliant on fatty acids for energy. The importance of 
fatty acid utilization for memory T cell development was first demonstrated in tumor necrosis factor 
receptor-associated factor 6 (TRAF6) deficient mice. TRAF6 deficiency is associated with 
defective AMPK activation, altered expression of genes required for fatty acid metabolism, and 
decreased memory T cell formation 248. Restoration of β-oxidation with metformin however, 
reestablished memory T cell generation in TRAF6 deficient mice, demonstrating its critical 
importance for memory T cell development 248. Interestingly, unlike Tregs, memory T cells derive 
most of their fatty acids from endogenous biosynthesis to provide immediate ATP for energy and 
a metabolic reserve that contributes to their longevity and secondary response 249. Furthermore, 
the importance of fatty acid metabolism for memory T cell survival has been demonstrated by 
blocking fatty acid transport into the mitochondria with etomoxir, which ultimately impaired T cell 
survival 250. 
 In addition to β-oxidation, a defining characteristic of memory T cell mitochondrial 
dynamics is the generation of a mitochondrial spare respiratory capacity (SRC) 250. SRC is the 
maximal amount of mitochondrial respiration that is available to a cell under times of stress. In 
comparison to other cell types, memory T cells possess a dramatically increased SRC that 
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provides them with a bioenergetic advantage to quickly produce energy in order to sustain viability 
and rapidly generate effector functions following re-challenge 251. There are two primary ways that 
SRC can be achieved. First, dampening the extent of OXPHOS engagement following TCR-
induced activation maintains respiratory reserve. This type of SRC is displayed in T cells that 
have been treated with OXPHOS inhibitors such as metformin, which dampens mitochondrial flux, 
and thereby preserves respiratory reserve. Alternatively, SRC can be enhanced by increasing 
mitochondrial mass through mitochondrial biogenesis. This phenomenon is observed in T cells in 
response to IL-15 signaling, which facilitates the generation of memory T cells with elongated 
mitochondria and increased overall mitochondrial mass 250, 251, 252. These fused mitochondria not 
only provide more surface area to increase OXPHOS but are also thought to spatially localize 
complexes of the ETC for more efficient energy production 252. This is in contrast with punctate 
mitochondria in effector T cells that promote glycolytic upregulation and maintain little to no SRC 
following cell activation 252. Mitochondrial morphology and SRC are, therefore, unique features 
that can be used to define memory versus effector T cells.    
 Furthermore, differences in mitochondrial membrane potential (ΔΨm) is also unique 
among memory and effector T cell populations 253. Membrane potential is the charge or difference 
in hydrogen ions across the intermembrane space and the lumen of the mitochondria 254 and is 
generated by the pumping of protons across the inner mitochondrial membrane at complexes I, 
III, and IV, in coordination with electron transfer through the ETC complexes. The electrochemical 
gradient achieved by the pumping of protons provides a proton-motive force that is essential for 
ATP production by driving the F0F1 ATPase, or ATP synthase. Membrane potential is required 
to maintain viability of healthy cells, while those that experience mitochondrial damage undergo 
depolarization, a point of no return for subsequent apoptotic cell death 254.  Additionally, 
mitochondria undergo hyperpolarization following TCR engagement, which is necessary for full T 
cell activation 253, 254, 255. Increased rates of respiration are accompanied by saturation of 
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respiratory chain complexes with reducing intermediates and the extrusion of hydrogen ions into 
the mitochondrial matrix. These excess ions ultimately reduce cytochromes in the ETC and lead 
to the generation of reactive oxygen intermediates that are required for cell signaling 255, 256. 
Mitochondria that fail to generate an increase in ΔΨm following activation are targeted for 
destruction through mitophagy 256. Although necessary for activation, ΔΨm is found to have a 
direct influence on ROS production and associated DNA damage that can ultimately lead to 
impaired self-renewal 253. Moreover, ΔΨm has been found to be directly linked to mTORC1 
activation through IL-2 induction and can be significantly reduced following inhibition with 
rapamycin 253. In association with cellular phenotype identification corresponding to mTORC1 
activation, low ΔΨm is characteristic of memory T cells with low mTORC1 and high self-renewal 
while high ΔΨm typifies effector T cells with increased mTORC1 and associated effector functions 
253. Furthermore, ΔΨm is found to serve as a biomarker and therapeutic target for the autoimmune 
diseases including type 1 diabetes and systemic lupus erythematosus (SLE) 254, 256, 257. 
Autoreactive T cells from SLE patients display persistently hyperpolarized mitochondria and 
elevated mTOR activity 256, 258. Normalization of T cell activation was successfully achieved with 
rapamycin, resulting in ΔΨm maintenance and decreased disease 259, 260. Together, these results 
suggest the importance of the mitochondria in energy production, signaling, and T cell 
differentiation through ΔΨm regulation. 
Finally, mitochondria are also extremely important mediators of T cell signaling, primarily 
through mitochondrial ROS (mtROS) production. Mitochondrial derived ROS makes up a large 
portion of overall cellular ROS and is produced predominantly at complexes I and III of the ETC 
233, 261. Immediately following T cell activation, mtROS spikes in association with a rapid influx of 
calcium. By increasing calcium concentrations, mitochondria become hyperpolarized resulting in 
ETC saturation and electron leakage, and ultimately mtROS formation. This phenomenon is 
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essential for appropriate T cell activation, whereby inhibition of mtROS, both in vitro and in vivo, 
resulted in attenuated IL-2 production and the loss of antigen-specific T cell expansion 233. One 
of the ways that mtROS promotes T cell activation is through its oligomerization of mitochondrial 
antiviral signaling proteins (MAVS), which are key signaling proteins that regulate the expression 
of immune pro-inflammatory genes including NFAT, NF-κβ, and IRFs 206, 261, 262. In addition, 
induction of mtROS through the inhibition of complex I is found to activate the NLRP3 
inflammasome, leading to the activation of caspase I and subsequently, IL-1β production 263. 
Though necessary for development of an effective T cell response, pharmacological inhibition of 
mtROS has been shown to reduce airway inflammation in mice infected with influenza A virus, 
demonstrating potential as a therapeutic target 264. Together, these studies demonstrate the 
importance of mitochondrial function beyond its role in metabolism for the formation of a 





Figure 2. T cell metabolism. Under homeostatic conditions, T cells uptake glucose through the glucose 
transporter Glut1 and metabolize it through glycolysis and the TCA cycle to generate the reduction 
intermediates, NADH and FADH2. These electron donors feed electrons to complexes I and II of the 
ETC and facilitate the pumping of hydrogen ions into the intermembrane space to generate a charge 
differential that drives ATP production by ATP synthase. Following TCR engagement and co-activation 
with CD28, the AKT/mTOR pathway is activated causing global metabolic changes that promote 
anabolism, cell growth, and proliferation. Increased Glut1 expression following TCR activation drives 
glycolytic flux to provide intermediates required for cell growth. Increased flux through the ETC also 
promotes ROS production, which is found to play important roles in T cell activation, cytokine 
production, and cell death. In addition to increased glucose internalization, glutamine uptake is 
increased through SLC1A5 and SLC7A5 transporters and undergoes glutaminolysis for entry into the 
TCA cycle. Fatty acid metabolism is utilized by long lived naïve and memory T cells through breakdown 
by β-oxidation or de novo synthesis using the TCA intermediate, citrate. 
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1.5 Metformin: Mechanisms of action and use as a host-directed therapy. 
Metformin’s mechanism of action. 
 Metformin is an anti-hyperglycemic drug that is most commonly prescribed for the 
treatment of type II diabetes. It is derived from the naturally occurring compound galagine, which 
was originally isolated from the French lilac, or Galega officinalis, and was used as an herbal 
medication in medieval Europe 265. In the 1920’s, galagine was found to induce glucose-lowering 
effects but treatment corresponded with high liver toxicity and it was therefore, unable to be used 
as an anti-glycemic therapeutic in its native form. Metformin, a synthetic derivative of galagine, is 
a member of the biguanide family along with phenformin that also possesses glucose lowering 
properties but is non-toxic. As a result, metformin has become the most widely prescribed drug 
for the treatment of type II diabetes, approved by the Food and Drug Adminstration (FDA) for 
clinical use in the United States in 1994 266. In addition to its anti-glycemic effects, metformin is 
more recently being evaluated for the treatment of various diseases including cancer, 
autoimmune, and infectious diseases, due to its less well-known effects on cellular proliferation, 
cell death, and immune modulation 267, 268, 269. Exploiting these off-target effects has been 
complicated, however, due to an incomplete understanding of metformin’s mechanisms of action, 
which appears to vary in response to individual diseases, timing of treatment, and dosage. Over 
the past 20 years, a vast amount of research has been performed to better understand these 
mechanisms, and though great advancements have been made, variability between studies and 
the multiple off-target effects has delayed the wide spread use of metformin as a host-directed 
therapy for other communicable and non-communicable diseases.  
The main anti-glycemic affects by metformin are attributed to decreased hepatic 
gluconeogenesis and increased glucose uptake by muscle cells 270, 271. Following oral delivery, 
metformin is predominantly absorbed through the gastrointestinal tract and delivered to the liver 
via the hepatic portal vein and then cleared from the body by renal excretion 272. Metformin is 
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detected at its highest concentration in the liver— around 40-80µM compared to ~10µM that is 
observed in the plasma— making hepatocytes one of its primary targets 273. Due to its cationic 
nature, metformin must be delivered into cells by organic cation transporters (OCT1, OCT2, and 
OCT3), which are expressed on many different tissues including the small intestine, liver, kidney, 
heart, skeletal muscle, placenta, lung, brain, immune cells, and even tumors  274, 275, 276. Organic 
cation transporter 1 is highly expressed in the liver, and mice lacking its expression display a 30-
fold decrease in metformin uptake. Moreover, studies show that OCT1 expression is required for 
anti-glycemic activity by metformin 274, 275. Following entry into the cell, metformin accumulates in 
the mitochondria due to its attraction to the negative charge differential, where it is found to inhibit 
complex I of the ETC. Early studies evaluating the mechanism of action of metformin 
demonstrated that treated cells displayed decreased OXPHOS, depolarized mitochondria, and a 
drop in ATP/ADP ratios, indicating a loss of mitochondrial function, or mitochondrial insufficiency 
277. Likewise, insufficient energy production by mitochondria corresponded to heightened cellular 
lactate excretion due to an increase in aerobic glycolysis 278, 279. Mitochondrial perturbations are 
most attributed to metformin’s partial inhibition of complex I of the ETC. This has been 
demonstrated using isolated mitochondria or functionally isolated complex I, which show that in 
response to metformin treatment, cells are unable to consume oxygen and become energetically 
inefficient 279, 280. The inability to facilitate ATP production by OXPHOS results in an overall 
decrease in ATP, corresponding to increased ADP: ATP and AMP: ATP ratios that alert energetic 
sensors to alter functionality. Selective binding of AMP or ADP to the γ subunit of AMPK induces 
phosphorylation and activation, which participates in various metabolic functions including the 
inhibition of fat synthesis and promotion of fat oxidation and thus reduced hepatic lipid stores and 
increased insulin sensitivity 265, 281. Moreover, increased AMP:ATP ratios are found to inhibit 
gluconeogenesis by repressing the expression of genes and the function of enzymes required for 
gluconeogenic processing 265, 271, 282, 283. These results and others imply that the inhibition of 
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complex I and AMPK activation are central to metformin’s downstream effects. Other studies 
exist, however, that suggest alternative mechanisms of action and downstream consequences. 
In one study evaluating the mechanistic effects of metformin on various cancer cell lines, 
whether metformin acted through an AMPK dependent mechanism was dependent on the cell 
line being assessed. While some cells displayed AMPK activation following metformin treatment, 
others failed to activate AMPK and rather displayed an increase in mitochondrial ROS production. 
The authors, therefore, suggested that ROS production may be an alternative mechanism that is 
employed by metformin 284.  Further evidence demonstrating the dispensability of AMPK for 
metformin to elicit its function effects show that mice lacking liver AMPK maintain similar blood 
glucose levels following metformin treatment in comparison to WT mice 271. Based on these 
findings, the authors hypothesized that AMP accumulation and the allosteric inhibition of the key 
gluconeogenic enzymes, such as fructose 1,6-bisphosphatase, may be responsible for these 
effects 271. In support of AMPs ability to induce metabolic modulations independent of AMPK, 
another study has demonstrated that AMP build-up following metformin treatment antagonizes 
glucagon actions, which also decreased glucose levels 285.  
To make sense of differences in the literature suggesting differences in the requirement 
for AMPK for the action of metformin, recent studies have begun to evaluate the influence that 
drug concentrations have on mechanistic targeting— an important consideration since many 
studies are carried out using supra-physiological concentrations. One study has argued the 
validity of the results reported from AMPK deficient mice demonstrating that when treated with 
physiological concentrations, AMPK activation is in fact required to suppress glucose production 
273, 286. Other studies evaluating alternative mechanisms of action using low-dose concentrations 
suggest that metformin functions by altering cellular redox status; specifically, by regulating 
glycerol-3-phosphate dehydrogenase activity, a key component of a transport system used to 
shuttle reducing equivalents from the cytosol to the mitochondria 287, 288. Results from these 
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studies and others, therefore, demonstrate the challenges faced in defining a clear picture of 
metformin’s mechanisms of action.  
As previously mentioned, a major complication in studying the mechanisms of action of 
metformin correspond to the dose used during experimentation. Extreme variations of drug 
concentration are used in in vitro versus in vivo settings as well as human versus animal dosing, 
which brings into question the biological relevance of many studies. Compared to the roughly 
10µM metformin concentration found in the plasma of human patients, in vitro studies require at 
least 100x this concentration to see comparable molecular alterations. In one study evaluating 
the pharmacokinetics of metformin in mouse tumors, they found that to achieve similar levels of 
AMPK activation in vitro as in vivo, concentrations in excess of 300-fold were required compared 
to the circulating concentrations measured in mice 289. Moreover, they demonstrated that only 10-
15% of the metformin concentration applied in the media was found inside of in vitro cultured 
cells, and cells treated with 1mM metformin in vitro possessed similar intracellular concentrations 
to that observed in the plasma in vivo 289. Additionally, metformin is known to accumulate in 
negatively charged organelles in the cell, hence its localization to the mitochondria, at 100- to 
500- fold higher concentrations than what is observed in the plasma. Therefore, differences in 
cellular membrane potential between cells that are maintained either in vitro or in vivo may also 
account for the differential concentrations required to see molecular effects 290. Cellular sensitivity 
to metformin is also found to vary greatly based on nutrient availability 290, 291. One study, which 
assessed the impact of serine availability on the antineoplastic effects of phenformin— a 
biguanide molecule that is structurally similar to metformin—found that serine withdrawal 
dramatically improved antineoplastic function 291. Therefore, the excessive nutrient availability in 
cell culture media is not a true representation of nutrient limitations that are encountered in 
biological microenvironments. In addition to in vitro dosing variations, high doses that are used to 
treat mice are also met with scrutiny. The human metformin dose is approximately 20mg/kg/day 
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while doses used in mouse studies exceed that by at least ten times, ranging from 250-500mg/kg 
272. Multiple studies have now demonstrated, however, that these much higher doses are required 
to achieve equivalent human serum concentrations and are therefore physiologically relevant 
(~10µM) 290.  
Metformin as a host-directed therapy. 
 In addition to metformin’s traditional use as an anti-glycemic drug, it possesses many off 
target effects that have been shown to be beneficial in the treatment of various diseases. The use 
of metformin as an adjunctive cancer therapeutic has widely been explored due to its anti-cancer 
properties, including inhibition of cellular proliferation and promotion of cell death pathways 292, 293, 
294, 295. Interestingly, in addition to its direct influence on cancer cells, metformin has been shown 
to contribute to cancer clearance by enhancing immune-mediated mechanisms. In multiple 
studies, metformin enhances tumor rejection in normal mice, yet fails to mediate protection in T 
cell immunodeficient mice, indicating the specific influence that it has on the T cell anti-tumor 
response 292, 293. In support of these data, increased tumor T cell infiltration and altered cytokine 
production are observed in response to metformin treatment, which contributed to enhanced 
protection. Specifically, metformin is shown to decrease the production of pro-inflammatory 
cytokines and subsequently, protects T cells from becoming functionally exhausted 293. The anti-
inflammatory effects of metformin have not only been exploited in cancer, but also for the 
treatment of various autoimmune and chronic inflammatory diseases including SLE, rheumatoid 
arthritis, type 1 diabetes (T1D), and tuberculosis 269, 296, 297, 298.  In experimental models of arthritis 
and T1D metformin alters the Th17: Treg cell ratio, favoring the generation of an anti-inflammatory 
immune environment and abolished disease. Furthermore, metformin has been used to facilitate 
the generation of memory T cells by inducing β-oxidation, suggesting its use to potentiate vaccine 
responses 248, 293. Considering these recent findings, metformin has become an attractive 
candidate for use as a host-directed therapy through its immunomodulatory effects. 
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 As a chronic inflammatory disease, the therapeutic potential for the treatment of 
tuberculosis with metformin has gained considerable attention. Epidemiological studies have 
found T2DM patients receiving metformin treatment dramatically decreases their risk of 
developing active TB and improves their treatment outcomes, hence providing evidence that 
metformin elicits protection against TB 299, 300, 301, 302. However, whether there is true value in 
treating TB patients with metformin and the mechanisms by which it may enhance host-mediated 
protection are currently not well understood. One hypothesis is that systemic hyperglycemia, as 
demonstrated in guinea pig models of Mtb infection, contributes to disease progression, whereby 
normalization of blood glucose by metformin results in improved disease outcome 29, 303. 
Alternatively, metformin may directly alter immune cell function, similar to what is observed in 
other chronic inflammatory diseases.  
 Singhal et al. provided the first line of evidence indicating metformin’s potential use for the 
treatment of TB in the absence of underlying T2DM. His group demonstrated that following Mtb 
challenge, mice that received metformin treatment displayed an increase in macrophage-induced 
bacterial killing, presumably through increased mitochondrial ROS and phagosome-lysosome 
fusion 302. Additionally, lung lesion burden and inflammation were reduced in metformin treated 
mice, which was associated with an increase in both the number and proportion of Mtb-specific 
CD8 T cells in the lung 302. A recent study has since validated these findings by showing an 
increased accumulation of CD8 T cell in the lungs of metformin treated compared to untreated 
Mtb infected mice 304. Furthermore, this study suggests that metformin rejuvenates metabolic and 
cellular function of CD8 T cells in response to Mtb infection, which corresponds with decreased 
production of pro-inflammatory cytokines including IL-2 and TNF-α 304. In another recent study, 
the investigators evaluated whether metformin confers the same anti-inflammatory and metabolic 
properties in human Mtb-exposed immune cells as in mice. Peripheral blood mononuclear cells 
(PBMC) were isolated from healthy humans and treated ex vivo with Mtb lysate in the presence 
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or absence of metformin 305. This study found that like mouse studies, metformin treated Mtb 
stimulated PBMCs produced significantly decreased amounts of pro-inflammatory cytokines 
(TNF-α, IFN-γ, and IL-17) and enhanced cellular metabolism 305. Based on these studies, there 
is a growing body of evidence that supports the positive influence that metformin has on TB 
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CHAPTER 2 - METFORMIN ENHANCES PROTECTION IN GUINEA PIGS CHRONICALLY 




Tuberculosis (TB) is a chronic inflammatory disease that is often associated with 
alterations in systemic and cellular metabolism that resolves following successful antimicrobial 
drug treatment. We hypothesized that altered systemic glucose metabolism as a consequence of 
Mycobacterium tuberculosis (Mtb) infection, contributes to TB pathogenesis, and when 
normalized with anti-glycemic drugs would improve clinical outcomes. To test this hypothesis, 
guinea pigs were treated daily with the anti-diabetic drug metformin starting 4 weeks prior or 
concurrent with aerosol exposure to the H37Rv strain of Mtb. In the chronic stages of infection, 
Mtb infected metformin-treated animals had restored systemic insulin sensitivity but remained 
glucose intolerant as determined by oral glucose tolerance testing. Despite persistent glucose 
intolerance, metformin-treated guinea pigs had a 2.8- fold reduction in lung lesion burden and a 
0.7 log decrease in CFUs. An alternative hypothesis that metformin treatment improved clinical 
disease by having a direct effect on immune cell energy metabolism was tested using extracellular 
flux analysis and flow cytometry. The proinflammatory immune response to Mtb infection in 
untreated guinea pigs was associated with a marked increase in energy metabolism (glycolysis 
and mitochondrial respiration) of peripheral blood mononuclear cells (PBMCs), which was 
normalized in metformin-treated guinea pigs. Moreover, both CD4+ and CD8+ T lymphocytes from 
Mtb infected, metformin treated animals maintained a more normal mitochondrial membrane 
potential while those isolated from untreated animals had persistent mitochondrial 
hyperpolarization. These data suggest that metformin promotes natural host resistance to Mtb 
1 This chapter is published in Scientific Reports as:  
Frenkel, J.D.H., Ackart, D.F., Todd, A.K. et al. Metformin enhances protection in guinea pigs 




infection by maintaining immune cell metabolic homeostasis and function during the chronic 
stages of active TB disease.  
Introduction  
The persistent proinflammatory immune response associated with  active Mycobacterium 
tuberculosis (Mtb) infection in some TB patients contributes to alterations in systemic glucose and 
lipid metabolism 1-3. The role elevated blood glucose levels has on TB disease severity and 
progression has been best characterized in diabetic patients, which have a 1.5 to 3-fold increased 
risk for developing active TB disease and are twice as likely to die or develop reactivation of a 
latent Mtb infection 4-8.  However, the impact non-diabetic hyperglycemia has on TB pathogenesis 
is less well understood. To determine the impact non-diabetic hyperglycemia has on the 
pathogenesis of TB we treated guinea pigs with the anti-diabetic drug metformin prior to or 
concurrent with aerosol exposure to Mtb. Metformin is among the safest and most widely 
prescribed drugs used to control blood glucose levels in patients with type 2 diabetes mellitus 
(T2DM). Metformin helps lower and maintain more normal blood glucose levels in diabetic 
patients by improving systemic insulin sensitivity and lowering glucose production by the liver 9,10. 
In the context of TB, several studies have suggested that Mtb infected individuals with T2DM 
taking metformin, have slower TB disease progression and improved clinical outcomes and 
survival compared to individuals not treated with metformin or with poor diabetes control 11-13.  
In addition to its anti-glycemic affects, metformin has also been widely studied as an 
immunomodulatory drug for the treatment of various other communicable and non-communicable 
diseases 14, with observed clinical improvement in patients with cancer, a variety chronic bacterial 
and viral infections as well as autoimmune diseases such as systemic lupus erythematosus (SLE) 
15-20. Although the exact mechanisms of action have not been determined, metformin has been 
shown to have a direct effect on immune cell metabolism, which is linked to T lymphocyte 
differentiation, function, and survival 21-26. This suggests that in addition to normalizing systemic 
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glucose metabolic derangements caused by chronic inflammation, metformin may also modulate 
the function of immune cells that are important in the protection and pathogenesis of TB.  We 
show here that metformin treatment of Mtb infected guinea pigs improved clinical disease in part 
by partially restoring systemic glucose metabolism as well as having a direct effect on cellular 
metabolism of immune cells that are important in the protection against TB. 
Materials and Methods 
Animals and sample collection 
 4-week, female, outbred Dunkin–Hartley guinea pigs, n=14 per group, were purchased 
from Charles River Laboratories and housed in a biosafety level 3 laboratory at the Colorado 
State University Laboratory Animal Resources facility accredited by the American Association for 
Accreditation of Laboratory Animal Care (AAALAC). All animal experiments were performed in 
accordance with the National Research Council's Guide for the Care and Use of Laboratory 
Animals and were approved by the Animal Care and Usage Committee at Colorado State 
University. 
Animals were chipped (BioMedic Data Systems, Inc.) for animal identification and continuous 
recording of body temperature. For serial blood collection, guinea pigs were anesthetized via 
isoflurane inhalation and blood collected by percutaneous venipuncture of the cranial vena cava. 
At the time of euthanasia, guinea pigs were administered 50 mg/kg of ketamine and 5 mg/kg of 
Xylazine via intramuscular injection for anesthetic induction. Under terminal anesthesia, blood 
was collected, and guinea pigs were euthanized by IP overdose of pentobarbital. Tissues were 
collected for histopathology by fixing in 4% paraformaldehyde or stored at -80℃ for 




Metformin treatment  
Guinea pigs received oral administration of either 20mg/kg of metformin (Spectrum 
Chemical MFG Corp, New Brunswick, NJ), purchased through the CSU Veterinary Teaching 
Hospital Pharmacy, in a carrier suspension of 50% ORA-sweet🄬 (Perrigo) 50% water or mock 
treatment, carrier suspension of 50% ORA-sweet🄬(Perrigo) 50% water, daily beginning 28 days 
prior to or concurrent with Mtb infection. Dosage was chosen based on the human equivalent 
serum concentration of ~10µM, confirmed by pharmacokinetic analysis (Figure S6). Treatment 
was continued once daily throughout the duration of the study. 
Mtb aerosol exposure 
 Culture stocks of Mtb strain H37Rv (TMC #102, Trudeau Institute) were agitated in glass 
test tubes, collected at an OD600nm between 0.8-1.0, and frozen at -80°C in Proskauer-Beck 
liquid medium containing 0.05% Tween-80. Titer was determined and bacteria were diluted in 
water to 1×106 CFU/ml. Approximately 20 bacilli were delivered to each animal using a Madison 
chamber aerosol generation device 3. 
Oral glucose and insulin tolerance testing 
 Glucose and insulin tolerance were measured as previously described 3. In brief, following 
an 8-12 hour fasting period glucose tolerance was measured by oral challenge with a 2 g/kg bolus 
of D-glucose (0.5 g/ml). Serum glucose concentrations were measured using the Freestyle Lite 
glucometer (Abbot) from a skin-prick site adjacent to the most peripheral vein on the pinna at 0, 
30, 60, 90, and 120 minutes following administration. Similarly, insulin sensitivity was measured 
following the SC injection of 0.5 units/kg of regular-acting human recombinant insulin (Humulin-




 Peripheral blood mononuclear cells were isolated from whole blood by density gradient 
centrifugation with lympholyte mammal (1.086 gm/cm3) according to manufacturer instructions 
(Cedarlane). Single-cell suspensions from BAL were prepared by centrifugation at 500xg followed 
by RBC lysis with Gey’s solution. 2x105 or 4x105 PBMCs and 1x105 BAL cells suspended in 
seahorse XF assay media (Agilent Technologies, Inc), were seeded onto CellTak (Corning Inc.) 
coated 8 or 24 well cell culture microplates, respectively. Cell adherence to microplates was 
achieved prior to assaying by centrifuging plates at 500xg for 5 minutes with no brake followed 
by a 30-minute incubation at 37℃ in the absence of CO2. OCR and ECAR were measured using 
a Seahorse XFp or Seahorse XFe24 bioanalyzer (Agilent Technologies, Inc). OCR and ECAR 
were measured basally and following the injection of 1µM oligomycin, 2µM fluorocarbonyl cyanide 
phenylhydrazone (FCCP), 0.5µM rotenone + antimycin A, and 50mM 2-deoxyglucose. 
Flow cytometry  
Peripheral blood mononuclear cells and BAL single-cell suspensions were prepared for 
antibody surface staining by seeding 1x106 cells in FACs buffer, PBS+1% BSA+0.1% sodium 
azide, into 96 well round-bottom plates. Fc blocking was performed in FACs buffer + guinea pig 
IgG + rabbit IgG on a rocker at 4℃ for 30 minutes prior to antibody staining. Fluorochrome-
conjugated antibodies including CD4, CD8 (Bio-Rad Laboratories Inc.), and MHCII (hybridoma 
line producing mAb IVA12 27) were prepared in FACs blocking buffer and added to cells for 20 
minutes at 4℃ on a rocker. Live/dead exclusion was assessed by staining with either Live/Dead 
aqua or 7-AAD. Data was collected with an LSR II (BD Biosciences) flow cytometer maintained 





 Mitochondrial membrane potential was evaluated by incubating PBMCs with 25nM 
DiOC6(3) (ThermoFisher Scientific) for 30 minutes at 37℃ + 5% CO2. Mitochondrial mass was 
assessed by staining by staining PBMCs with 100nM mitotracker deep red (ThermoFisher 
Scientific) for 30 minutes at 37℃ + 5% CO2. To quantify mitochondrial superoxide production, 
MitoSOX red (ThermoFisher Scientific) was suspended at a final concentration of 2.5µM in HBSS 
and incubated with PBMCs for 10 minutes at 37℃ with CO2. To obtain a positively stained 
MitoSOX control, PBMCs were incubated with 93nM tert-butyl hydroperoxide for 30 minutes at 
37℃ + CO2 prior to MitoSOX staining. All samples were analyzed using an LSR II (BDBiosciences) 
flow cytometer maintained within BSL-3 facilities and the data was analyzed using FlowJo 
software (FlowJo, LLC). 
GSH/GSSG ratio 
GSH/GSSG ratios were analyzed in isolated PBMCs during acute, subacute, and chronic 
stages of Mtb infection by luciferin detection using the GSH/GSSG-Glo™ Assay kit (Promega). 
2.5x105 live PBMCs were assayed in a 96 well white-walled plate, according to manufacturer 
instructions, and luminescence was read on a BioTek Synergy2 instrument. 
qRT-PCR 
 The right caudal lung lobe was collected post-mortem from metformin and mock treated 
animals and minced in RNAlater (Qiagen), incubated at 4℃ for 24 hours, then frozen at -80℃ for 
extraction at a later date. Approximately 50mg of minced tissue was homogenized with a bead 
beater in RLT buffer then digested with proteinase K for 30 minutes at 55℃. Nucleic acid was 
extracted with an RNeasy mini kit (Qiagen). The nucleic acid was eluted, and DNA was digested 
in solution with DNase I (Qiagen) for 30 minutes at RT then re-purified on the RNeasy mini 
columns. The resulting RNA was quantified by nanodrop and integrity determined by agarose gel 
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electrophoresis.  1ug of RNA was reverse transcribed to cDNA and quantitative RT-PCR was 
performed with the SYBR Green detection kit (Bio-Rad) and signal detected in the Bio-Rad CFX-
96 real-time thermal cycler. Each reaction was performed in duplicate for each animal with 
0.2mmol/L of each primer and 50ng of cDNA template. The gene expression was normalized 
using two reference genes- hypoxanthine-guanine phosphoribosyltransferase (HPRT) and TATA-
box binding protein (TBP), which were validated for consistent expression with these experimental 
conditions. The primer design and sequences for guinea pig TNFα, IL-6, IL-12p40, IL-1β MCP-1, 
TGFβ, IL-10, IFNγ, IL-17A, and FOXP3 are thoroughly described in our previous work 8. 
Bacterial burden/CFU 
Lung, spleen, and liver were weighed and diluted 1:10 in PBS prior to homogenization. 
Serial dilutions of tissue homogenates were performed in PBS and plated on BD Difco™ 7H11 
agar (VWR). Following 3-6 weeks of incubation at 37℃, colony-forming units were counted, and 
CFUs per gram of tissue was calculated. 
Histology  
Tissue sections fixed with 4% paraformaldehyde were paraffin embedded, sectioned at 
5µm, and stained with hematoxylin and eosin. Total and lesion area of lung, spleen, and liver 
were quantified using Stereo Investigator area fraction fractionator software (MBF Bioscience) 
and the Nikon Eclipse 80i microscope. The area of inflammation relative to the area of normal 
tissue parenchyma was estimated from representative lung, liver, and spleen tissue sections 
evaluated at 200X magnification. A total of 20 to 25 fields were randomly selected by the 
computer, and a counting frame (2,000 μm2) containing probe points with a grid spacing of 200 
μm was used to define the areas of interest (lesions and lungs). Lesion burden was calculated as 
ratio of tissue area to lesion area and expressed as a percentage of lesion to tissue 3.  
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Data analysis  
Lesion burden and metabolic phenotyping data set was normalized to the initial time point 
of mock treated. Tukey’s IQR method was used to identify outliers in data sets. Based on data 
sets, Two-way ANOVA or T-test were used to determine differences between groups. When 
necessary, data was log transformed to achieve normality and homoscedasticity of residuals or 
data. If normality or homoscedasticity could not be achieved, data was analyzed using non-
parametric methods.  Post-hoc comparisons methods were Tukey, Sidak's, or Mann-Whitney 
















Metformin restores insulin sensitivity but not glucose intolerance during Mtb infection. 
Previously, human and animal studies have demonstrated that glucose intolerance, 
consistent with systemic insulin resistance, develops in response to chronic Mtb infection 1, 3, 28. 
We hypothesized that insulin resistance is responsible for altered systemic glucose metabolism 
that is characteristic of chronic infection. We tested whether treatment with metformin initiated 
prior to Mtb infection restored systemic glucose metabolism. Guinea pigs infected with Mtb 
developed non-diabetic hyperglycemia (Figure 2.1B) and systemic insulin resistance as 
determined by glucose and insulin tolerance testing, respectively (Figure 2.1A and Figure 2.2A). 
In contrast, guinea pigs treated with metformin maintained systemic insulin sensitivity comparable 
to uninfected animals (Figure 2.1A and Figure 2.2A). Consistent with previous findings in humans, 
oral glucose tolerance testing showed Mtb infected guinea pigs developed systemic glucose 
intolerance that was not reversed by metformin treatment. 
A. B. 
Figure 2.1.  Metformin restores insulin sensitivity but not glucose tolerance 30 days 
following Mtb infection. Duncan Hartley guinea pigs received oral administration of 25mg/kg 
metformin or mock treatment once daily beginning 28 days prior to low-dose aerosol infection with Mtb 
H37Rv. Thirty days following infection guinea pigs were subjected to an insulin tolerance test by 
injecting 0.5 units/kg human recombinant insulin SC (A) or an oral glucose tolerance test by challenging 
fasted animals with a 2g/kg bolus of D-glucose (B). Blood glucose concentrations were measured at 0, 
25, 50, 75, and 100 minutes post insulin injection and 0, 30, 60, 90, and 120 minutes post oral glucose 
challenge. A 2-factor mix model was used to determine significances with Tukey’s correction for multiple 
comparisons. N=9 *** p ≤ 0.001 ** p ≤ 0.01   
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Metformin enhances host resistance to Mtb.  
To evaluate whether the effects of metformin on systemic metabolism influenced the 
outcome of TB disease severity, we quantified Mtb colony forming units (CFUs) and lesion burden 
at acute (21-30 days), subacute (45-60 days), and chronic (75-90 days) stages of infection. At 
acute and subacute timepoints, there were no differences in lesion burden nor CFUs in the lungs, 
spleens, or livers of infected animals (Figure 2.3 A-E). During chronic stages of infection however, 
we observed a 2.8-fold decrease in lung lesion burden and 0.7 log reduction in CFUs in metformin-





Figure 2.2. Oral glucose and insulin tolerance tests over the course of Mtb infection. On days -
7, 23, 51, 86, and 107 following Mtb infection, guinea pigs were subjected to an insulin tolerance test 
by injecting 0.5 units/kg human recombinant insulin SC (A). Blood glucose concentrations were 
measured at 0, 25, 50, 75, and 100 minutes post insulin injection. On days -35, -14, -7, 7, 21, 28, 49, 
63, 91, and 112 following infection guinea pigs were subjected to an oral glucose tolerance test by 
challenging fasted animals with a 2g/kg bolus of D-glucose (B). Similarly, blood glucose was measured 
at 0, 30, 60, 90, and 120 minutes post oral glucose challenge. The area under the curve (AUC) was 
calculated for each treatment group at each individual timepoint (A-B). Graphs represent the 
corresponding averages of the AUC of either untreated or metformin treated guinea pigs at each 
timepoint. Significance of treatment effect was found using a 2-factor ANOVA. There was no significant 
difference in glucose tolerance between mock- and metformin-treated Mtb infected pigs over the course 
of infection (B). N=9   
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Figure 2.3. Metformin enhances host resistance to Mtb. During acute, subacute, and chronic stages 
of infection lungs, spleens, and livers were harvested from euthanized, Mtb infected untreated- and 
metformin-treated guinea pigs to evaluate lesion burden (A, C, & E) and bacterial burden (CFUs) (B, 
D, & F). Stereo Investigator software was used to calculate the percent of lesion to uninvolved tissue 
in guinea pig lungs and spleens (A, C, & E). Percent lesion involvement was normalized to acute 
untreated. Colony forming units were generated by plating homogenized (C) lung, (D) spleen, or (E) 
liver tissue on 7H11 agar plates and were quantified per gram of tissue. N=7-12 animals per group per 
timepoint. Two outliers were found using Tukey IQR method (B). All outliers were greater then 2.0 times 
the IQR. Mann-Whitney test was used to determine significances between treatments within stage of 






Lung tissue histology showed distinct differences in granuloma morphology in comparison to 
those from untreated animals. Granulomas from metformin-treated animals had a higher 
proportion of lymphocytes at acute and subacute time points that progressed to well organized 
and delineated granulomas with less severe perilesional inflammation in the chronic stages of 
disease (Figure 2.4A-E).  
Figure 2.4. Metformin treatment of Mtb infected guinea pigs resolve lung lesions in the chronic 
stages of infection.  Guinea pigs were treated orally with mock treatment (OraSweet) (A, 
C, E) or metformin (B, D, F) and euthanized during the acute (A, B), subacute (C, D) or chronic (E, F) 
stages of infection with the H37Rv strain of Mtb. The progression of disease from the acute to chronic 
stages of infection in mock treated animals showed progressive perilesional inflammation (arrows) that 
corresponded to a higher lung lesion burden. In contrast, in metformin treated guinea pigs, inflammatory 
cells in the acute and subacute stages of infection are predominately lymphocytes (L) with less peri-
leional spread (arrowheads). In the chronic stages of infection in metformin treated animals the 
decreased overall lung lesion burden was accompanied by well-encapsulated granulomas that were 
sharply demarcated from the more normal lung parenchyma (arrowheads). H and E stain, 100X 
magnification.   
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Clinical signs of disease were only modestly improved in metformin-treated animals with 
a less, but nonsignificant, increase in body temperature in metformin-treated compared to 
untreated animals (Figure 2.5A-B). There were no significant differences in body weights between 
treated and untreated animals over the course of infection (Figure 2.5 C), and survival at 250 days 




Figure 2.5. Clinical parameters of TB disease. Clinical signs of disease were assessed in metformin-
treated (A) and untreated (B) Mtb infected guinea pigs by tracking and body temperature, body weight 





T cell metabolism is regulated by metformin. 
Given metformin’s effect in decreasing disease burden without fully restoring systemic 
glucose metabolism, we hypothesized that improved protection might be due to restoration of 
cellular rather than systemic metabolic alterations. To assess whether metformin modulated 
immune cell metabolism following Mtb infection, we evaluated metabolic profiles and the relative 
abundance of CD4+, CD8+, and MHCII+ cells of PBMCs from Mtb infected, treated and untreated 
guinea pigs. At all stages of infection, PBMCs were comprised of approximately 60% T cells with 
no significant changes in the proportions of phenotypes, regardless of treatment (Figure 2.6A-C). 
Metabolic profiles were assessed in PBMCs ex vivo using extracellular flux analysis, which 
measures the rate of oxidative phosphorylation (OXPHOS), expressed as oxygen consumption 
rate (OCR), and the rate of glycolysis, measured by the change in extracellular pH, expressed as 
extracellular acidification rate (ECAR).  
Following acute Mtb infection, dramatic increases in the utilization of OXPHOS and 
glycolysis were observed in both metformin-treated and untreated animals (Figure 2.7A and C). 
During subacute infection, PBMC metabolic rates decreased to levels comparable to uninfected 
animals in both metformin treated and untreated groups (Figure 2.7A and C). Following the onset 
of chronic infection however, PBMCs from untreated animals increased OXPHOS and glycolysis 
by roughly 3 and 2- fold, respectively. In contrast, PBMCs from metformin-treated guinea pigs 
maintained OXPHOS and glycolysis levels similar to that of uninfected guinea pigs during chronic 








Figure 2.6. CD4+ and CD8+ T cell and MHCII+ cell analysis and metabolic profiles. Flow 
cytometry analysis was used to quantify the percentages of CD4+ (A), CD8+ (B), and MHCII+ (C) cells 
from untreated and metformin-treated guinea pigs prior to and following low dose aerosol infection 





Metformin modulates T cell mitochondrial membrane potential and superoxide production.  
Previous studies have shown that metformin reduces pathology associated with chronic 
inflammation in a mouse arthritis model by reprogramming metabolism, and thus function, of T 
lymphocytes 29, 30. In particular, mitochondrial membrane potential (ΔΨm) and mitochondrial 
superoxide (mtSO) are found to be heightened in persistently activated T cells in models of 
Figure 2.7. T cell metabolism is regulated by metformin. Live PBMCs were isolated from untreated 
or metformin-treated guinea pigs prior to or during acute, subacute, or chronic Mtb infection. Basal 
oxidative phosphorylation (OCR) and (C) basal glycolysis (ECAR) were measured in live PBMCs by 
extracellular flux analysis (A). Data was normalized to the mean of the uninfected untreated group 
between two independent experiments. Mean values from a mitochondrial stress test performed 75 
days post infection (B & D). Curves represent raw OCR (B) and ECAR (D) values generated in response 
to the addition of oligomycin, FCCP, or rotenone and antimycin A. Mann-Whitney test was used to 




chronic inflammation, ultimately leading to cell death and oxidative damage 31, 32.  To determine 
whether the differences in PBMC metabolic phenotypes are linked to alterations in T cell 
metabolism, we measured mitochondrial membrane potential and mitochondrial superoxide 
production in CD4+ and CD8+ T cells from PBMCs of Mtb-infected guinea pigs. During acute and 
chronic stages of infection, we observed significantly lower mitochondrial membrane potential in 
CD4+ and CD8+ T cells from metformin-treated guinea pigs compared to untreated animals 
(Figure 2.8A-B). We ensured that the differences in membrane potential were not due to 
variations in mitochondrial size or numbers by measuring mitochondrial mass; and despite 
differences in membrane potential, mitochondrial mass remained consistent between both 
groups at all stages of infection (Figure 2.8C-D). We noted that mitochondrial superoxide was 
increased nearly 2-fold higher in CD4+ T cells from metformin-treated compared to untreated 
animals during chronic infection (Figure 2.9A). Because superoxide is produced in response to 
oxidative stress, we measured the ratio of glutathione (GSH) to glutathione disulfide (GSSG) to 
determine whether an increase in superoxide resulted in cellular stress. Although superoxide 
was increased in CD4+ T cells from metformin treated animals during chronic infection, cellular 









Figure 2.8. Metformin modulates T cell mitochondrial membrane potential. Peripheral 
mononuclear cells isolated from Mtb infected untreated and metformin-treated guinea pigs were stained 
with anti-CD4, anti-CD8, anti-MHC II, the ΔΨm dye DiOC(6)3 (25nm), and the mitochondrial specific dye 
Mitotracker deep red (100nM) at different stages pre- or post-infection. Differential ΔΨm was 
determined between (A) CD4+ and (B) CD8+ by measuring the median fluorescent intensity of DiOC(6)3 
by flow cytometry. Mitochondrial mass was measured in (C) CD4+ and (D) CD8+ by mitotracker deep 
red staining and MFI measurement. (A) One outlier was identified using Tukey IQR method which was 
greater than 2.0 times the IQR. (A-B) Unpaired t-tests with Welch’s correction was used to determine 
significance between groups within stage of infection. N=3-12 animals per group per timepoint. * p ≤ 






Metformin decreases inflammatory cytokine production in the lung during Mtb infection. 
To further understand the differences observed between disease burden and granuloma 
morphology in response to metformin treatment, we sought to evaluate cytokine and transcription  
factor gene expression in granulomas from untreated and metformin-treated animals during 
chronic Mtb infection. In comparison to metformin-treated animals, untreated guinea pigs 
C. 
A. B. 
Figure 2.9. Metformin modulates CD4+ T cell mitochondrial superoxide production. (A-
B) Peripheral mononuclear cells isolated from Mtb infected untreated and metformin-treated guinea 
pigs were stained with anti-CD4, anti-CD8, and the mitochondrial superoxide inicator dye mitoSOX at 
different stages pre- or post-infection. Data represents the % of total mitosox+ (A) CD4+ or (B) CD8+ 
cells. (C) GSH to GSSG ratios were measured in PBMCs by lucierein detection. N=6-13 per group per 
timepoint.  
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displayed significantly more production of the pro-inflammatory cytokines TNFα, IL-12p40, and 
IL-1β, and enhanced production of IFN-γ and IL-6, though not statistically significant (Figure 
2.10). Furthermore, metformin-treated animals displayed significantly higher expression of the 
regulatory T cell transcription factor FOXP3, however there were no significant differences in the 
abundance of anti-inflammatory IL-10 or TGF-β. Additionally, we observed a significant increase 
in monocyte chemoattractant protein (MCP-1) in granulomas from metformin compared to 






Figure 2.10. Metformin decreases inflammatory cytokine production in the lung 
during Mtb infection. Rneasy columns were used to extract RNA from homogenized lung tissue from 
chronically Mtb infected guinea pigs (day 75), which were either untreated or received metformin-
treatment. 1ug RNA was converted to cDNA and primers against TNFα, IL-6, IL-12p40, IL-1β MCP-1, 
TGFβ, IL-10, IFNγ, IL-17A, and FOXP3 were used to quantify gene expression by qRT-PCR. Unpaired 
Student’s t-test with Welch’s correction or Mann-Whitney test was used to determine significances with 
Bonferroni correction for multiple comparisons. N=5 * p ≤ 0.05 ** p ≤ 0.01      
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Discussion 
In these studies, we tested the hypothesis that reversing non-diabetic hyperglycemia in 
response to Mtb infection with metformin, would improve clinical outcomes in Mtb infected guinea 
pigs. When metformin treatment was initiated 28 days prior to Mtb infection, treated guinea pigs 
had significantly reduced lung lesion and bacterial burdens in the chronic stages of infection 
compared to untreated animals. This improvement corresponded with improved systemic insulin 
sensitivity, similar to the expected treatment response in diabetic patients. However, significant 
improvements in fasting blood glucose levels or glucose tolerance following Mtb infection were 
not achieved following metformin treatment. These data suggest that although metformin 
improved TB disease outcome, maintenance of systemic glucose tolerance alone was not 
responsible for these effects and suggests an alternative mechanism of action.  
Multiple reports have shown metformin’s potential use as an immune-modulatory drug in 
the treatment of various chronic inflammatory diseases 14,17,19,33. These effects are, in part, due to 
its partial inhibition of complex I of the electron transport chain, which leads to downstream 
signaling events that regulate cell metabolism, growth, and function in T cells and other cell types 
34-36. Here, we show that following chronic Mtb infection, metabolic flux through mitochondrial 
respiration and glycolysis are dramatically upregulated in T cells isolated ex vivo from untreated 
Mtb infected guinea pigs. This response was not unexpected given the systemic inflammation 
and resulting acute and chronic immune cell activation associated with active TB disease 37,38. 
Interestingly however, our results are in contrast with recent studies performed by Russell et al, 
in which they report a decrease in CD8+ T cell mitochondrial respiration following Mtb infection in 
mice 24. It is therefore, important to note that among differences in animal models and evaluation 
of PBMCs versus isolated CD8+ T cells, we found that different stages of disease corresponded 
to fluctuating metabolic phenotypes, which may help to explain variability within the literature.  
Furthermore, we show that during chronic infection, PBMC metabolism is restored to normal in 
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metformin but not untreated animals. This was not due to variations in the percentages of 
circulating immune cells, but rather resulted from inherent cellular metabolic changes in response 
to metformin treatment. These findings are consistent with those observed in mouse models of 
systemic lupus erythematosus, in which metformin combined with 2-deoxyglycose normalized 
PBMC metabolism and resulted in decreased immune activation and the subsequent resolution 
of clinical disease 19. We therefore, reasoned that changes in peripheral blood T cell metabolism 
reflect the waxing and waning of inflammation in response to persistent antigen stimulation, which 
was normalized by metformin treatment 39-41. These data are consistent with similar studies and 
suggest that the beneficial effects of metformin treatment were not due to the restoration of normal 
systemic glucose metabolism, but rather a direct immunomodulatory effect on immune cells 
responding to Mtb infection 24,42.   
In addition to similar work done in TB, non-TB studies also show that metformin treatment 
dampens inflammation and limits tissue destruction in a variety of communicable and non-
communicable diseases by limiting the differentiation and pro-inflammatory potential of T 
lymphocytes 28,29. Although we were limited in our ability to directly assess T cell function and 
differentiation of other T cell subsets due to the lack of available guinea pig reagents, we 
evaluated direct parameters of CD4+ and CD8+ T cell energy metabolism that correspond to their 
function, including mitochondrial membrane potential and mitochondrial superoxide production. 
Mitochondrial membrane potential, a measure of the gradient of hydrogen ions in the 
mitochondrial inner membrane space, is the primary driver of ATP production by the cellular 
electron transport chain. Inhibition of complex I has been shown to decrease mitochondrial 
membrane potential and lead to the downregulation of anabolic metabolism that is associated 
with effector T cell growth and function 31,43,44. In addition, a recent study found that T cells with a 
high mitochondrial membrane potential correspond to highly differentiated effector cells with 
increased metabolism, while those with low membrane potential are less differentiated cells that 
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possess the ability to self-renew and retain immunological plasticity 31. In our studies, peripheral 
CD4+ and CD8+ T cells isolated from guinea pigs treated with metformin had significantly reduced 
membrane potential compared to untreated animals during acute and chronic stages of Mtb 
infection. These data suggest that metformin, by maintaining a lower mitochondrial membrane 
potential, has the potential to influence the differentiation and function of T cells responding to 
Mtb infection, which is currently being investigated in our laboratory.  
Mitochondrial superoxide production is also critical for the functional response of T cells 
and is found to play dual roles in both the promotion of effector functions and/or oxidative damage 
that can ultimately lead to cell death 30,31,45. A direct link between membrane potential and 
superoxide has been described in systemic lupus erythematosus (SLE), where high membrane 
potential and inadequate ATP production correspond to obstructed electron flow, resulting in 
electron leakage and ROS production 30. Due to the increased respiratory rates observed in 
response to Mtb infection, we hypothesized that mitochondrial superoxide would also be 
increased in T cells from untreated Mtb infected guinea pigs, while animals that received 
metformin would display reduced superoxide. Surprisingly, metformin significantly enhanced 
mitochondrial superoxide production by CD4+ T cells during chronic infection. This result was 
unexpected given that both mitochondrial respiration and membrane potential were reduced in T 
cells from metformin treated animals.  One possible explanation is that increased mitochondrial 
superoxide is associated with maintenance of T cell functionality during chronic infection rather 
than oxidative damage and dysfunction 46,47.  
To assert whether increased superoxide production was indicative of increased oxidative 
stress we measured the relative abundance of GSH: GSSG. Despite the increase in superoxide 
by CD4+ T cells from metformin treated animals, GSH: GSSG ratios remained consistent between 
both groups. These data provide further evidence that metformin’s influence on CD4+ superoxide 
production may function to maintain important cell signaling events in CD4+ T cells 48.  
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The differential expression of cytokine genes in metformin treated and untreated guinea 
pigs by mRNA analysis also supports the hypothesis that metformin elicits its effects by altering 
immune cell function during Mtb infection and is consistent with findings by others 24.  We found 
that animals treated with metformin had dramatically decreased expression of pro-inflammatory 
cytokines. Moreover, although we observed increased expression of FOXP3, there was no 
difference in the production of regulatory cytokines, suggesting that the anti-inflammatory 
response was due to decreased pro-inflammatory cytokine production by effector cells. Taken 
together, these data provide strong evidence that metformin exerts its immunomodulatory effects 
directly on T cells during Mtb infection, resulting in a decreased pro-inflammatory response which 
explains the decreased lung inflammation and evidence of lesion resolution seen primarily in 
treated animals. 
Importantly however, although metformin significantly reduced disease manifestation 
during chronic stages of infection in our studies, these findings did not correspond to increased 
guinea pig survival. In contrast to decreased lung lesion burden, there were no significant 
differences in the extrapulmonary lesion or bacterial burden in metformin treated animals, which 
likely explains the lack of improved survival. In addition, these studies did not assess the use of 
metformin as a therapy for pre-existing infection or as adjunctive therapy in combination with 
antimicrobial drug treatment of TB 49. These are critical questions that will be evaluated in our 
future work and must be taken into consideration before metformin is evaluated as a practical 
host-directed therapy in humans. 
Together, these studies show that alterations to host metabolism play an important role in 
the progression and severity of TB disease. Although we were unable to directly link the impact 
of non-diabetic hyperglycemia to TB disease pathogenesis using metformin, we discovered novel 
immune metabolic correlates of protection. Moreover, our results are consistent with previous  
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reports showing metformin’s protective efficacy against Mtb infection in mice 14,18,24. Our results 
and others, therefore, warrants further evaluation of metformin and other drugs that target immune 
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CHAPTER 3 – METFORMIN PREVENTS TERMINAL DIFFERENTIATION OF AND PROVIDES 





Despite major efforts to elucidate what constitutes a protective immune response against 
Mycobacterium tuberculosis (Mtb) infection, knowledge gaps exist that hinder our ability to 
prevent or treat Tuberculosis (TB) disease. Our data show that metformin has in vitro and in vivo 
immunomodulatory activity and enhances protection against Mtb in guinea pigs. The mechanisms 
by which metformin alters T cell function following activation and whether these cells are 
responsible for the protection observed against Mtb is currently unknown. We hypothesize that 
metformin promotes the development of more-protective, memory like T cells that are capable of 
self-renewal, multipotency, and persistence by targeting mitochondrial function.  To test this, we 
used an in vitro model system that generates different levels of T cell differentiation through anti-
CD3/anti-CD28 activation. In response to metformin treatment, we find that in vitro differentiated 
CD4+ T cells display decreased levels of differentiation as determined by functional and 
phenotypic profiling. Increased expression of the lymphocyte homing and tissue retention markers 
CD44 and CD69 were observed while the T cell activation marker, CD25, was significantly 
decreased in metformin treated compared to untreated T cells. Altered surface marker expression 
corresponded with significant reduction of the terminal differentiation marker KLRG1 and an 
increase in the ratio of expression between the antagonistic transcription factors Blimp-1 and 
BCL6, which control terminal differentiation and memory T cell properties, respectively. Metabolic 
profiling of non-terminally differentiated metformin treated T cells revealed a novel metabolic 
phenotype displaying characteristics of both effector and memory T cell phenotypes, including 
increased glycolytic reliance, reduced mitochondrial metabolism, maintenance of spare 
respiratory capacity, and reduced mitochondrial membrane potential. Altered differentiation 
potential and metabolism by metformin treatment ultimately resulted in enhanced cellular survival 
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and recall capacity following secondary antigen challenge. These results demonstrate that during 
differentiation, metformin provides T cells with metabolic and functional advantages 
corresponding to enhanced protection against chronic Mtb infection. With this study, we provide 
insights into favorable CD4+ T cell phenotypic and metabolic properties that aide our 
understanding of immune protection against Mtb and provide markers in which future vaccines 
can be designed and evaluated. 
Introduction 
 
The first vaccine approved for the prevention of tuberculosis disease (TB), bacille 
Calmette-Guérin (BCG), was discovered over 100 years ago following the attenuation of a virulent 
strain of bovine tuberculosis 1. Today, BCG remains the only available TB vaccine, and although 
a significant contribution to science and medicine, it fails to provide full protection against the most 
common form of disease, adult pulmonary TB 2, 3. As a result, TB is the current single cause of 
death by an infectious disease worldwide 4. One barrier that has significantly hindered the 
development of new and more effective vaccines is our incomplete understanding of the immune 
response against the bacteria that causes TB, Mycobacterium tuberculosis— and particularly, 
what constitutes immune protection. 
Based on evidence from animal models and human patients with underlying T cell 
immunodeficiencies, the CD4 T cell response is well appreciated for its protective role against 
Mtb infection 5, 6, 7. Specifically, the T helper type 1 (Th1) response, which is characterized by the 
production of IFN-γ and macrophage mediated killing of intracellular pathogens 8. As a result, 
recent vaccination strategies have focused on generating robust IFN-γ responses; however, the 
translational value of IFN-γ as a biomarker of protection has proven inadequate. This is 
exemplified by various BCG vaccination strategies, which induce differential amounts of IFN-γ, 
yet provide comparable levels of protection 9, 10. In addition, studies have demonstrated that while 
CD4 knock-out mice are at greater risk of TB disease progression and death, IFN-γ levels are not 
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compromised, but are compensated for by increased production by CD8 T cells 10, 11. These 
studies suggest that IFN-γ alone is not responsible for CD4 T cell mediated protection, highlighting 
the critical need to discover novel immune correlates of CD4 T cell mediated protection for the 
development of effective vaccines.  
In our laboratory, we have shown that the anti-diabetic drug metformin can be repurposed to 
enhance host resistance against Mtb infection. Metformin is commonly prescribed for the 
treatment of type II diabetes due to its glucose lowering effects and demonstrates a high safety 
profile in human patients, rendering its approval by the Food and Drug Administration (FDA) 12. 
In addition to its anti-glycemic affects, metformin also has various other off-target effects that 
correspond with improved clinical outcomes of both communicable and non-communicable 
diseases 12, 13, 14, 15, 16, 17. Studies performed in guinea pigs by our laboratory, and mice by others, 
show that when initiated prior to Mtb infection, metformin leads to significantly reduced disease 
severity. The exact mechanism by which this occurs, however, is not well understood.  
One way that metformin is known to influence the host response to disease is through 
immunomodulation 18, 19. T cell function has been shown to be a direct target of metformin in 
multiple chronic inflammatory illnesses, corresponding to decreased production of pro-
inflammatory mediators that results in reduced tissue damage and inflammation 14, 15, 18, 20. 
Moreover, increased generation of memory T cells following metformin treatment has been 
demonstrated in an in vivo vaccination model, which is attributable to increased fatty acid 
metabolism 19. These studies suggest that T cell functionality and differentiation in response to 
metformin treatment are also a rational and important are for investigation during Mtb infection. 
Furthermore, data from our studies in Mtb infected guinea pig studies show direct changes to T 
cell metabolism in response to metformin treatment, which are likely to correspond to altered cell 
functions and phenotypes. 
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Immunometabolism, or the study of immune cell metabolism has emerged as a novel means 
to investigate temporal changes in immune cell phenotypes due to the intricate relationship 
between metabolism and cellular fate and function 21, 22. This strategy of cellular identification is 
particularly attractive due to the unnecessary reliance on known surface marker expression, 
opening the opportunity to discover novel cell types without pre-determined phenotypic bias. In 
response to chronic Mtb infection, T cells from peripheral blood mononuclear cells dramatically 
upregulate their utilization of both oxidative phosphorylation (OXPHOS) and glycolysis and 
undergo mitochondrial hyperpolarization, which are classic characteristics of highly differentiated 
pro-inflammatory T cells 23. In contrast, PBMC T cells from metformin treated Mtb infected animals 
had normalized rates of glycolysis and OXPHOS and maintained mitochondrial membrane 
potential, similar to uninfected animals. Notably, cells with this metabolic phenotype are 
characterized as less differentiated phenotypes (i.e. memory T cells) that possess the ability to 
persist and self-renew following antigen encounter 23. Importantly, while highly differentiated T 
cells produce cytokines that imply their protection against Mtb, recent studies show that less 
differentiated cell phenotypes confer increased protection against Mtb challenge 24, 25, 26, 27. In 
addition, non-terminally differentiated T cell phenotypes show superior plasticity, proliferative 
capacity, migration and long-term survival in response to recurring antigen stimulation 24. 
Based on our studies and the literature, we therefore, hypothesized that metformin, through 
metabolic regulation, enhances the generation of a memory T cell phenotype that has the capacity 
to persist and confer protection throughout chronic infection. Our studies address the impact that 
metformin has on T cell differentiation by evaluating functional and metabolic T cell phenotypes 
in response to in vitro activation. We demonstrate that, metformin, rather than increasing memory 
T cell formation, prevents pre-mature terminal differentiation of effector T cells, which have an 
increased capacity to respond to secondary Mtb antigen challenge, demonstrated by enhanced 
proliferation and survival. Furthermore, we discovered a novel metabolic phenotype of non-
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terminally differentiated effector T cells that has not been previously described, that may be used 
to distinguish cell types in response to both infection and disease.  
Materials and Methods 
Animals and sample collection   
Spleens were collected from eight- to twelve-week old, mixed gender, C57BL/6-Tg(H2-
Kb-Tcra,-Tcrb)P25Ktk/J (P25 TCR-Tg) mice (generously provided by Kevin Urdahl, Seattle 
Children’s Research Institute, Seattle, WA). Prior to tissue collection, animals were euthanized 
by carbon dioxide (CO2) overdose. Spleens were aseptically removed and splenocytes were 
isolated by pushing tissue through a 70μM cell strainer with the plunger of a 3ml syringe. Isolated 
splenocytes were resuspended at a concentration of 2x106 cells/ml in T cell media (TCM) (RPMI-
1640 with L-glutamine + 1x non-essential amino acids + 10mM HEPEs + 0.5μM 2-
mercaptoethanol) containing either 0μM, 600μM, or 1200μM metformin. Cell suspensions were 
then plated at a final concentration of 2x106 cells/ml in a volume of 1ml into a 48-well tissue culture 
treated plate. T cell activation was achieved using either plate bound anti-CD3 (2μg/ml; clone 
17A2; Biolegend, San Diego, CA) with anti-CD28 (1μg/ml; clone 37.51; Biolegend, San Diego, 
CA) (TEL) or soluble anti-CD3 (5μg/ml; clone 17A2) with anti-CD28 (1μg/ml; clone 37.51) (TML). 
For plate-bound activation, 200μl of 2μg/ml anti-CD3 antibody in 1x PBS was added to each well 
of a 48-well tissue culture treated plate and incubated at 4℃ overnight. Each well was gently 
rinsed with 1x PBS two times prior to adding cells to wells. Cell cultures were incubated in a 
humidified incubator held at 37℃ + 5% CO2 for 120 hours prior to analysis. 
All animals were housed at the Colorado State University Laboratory Animal Resources 
facility in a BSL-1 laboratory. Experiments were performed in accordance with the National 
Research Council's Guide for the Care and Use of Laboratory Animals and were approved by the 
Animal Care and Usage Committee at Colorado State University.  
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Metabolic extracellular flux analysis   
Activated CD3+ T cells were negatively selected for 120 hours following activation using a 
MojoSort Cell Isolation Kit (Biologend Inc., San Diego, CA). Dead cells were simultaneously 
removed from cell suspension using biotinylated annexin and streptavidin labeled MojoSort 
beads. A total of 2x105   live CD3+ T cells were suspended in seahorse XF assay media and were 
seeded onto a 24 well microplate (Agilent Technologies Inc., Santa Clara, CA) coated with 
CellTak (22.4µg/ml) (Corning Inc., Corning, NY.). Cell adherence to microplates was achieved by 
centrifugation (500xg, without brake) and confirmed by microscope evaluation, followed by a 30-
minute incubation at 37℃ in the absence of CO2. Oxygen consumption rates (OCR) and 
extracellular acidification rates (ECAR) were measured using a Seahorse XFe24 
bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA). Injection of 1μM oligomycin, 
2.5μM fluorocarbonyl cyanide phenylhydrazone (FCCP), 0.5μM rotenone + antimycin A, 
and 50mM 2-deoxyglucose was performed for quantification of basal OCR and ECAR, 
mitochondrial ATP production (basal – oligomycin), maximum respiration (FCCP – antimycin 
A/rotenone), spare respiratory capacity (FCCP – basal), glycolytic capacity (oligomycin - 2-DG), 
proton leak (oligomycin – antimycin a/rotenone), and non-mitochondrial oxygen consumption 
(antimycin a/rotenone). 
Flow cytometry  
At 0- and 120-hours following T cell activation, single-cell suspensions were prepared for 
antibody surface staining and/or intracellular staining. First, cells were harvested from 48-well 
plates and transferred into 5 ml polystyrene tubes, spun down at 500xg, and washed in 1x PBS 
prior to staining. Next, cells were resuspended in 200μl of the viability dye Zombie NIR (1:3500) 
(Biolegend Inc., San Diego, CA) prepared in 1x PBS, incubated in the dark for 15 minutes at room 
temperature, and then washed in 200μl FACs Buffer (1x PBS + 1% BSA). Fluorochrome-
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conjugated surface antibodies including CD4 -BV510, -FITC, or -PECy7 (clone RM4-5), CD8 -
BV421, or -BV570 (clone 53-6.7), CD44-FITC (clone IM7), CD25-Alexa Fluor 700 (clone PC61), 
CD69-PECy7 (clone H1.2F3), CD62L-Pacific Blue (clone MEL-14), CCR7-PE/Dazzle 594 (clone 
4B12), and KLRG-1-BV605 (clone 2F1/KLRG1) were prepared in FACs buffer containing 1μg 
CD16/32 (clone 93) and added to cells for 20 minutes at 4℃ in the dark. Samples that were not 
prepared for intracellular staining were then washed with 200μl FACs buffer and resuspended in 
a final volume of 300μl for flow cytometry analysis.  
Samples that were stained for intracellular markers were spun down and washed with 
200µl of 1x permeabilization buffer three times following extracellular staining. Intracellular 
antibodies were then suspended in 200µl of 1x permeabilization buffer + 1μg CD16/32 (clone 93) 
per sample, added to cell pellets, and incubated at 4℃ for 20 minutes in the dark.  Samples were 
then washed in 1x permeabilization buffer, suspended in 200µl fixation buffer, and incubated in 
the dark for 20 minutes at room temperature. Following fixation, samples were washed two times 
in FACs buffer and resuspended in a final volume of 300µl FACs buffer for flow cytometry analysis 
(Biolegend Inc., San Diego, CA). Fluorochrome-conjugated intracellular antibodies assessed 
include: Blimp-1-Alexa Fluor 647 (clone 5E7, BD Bioscience, San Jose, CA), Bcl-6-PE (clone 
IG191E/A8), FOXP3-Alexa Fluor 488 (clone MF-14), T-bet-APC (clone 4B10), RORgt-BV786 
(clone Q31-378, BD Bioscience, San Jose, CA), and GATA3-Alexa Fluor 647 (clone 16E10A23). 
All antibodies were purchased from Biolegend Inc., San Diego, CA unless otherwise stated.  
All samples were run on a Cytek™ Aurora Spectral Flow Cytometer (Cytek Biosciences, 
Fremont, CA). Data was interpreted using the median fluorescent intensity of each indicated dye 




Metabolic staining   
The mitochondrial sensitive dye tetramethylrhodamine (TMRM) (ThermoFisher Scientific, 
Waltham, MA) was used to measure mitochondria membrane potential of naïve and activated T 
cells at 0- and 120-hours following in vitro activation. Briefly, 200μl of 25nm TMRM prepared in 
Hank’s Balanced Salt Solution was added to cell suspensions following live/dead and extracellular 
antibody staining. Cells were then incubated in the dark for 30 minutes at 37℃ + 5% CO2, washed 
in FACs buffer, and resuspended in 300μl FACs for flow cytometry analysis.  
Glucose uptake was measured in live T cells at 0- and 120-hours following in vitro 
activation using the glucose analogue D-Glucose, 2-deoxy-2-((7-nitro-2,1,3-benzoxadiazol-4-
yl)amino) (2-NBDG) (ThermoFisher Scientific, Waltham, MA). Following splenocyte 
isolation/cellular activation, cells were harvested from 48-well plates, transferred into 5 ml 
polystyrene tubes, and washed with 1x PBS prior to staining. Cell pellets were then resuspended 
in 200μl of 50μM 2-NBDG prepared in glucose-free RPMI-1640 + 10% FBS at 37℃ + 5% CO2 for 
2 hours in the dark. Samples were subsequently stained for viability and CD4/CD8 surface 
markers, as previously described, suspended in 300μl FACs buffer, and analyzed by flow 
cytometry. 
 Fatty acid uptake was assessed at 0- and 120-hours following in vitro T cell activation 
using the palmitate analogy BODIPY FL C16 (ThermoFisher Scientfic, Waltham, MA). As 
previously described, cells were harvested from 48-well plates into 5ml polystyrene tubes and 
washed with 1x PBS. Cell pellets were then resuspended in 200μl of 0.5μM BODIPY FL C16 in 
RPMI-1640 + 1% fatty acid free BSA and incubated in for two hours at 37C + 5% CO2 in the dark. 
Samples were subsequently washed with 1x PBS and then stained for viability and CD4/CD8 cell 
surface markers, as previously described. 
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All samples were run on a Cytek™ Aurora Spectral Flow Cytometer (Cytek Biosciences, 
Fremont, CA). Data was interpreted using the median fluorescent intensity of each indicated dye 
following gating on live, CD4+/CD8+, single cells using FlowJo software (FlowJo, LLC, Ashland, 
OR). 
LEGENDplex cytokine analysis  
Cell culture supernatants were collected from TEL and TML cells 120 hours following 
primary activation. Additionally, supernatants were collected from antigen re-challenged cells 96 
hours following secondary stimulation ± Ag85b peptide. Concentrations of the cytokines IFN-γ, 
IL-6, IL-2, IL-5, IL-4, IL-21, IL-22, IL-17A, IL-10, and TGF-β1 were quantified using a custom 
designed LEGENDplex™ bead array (Biolegend Inc., San Diego, CA). Briefly, 25μl of supernatant 
was combined with an equal volume of assay buffer and 25μl of LEGENDplex™ beads in a V-
bottom plate. Samples were then incubated at room temperature on a plate shaker for two hours 
protected from light. Following incubation, samples were washed two times with wash buffer and 
25μl of detection antibodies were added to each well. Samples were incubated for one hour at 
room temperature on a plate shaker. Next, 25μl of SA-PE was added directly to each well and 
incubated at room temperature on a plate shaker for 30 minutes. Samples were then washed two 
times in wash buffer and resuspended in a final volume of 150μl of wash buffer for analysis. A 
standard curve was prepared in parallel using the provided standard. All samples were prepared 
in duplicate and were ran using a FacsAria flow cytometer (BD Biosciences). Data was analyzed 
using LEGENDplex™ software (Biolegend Inc., San Diego, CA).  
NAD: NADH and ADP: ATP ratios  
At 120 hours following activation, CD3+ T cells were negatively isolated from TEL activated 
cells that were either left untreated (0μM) or treated with 600μM or 1200μM metformin using a 
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MojoSort magnetic bead cell separation kit (Biolegend Inc., San Diego, CA). Prior to cell 
separation, activated cells were harvested from 48-well plates and counted using a 
hemocytometer and trypan blue dead cell exclusion dye. A total of 1x107 live cells were then 
added to 5 ml polypropylene tubes, washed in 1x MojoSort buffer, and resuspended to a total 
volume of 100μl in 1x MojoSort buffer. A 10μl volume of antibody cocktail was added to each tube 
and samples were incubated for 20 minutes at room temperature on ice. A total of 10ul of MojoSort 
beads was then added to cell samples and incubated for 20-minutes on ice. Beads were then 
removed from cell samples by placing tubes on a magnetic tube rack for 5 minutes. CD3+ cells 
were collected from the remaining supernatant into a fresh tube, washed in 1x PBS, and counted. 
A total of 1x104 live CD3+ cells per sample was transferred into a white walled white bottom plate 
and assessed for NAD and NADH using an NAD: NADH luminescence detection kit (Promega, 
Madison, WI). Additionally, ratios of ADP: ATP were measured by transferring 1x105 live cells into 
a white walled white bottomed plate for ADP and ATP quantification by luminescence detection 
(BioAssay Systems, Hayward, CA). For both assays, a Beckman Coulter LD400 plate reader was 
used to measure luminescence. Values were calculated by generating standard curves of each 
respective substrate.  
Fatty acid utilization 
 Cellular fatty acid utilization capacity was measured using a Biolog Mitochondrial Function 
Assay (Biolog, Hayward, CA). Live CD3+ TEL cells that were treated with either 0μM, 600μM, or 
1200μM metfomin were negatively isolated 120 hours following in vitro activation using a magnetic 
bead cell isolation kit (Biolegend Inc., San Diego, CA). Cells were suspended in Biolog MAS buffer 
+ redox dye + saponin at a final concentration of 5x106 cells/ml. A total of 1.5x105 lysed cells were 
then seeded into the wells of a Biolog 96 well plate pre-coated with acetyl-l-carnitine, octanoyl-l-
carnitine, or palmitoyl-d, l-carnitine. Absorbance (OD590) measurements were recorded every 15 
minutes using a SpectraMax M2e plate reader held at 37℃ for a total of four hours. All analyses 
114 
were conducted in Rstudio 1.3.959.  Interaction second-degree polynomial models were 
constructed with an interaction on the Time variable alone, and with separate intercepts for 
each grouped substate by run, using the lm test function for p-values. The rates of change 
presented are the coefficients for the linear effect; Time was centered on 2 (that is, 2 
was subtracted from each Time value) so that the coefficients reflected the instantaneous rate of 
change at Time = 2. Confidence intervals were constructed using the standard errors for the 
differences as estimated by the models. Degrees of freedom were calculated with Satterthwaite’s 
method for denominator degrees of freedom to account for the unbalanced data 28. P-values for 
the differences in rate of change were adjusted within each substrate with a Bonferroni method 
29. Adjustments were made separately for each group represented in a plot. 
Ag85b recall  
Splenocytes from p25 mice were stimulated under TEL or TML conditions for 120 hours 
(described above). After 120 hours, cells were harvested and stained with 0.5μM CellTrace violet 
(ThermoFisher, Waltham, MA) in 1x PBS for 20 minutes at room temperature in the dark. 
Following staining, cells were counted, re-suspended in fresh TCM at a density of 1x106 live 
cells/ml, and re-plated into 48-well cell culture treated plate. Cells were rested at 37℃ + 5% CO2 
for 24 hours prior to re-stimulation. Re-stimulation was performed with either 1μg/ml Ag85baa240-
254 (GenScript Biotech, Piscataway, NJ) or dimethyl sulfoxide (DMSO) mock treatment. Cells were 
incubated an additional 96 hours at 37℃ + 5% CO2 to achieve secondary stimulation and then 
harvested and stained with Zombie NIR, anti-CD4, and anti-CD8 for flow cytometry analysis. Live, 
CD4+/CD8+, single cells were evaluated for CellTrace violet dye dilution to quantify proliferation. 
The parent population (P0) was set to include all cells in unstimulated samples, and therefore, 
eliminate residual proliferation from primary stimulation. P1 was set to include all cells that 
proliferated beyond P0. Samples were ran using a Cytek™ Aurora Spectral Flow Cytometer 
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(Cytek Biosciences, Fremont, CA) and analysis was performed using FlowJo software (FlowJo 
LLC., Ashland, OR). 
Data analysis   
Tukey’s IQR method was used to identify outliers in data sets. Based on data sets, One-
way ANOVAs or T-tests were used to determine differences between groups. When necessary, 
data was normalized to account for technical variations between experimental data sets. If 
normality or homoscedasticity could not be achieved, data was analyzed using non-parametric 
methods.  Post-hoc comparison methods were Tukey, Sidak's, or Mann-Whitney multiple 
comparisons test. Data was analyzed with Graph Pad Prism v.8 (GraphPad Software, San Diego, 
CA).   
Results 
Varying anti-CD3 signal strength generates effector-like and memory-like T cell subsets, in vitro. 
To evaluate whether metformin has a direct influence on T cell differentiation, and the 
mechanism by which this occurs, we utilized an in vitro model of effector-like and memory-like T 
cell development. Splenocytes from P25 TCR-Tg mice, which specifically recognize the MHC 
class II restricted Mtb antigen, Ag85baa 240-254, were isolated and stimulated with varying strengths 
of activating antibodies, including plate bound anti-CD3 plus anti-CD28 or soluble anti-CD3 plus 
CD28. Flow cytometry tSNE analysis of the memory/effector T cell differentiating surface makers 
CD62L, CCR7, and CD44 demonstrate spatial clustering into two distinct populations unique to 
different activation conditions (Figure 3.1A). Consistent with typical effector (CD62L-CCR7-
CD44+) and memory (CD62L+CCR7+CD44+) T cell phenotypes, plate bound stimulation 
generated cells that expressed CD62L-CCR7-CD44+ (effector-like) while soluble conditions 
generated CD62L+CCR7+CD44+ (memory-like) cells (Figure 3.1A-B). To confirm complete cellular 
activation of both phenotypes, the transient activation marker CD69 was quantified by flow 
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cytometry 48 hours following stimulation. We show that >90% of all CD4+ T cells positively 
expressed CD69, regardless of the activating condition (Figure 1C). Memory- and effector-like 
phenotypes were also confirmed by performing a re-call response with Ag85b peptide and 
measuring cellular proliferation with the dye CellTrace Violet. At 96 hours following re-challenge 
we show that approximately twice as many (51.1%) soluble anti-CD3 stimulated cells underwent 
recall proliferation compared to cells activated under plate bound conditions (25.7%; p=0.0007) 
(Figure 1C & D). Based on these distinguishing characteristics, the remainder of our studies utilize 
plate bound anti-CD3 activated T cells as an effector like phenotype and soluble anti-CD3 







Figure 3.1. Phenotypic and functional features of in vitro differentiated CD4+ T cells. Splenocytes 
were isolated from 8-12-week-old P25 mice and stimulated with either 2ug/ml plate bound α-CD3 plus 
1ug/ml soluble α-CD28 or 5ug/ml soluble α-CD3 plus 1ug/ml soluble α-CD28. (A-C) Surface marker 
expression of CD44, CD62L, CCR7, and CD69 were measured by flow cytometry. (A) A tSNE plot of 
soluble (gray) versus bound (black) stimulated CD4+ T cells based on CD44, CD62L, and CCR7 
expression and their corresponding histograms. (B) Differential comparison of surface marker 
expression normalized to the mean MFI values of naïve CD4+ T cells. (C) % CD69 expressing T cells 
48 hours following stimulation. (D-E) 120 hours following primary activation, soluble or bound anti-CD3 
differentiated T cells were stained with the proliferation dye CellTrace violet and re-challenged with 
Ag85b peptide (1μg/ml). (D) Flow cytometry histograms representing CD4+ T cell proliferation. (E) 
Comparison of percent proliferation between bound and soluble differentiated CD4+ T cells. Data 
represents three independent experiments 
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Metformin reduces CD4+ T cell mitochondrial membrane potential following activation, like a 
memory T cell phenotype. 
In vivo experiments suggest that the level of mitochondrial polarization, or mitochondrial 
membrane potential (ΔΨm), can be used to identify memory versus effector CD8+ T cell 
phenotypes. Within these studies, low ΔΨm corresponds to memory while high ΔΨm corresponds 
to effector T cell phenotypes 30. To determine whether this observation is consistent with in vitro 
generated TEL and TML cells and could be used as a predictive marker of cellular phenotype, we 
measured ΔΨm using the membrane potential sensitive dye tetramethylrhodamine (TMRM) and 
flow cytometry. Relative to naïve T cells, CD4+ TELs possessed a 20-fold and TML a 10-fold 
increase in TMRM median fluorescence intensity (MFI), indicative of mitochondrial polarization 
(Figure 1A). Correspondingly, TEL cells generated a two-fold greater ΔΨm compared to TMLs 
following differentiation, confirming the validity of ΔΨm as a marker of TEL or TML phenotypes 
(Figure 3.2A & B).  
A. B. 
Figure 3.2. TEL and TML mitochondrial membrane potential. T effector “like” (TEL) or T memory (TML) T 
cells were differentiated in vitro for 120hrs and then stained with the viability dye Zombie NIR, anti-CD4, 
and ΔΨm dye TMRM (25μM). (A-B) TMRM median fluorescence intensity (MFI) was measured by flow 
cytometry and used to compare ΔΨm of CD4+ TEL (black) and TML (gray) T cells. (B) Data was normalized 
to ΔΨm of naïve T cells between three independent experiments (N=10-12). Significance was determined 
using an unpaired t-test. 
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Previously, our lab showed that metformin treatment was associated with decreased ΔΨm 
in CD4+ T cells isolated from PBMCs of Mtb infected guinea pigs compared to animals that did 
not receive metformin. We, therefore, hypothesized that metformin reduces T cell ΔΨm in 
response to antigen recognition and ensuing differentiation. To evaluate this, we differentiated 
TELs in the presence of either 0, 600μM, or 1200μM metformin and measured ΔΨm by TMRM 
staining and flow cytometry. 1200μM metformin treatment was associated with a 2-fold reduction 
and 600μM with a 1.5-fold reduction in TMRM MFI compared to untreated cells, showing 
metformin’s direct influence on ΔΨm (Figure 3.3A-B).  
Metformin modulates surface marker expression and cytokine production following T cell 
activation 
Surface marker expression 
Based on the relationship between T cell phenotype and ΔΨm, we hypothesized that the 
decrease in ΔΨm associated with metformin treatment would correspond to increased generation 
of memory like T cells (CD44+CD62L+). There was no increase in the proportion of neither CD4+ 
Figure 3.3. ΔΨm of TELs ± metformin. TELs cultured in the presence of 0μM, 600μM, or 1200μM 
metformin were stained with TMRM 120 hours following. TMRM MFI was evaluated by flow cytometry 
in CD4+ gated T cells. A. TMRM histograms. B TMRM MFI quantification normalized to 0μM. Data 
represents four independent experiments (N=8). Significance determined using a non-parametric one-




nor CD8+ cells that resembled a TML phenotype in the presence of metformin at any concentration 
(Figure 3.4). The relative expression of surface markers associated with T cell activation and 
differentiation— including CD25, CCR7, CD44, and CD62L— were measured by flow cytometry. 
In comparison to metformin un-exposed CD4+ TELs, 600μM and 1200μM metformin reduced 
expression of CD25 by 10% or 22% (p=0.0014) and increased the expression of CD44 by 52% 










Figure 3.4. CD4+ TEL surface marker expression, ± metformin. Surface markers were evaluated on 
CD4+ TELs ± metformin (0μM: black; 600μM gray; 1200μM blue) at 120 hours post-activation using flow 
cytometry analysis. (A) Percent of CD4+ or CD8+ T cells that express the memory phenotype markers, 
CD44 and CD62L. (B) MFIs of the activation markers CD25, CCR7, CD44, CD62L, and CD69 on CD4+ 
TEL cells. (C, D, &E) Representative flow cytometry histograms of (C) CD25, (D) CD44, and (E) CD69. 
(A-B) Data represents four independent experiments (N=6-8). (B) MFIs were normalized to the mean 
of the 0μM group for each experiment. Significance was determined using either an ordinary one-way 
ANOVA using Dunnet’s multiple comparison. 
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To examine whether altered surface marker expression was associated with differences 
in T cell cytokine production, supernatant was collected from TELs cultured in the presence of 0 
or 1200μM metformin 120 hours following activation. Concentrations of the T cell cytokines IFN-
γ, IL-6, IL-2, IL-5, IL-4, IL-21, IL-22, IL-17A, IL-10, and TGF-β1 were quantified using a custom-
designed LEGENDplex™ bead array and flow cytometry analysis. In comparison to untreated 
(0µM) samples, metformin significantly decreased concentrations of IL-6 by 1.67- (p=0.0011), IL-
5 by 3.44  (p=0.0004), IL-4 by 6.87- (p=0.0002), IL-21 by 3.125- (p<0.0001), IL-22 by 7.51 
(p=0.0002),  and IL-10 by 11.5-fold (p=0.0016) (Figure 2E). IL-2 was increased 2.54-fold 
(p<0.0001) in metformin exposed compared to unexposed cells (Figure 2E). 
Transcription factors 
Figure 3.5. TEL cytokine production ± metformin. (A) Supernatants were collected from TEL cell 
suspensions, ± metformin (0μM: black; 1200μM blue), 120 hours post-activation and assessed for 
cytokine production (pg/ml) using a LEGENDplex™ bead array. Data represents four independent 
experiments (N=8). Concentrations were normalized to total cell numbers and values represent the 
concentration of each cytokine relative to the overall mean average. Significance was determined using 




 CD25 serves as both a marker of T cell activation and regulatory T cell (Treg) identification. 
To ensure that the high expression of CD25 on in vitro differentiated T cells did not correspond to 
the generation of Tregs we evaluated the Treg transcription factor FOXP3. FOXP3 expression 
was not detected in neither TML nor TEL differentiated populations. Moreover, exposure to 1200μM 
metformin did not alter FOXP3 expression.  
In response to altered cytokine expression, lineage differentiating transcriptions factors 
Tbet (T helper 1), RORγt (T helper 17), GATA3 (T helper 2) were evaluated in 0μM and 1200μM 
metformin exposed CD4+ TEL cells. Approximately 78% of cells expressed Tbet, 46% expressed 
GATA3, and 28% expressed RORγt (Figure 3.7A, C, & E). While no significant differences in the 
percent of cells expressing each transcription, factor were observed in association with metformin 
treatment, the MFI of GATA3 was reduced by 50% (p=0.0772) and RORγt expression was 
increased by 13% (p=0.0218) in cells exposed to 1200μM metformin compared to those that were 
unexposed (0μM) (Figure 3.7A-F).  
 
A. B. 
Figure 3.6. CD4+ FOXP3 expression ± metformin. FOXP3 expression was measured by flow 
cytometry in (A) TML, (B) TEL, and (C) 1200uM metformin exposed TELs 120 hours following in vitro 









Figure 3.7. CD4+ TEL Tbet, GATA3, and RORγt expression. Expression of the transcription factors 
(A-B) Tbet, (C-D) GATA3, and (E-F) RORγt were measured in CD4+ TEL cells, ± metformin (0μM: black; 
600μM gray; 1200μM blue), by flow cytometry. (A, C, & E) Percent of total CD4+ TELs expressing (A) 
Tbet, (C) GATA3, or (E) RORγt. (B, D, & F) Total MFI of (B) Tbet, (D) GATA3, or (F) RORγt. Data 
represents three independent experiments (N=4-8). MFIs from each experiment were normalized to the 
mean of the 0μM group. (D) Significance was determined using an ordinary one-way ANOVA. 
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Metformin prevents terminal differentiation of TEL cells 
Although metformin did not increase the proportion of memory T cells, the dramatic 
changes in surface marker expression supports the hypothesis that metformin modulates T cell 
differentiation. The level at which this is occurs along the T cell differentiation axis, however, is 
yet to be defined. We hypothesized that rather than increasing the memory T cell pool, as defined 
by CD44 and CD62L expression and strict phenotypic compartmentalization, metformin interferes 
with the generation of highly differentiated pro-inflammatory T cells. To test this, we measured 
the expression of the terminal differentiation marker KLRG1 and the ratio of expression between 
the transcription factors Blimp-1 and BCL6, which act as antagonistic genetic switches underlying 
T cell death or self-renewal and persistence 31. 
KLRG1  
Following in vitro differentiation, approximately 21% of CD4+ TEL and 2% of TML cells 
positively expressed the terminal differentiation marker KLRG1 (<0.0001) (Figure 3.8A). In the 
presence of 600μM or 1200μM metformin, the percentage of CD4+ TEL KLRG1 positive cells 







The ratio of Blimp-1 to BCL6 was measured in TEL and TML cells by flow cytometry 120 
hours following in vitro activation. Relative to CD4+ TEL cells, TMLs displayed an approximate 4-fold 
decrease in their ratio of expression of Blimp-1 to BCL6 (p=.0064) (Figure 3.9A). In CD4+ TELs 
differentiated in the presence of 1200μM metformin, this ratio was decreased by 7.58-fold in 
comparison to cells that were not exposed to metformin (p=0.0002) (Figure 3.9A), which is 
attributable to both a decrease in Blimp-1 expression and an increase in BCL6 (Figure 3.9B & C). 
Together, these data demonstrate that metformin dramatically reduces terminal differentiation 
Figure 3.8. Differential KLRG1 expression on in vitro differentiated CD4+ T cells, ± metformin. 
KLRG-1 expression was measured on in vitro differentiated (A-D) TEL and (C) TML cells by flow 
cytometry. Differential expression of KLRG1 on CD4+ TEL cells that were differentiated in the presence 
of (B) 0μM, (C) 600μM, or (D) 1200μM metformin. Data represents four independent experiments (N= 







characteristics of CD4+ TEL cells, resulting in a phenotype that more closely resembles their less-
differentiated TML counterparts (Figure3.9 D).  
Metformin increases TEL glycolytic flux to maintain ATP production.  
T cells are characterized by unique metabolic phenotypes that directly influence their 
phenotypic and functional properties. Highly differentiated effector T cells display high rates of 
glucose uptake and metabolic flux and increase their reliance on glycolytic metabolism for the 




Figure 3.9. Differential expression of Blimp-1 and BCL6 in CD4+ T cells, ± metformin. (A-C) Blimp-
1 and BCL6 expression were measured by flow cytometry in CD4+ TMLs and TELs, ± metformin (0μM: 
black; 600μM gray; 1200μM blue). (A) The ratio of Blimp-1 to BCL6 expression was calculated by 
normalizing the MFI of each transcription factor to their respective mean MFI and dividing Blimp-1 by 
BCL6. Data represents four individual experiments (N= 7-8). (B) Representative histograms of Blimp-1 
(B) and BCL6 (C) expression in CD4+ TELs. (D) Graphic representation of the axis of expression between 
KLRG-1, BCL6, and Blimp-1 in response to metformin and levels of T cell differentiation. (A) 
Significance was determined using an ordinary one-way ANOVA with Dunnet’s multiple comparison. 
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differentiated quiescent T cells, including memory and naïve subsets, maintain low levels of basal 
metabolism and predominantly rely on oxidative metabolism (OXPHOS) for the continuous 
production of ATP required for long-term cell survival. In our studies we evaluated 1. whether in 
vitro differentiated TEL and TML cells align with these traditional metabolic phenotypes and 2. how 
metformin influences T cell metabolism following early differentiation. 
Extracellular flux analysis 
Metabolic function of negatively isolated CD3+ TEL and TML cells was characterized by 
extracellular flux analysis, which indirectly measures glycolysis by extracellular acidification rate 
(ECAR) and OXPHOS by oxygen consumption rate (OCR). TELs that were exposed to either 
600μM or 1200μM metformin during differentiation displayed ECAR that was increased by 1.3- or 
1.46-fold compared to untreated cells, respectively (p=0.0048; p=0.0014) (Figure 3.10A). 
Alternatively, 600μM metformin decreased OCR by 1.8-fold and 1200μM by 4.3-fold (p=0.0286; 
p=0.0004) (Figure 3.10B). Together, increased OCR and decreased ECAR in response to 
metformin corresponded to a dose-dependent decrease in the overall OCR to ECAR ratio, 
demonstrating increased reliance on glycolysis (p<0.0001) (Figure 3.10C & D). Additionally, TEL 
OCR was found to be 2.6- and ECAR 8.55-fold greater than that measured in TMLs (p<0.0001; 
p<0.0001) (Figure 3.10A-C). OCR to ECAR ratios show that, relative to their overall metabolic 
utilization, TMLs were 3.42 times more reliant on OXPHOS than TELs (Figure 3.10D).  
NAD: NADH ratios 
One of the main ways that metformin targets cellular metabolism is through partial 
inhibition of complex I of the ETC, the primary site for oxidation of NADH into NAD+ 32, 33. To 
confirm that reductions in mitochondrial metabolism were due to inhibition of complex I, we 
measured the ratios of NAD: NADH in metformin treated and untreated TELs. In response to 
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600uM and 1200uM metformin, 3.07- and 4.09-fold decreases were observed in the ratios of NAD 
to NADH compared to untreated cells, respectively (p=0.0001). 
Figure 3.10. Energy metabolism of TML and TEL cells ± metformin. CD3+ T cells were negatively 
purified from in vitro differentiated TML or TELs, ± metformin (0μM: black; 600μM gray; 1200μM blue). 
(A-D) Extracellular flux analysis was used to measure basal levels of (A) glycolysis (ECAR) and (B) 
OXPHOS (OCR). (C) Energy map of OCR and ECAR utilization. (D) OCR/ECAR ratio. (E) CD3+ TEL 
NAD: NADH ratios. Data represent three independent experiments (N=6-13). Significance was 









Mitochondrial stress tests were performed to investigate mitochondrial functions through 
the addition of complex-specific inhibitors (oligomycin, rotenone, antimycin A) and a proton 
uncoupler (FCCP). Oligomycin, an ATP synthase inhibitor, was injected following basal readings 
to measure mitochondrial-derived ATP production. Compared to unexposed cells, TELs 
differentiated in the presence 600μM or 1200μM metformin displayed a 2.67- and 6.6-fold 
reduction in mitochondrial ATP production (p<0.0001) (Figure 3.11A). To determine whether this 
led to an overall change in ADP ATP redox balance, we further quantified cellular ADP and ATP 
concentrations by luciferase detection. Despite reduced mitochondrial-derived ATP, there was no 
difference in ADP/ATP ratios between metformin-exposed and unexposed cells, at any 
concentration (Figure 3.11B).  
Glucose uptake 
Relative glucose uptake between metformin exposed and unexposed TELs was measured 
to determine whether there was a contaminant increase in glucose demand associated with the 
A. B. 
Figure 3.11. TEL ATP production ± metformin.  ATP production of negatively isolated CD3+ TELs, ± 
metformin (0μM: black; 600μM gray; 1200μM blue), measured by (A) extracellular flux analysis or (B) 
ADP/ATP ratios measured using a luminescent detection kit. Data represents three independent 
experiments (A. N=6-13; B. N=6). Significance was determined using ordinary one-way ANOVAs. 
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increased glycolytic flux. At 120 hours following in vitro activation, TELs were incubated with the 
fluorescent glucose analogue 2-NBDG and fluorescent intensity was measured by flow cytometry. 
Uptake of 2-NBDG was increased by ~32% in 1200μM metformin-exposed CD4+ TELs compared 
to unexposed cells (p=0.0045) (Figure 3.12A & B). 1200μM metformin exposed CD8+ TELs 
displayed a 16% increase in 2-NBDG uptake compared to unexposed cells, or the equivalent of 
2-fold less (~16%) 2-NBDG uptake in comparison to CD4+ cells (Figure 3.12A). 
TEL mitochondrial function is decreased by metformin. 
Extracellular flux analysis 
Other parameters of mitochondrial function, including proton leak and spare respiratory 
capacity, were measured by extracellular flux analysis. Proton leak is the amount of oxygen that 
is consumed independent of ATP synthase and is often attributable to an oversaturation of the 
electron transport chain (ETC) and corresponds to the formation of free radicals and mitochondrial 
A. B. 
Figure 3.12. TEL glucose uptake, ± metformin. Glucose uptake was measured in CD4+ and CD8+ 
TELs, ± metformin (0μM: black; 600μM gray; 1200μM blue), by flow cytometric measurement of 2-NBDG 
fluorescence. (A) Differential comparisons among treatment groups were made by normalizing 2-NBDG 
MFIs to the mean of 0μM group. (B) Representative 2-NBDG flow cytometry histograms. Data 
represents three independent experiments (N=6). Significance was determined using a Kruskal-Wallis 
test. 
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damage. In comparison to highly metabolic TELs, TML cells displayed 3.28-fold less proton leak 
120 hours following in vitro differentiation (p<0.0001) (Figure 3.13A). Moreover, TELs displayed a 
dose-dependent decrease in proton leak corresponding to metformin treatment, including a 1.36-
fold reduction following 600μM and a 2.41-fold reduction in response to 1200μM metformin 
(Figure 3.13A). Spare respiratory capacity (SRC), or the difference between a cell’s basal and 
maximum respiration, represents a metabolic reserve that can be harnessed during times of 
stress and is a defining characteristic of memory T cells. While TEL cells had no SRC remaining 
following their in vitro differentiation, TMLs maintained an SRC equivalent to 143 times that of TELs 
(p<0.0001) (Figure 3.13B). A dose-dependent increase in SRC was observed in metformin 
treated TELs corresponding to a 23- and 62-fold increase in the presence of 600uM and 1200uM 
metformin, respectively (p=0.0065) (Figure 3.13B). 
Fatty acid metabolism 
Given the increased SRC observed in metformin exposed TELs, we questioned whether 
metformin also promotes the uptake and storage of fatty acids, which are required for SRC 
Figure 3.13. Mitochondrial function of TML and TEL cells ± metformin. Extracellular flux analysis was 
used to measure (A) proton leak and (B) mitochondrial spare respiratory capacity (SRC) in negatively 
isolated CD3+ in vitro differentiated TML and TEL cells, ± metformin (0μM: black; 600μM gray; 1200μM 




maintenance. To examine the extent to which metformin influenced fatty acid uptake, TELs were 
incubated with the fluorescent palmitate analogue BODIPY FL C16. Both CD4+ and CD8+ TELs 
exposed to 1200μM metformin displayed an approximate 35% increase (CD4: p=0.0034; CD8: 
p=0.0239) in BODIPY FL C16 uptake in comparison to unexposed cells, though only CD4+ cells 
significantly increased uptake in response to 600uM metformin (p=0.0137) (Figure 3.14A & B).  
 
To determine whether metformin increases fatty acid utilization by TEL cells, we used a 
Biolog mitoplate assay to measure cellular capacity to undergo β-oxidation. The principle of this 
assay relies on the generation of reduction intermediates generated in response to substrate 
availability and utilization. These intermediates subsequently enter the ETC and undergo a 
reduction reaction with a tetrazolium redox dye creating a colorimetric reaction that provides 
quantifiable utilization of the available substrate. Capacity to utilize short chain, medium chain, 
Figure 3.14. TEL fatty acid uptake ± metformin. Fatty acid (palmitate) uptake was measured in CD4+ 
and CD8+ TELs, ± metformin (0μM: black; 600μM gray; 1200μM blue), by flow cytometric measurement 
of BODIPY™ FL C16 fluorescence. (A) Differential comparisons among treatment groups were made 
by normalizing BODIPY™ FL C16 MFIs to the mean of 0uM group. (B) Representative BODIPY™ FL 
C16 flow cytometry histograms from CD4+ TELs. Data represents three independent experiments (N=6). 




and long chain fatty acids was achieved by supplementing lysed cells with of acetyl-l-carnitine 
(short chain fatty acids), octanoyl-l-carnitine (medium and long chain fatty acids), and palmitoyl-
d, l-carnitine (medium chain fatty acids). Additionally, L-malic acid was supplemented to each well 
to ensure continuous cycling of the tricarboxylic acid cycle. Using this assay, we show that supply 
of short chain fatty acids (acetyl-l-carnitine) alone do not facilitate ETC function in negatively 
isolated CD3+ TEL cells (Figure 3.15A). Medium and long chain fatty acids (octanoyl-l-carnitine 
and acetyl-l-carnitine), however, result in detectable metabolic activity in untreated TELs (Figure 
3.15A-B). In response to 600μm or 1200μM metformin treatment we show a dramatic decrease 
in both octanoyl-l-carnitine and palmitoyl-d, l-carnitine utilization capacity compared to untreated 
cells. These results correspond to an overall significant decrease in fatty acid utilization capacity 





Figure 3.15. TEL fatty acid utilization capacity, ± metformin. Negatively isolated CD3+ TELs treated 
with either 0μM, 600μM, or 1200μM were subject to a Biolog Mitochondrial Functional assay 120 hours 
following activation. Data represents cellular utilization capacity of L-malic acid (LMA), acetyl-l-carnitine 
+ LMA, octanoyl-l-carnitine + LMA, and palmitoyl-d, l-carnitine + LMA. The rate of substrate utilization 
was measured over 4 hours and differential comparison was achieved by fitting a quadratic curve to the 
data then calculating the slopes at 2 hours. LMA was subtracted from all groups to represent fatty acid 
utilization only. (A) Heatmap representation of differential substrate utilization between metformin 
treated and untreated cells. (B) Combined utilization capacity for all fatty acids. Data represents three 




CD4+ T cell survival and proliferative capacity are enhanced by metformin following antigen re-
challenge 
Because metformin treatment promoted the generation of a TEL phenotype that possessed 
TML characteristics, we hypothesized that these cells would also respond more effectively to 
secondary antigen challenge, as measured by increased proliferation and cell survival. At 96 
hours following secondary challenge, we show that approximately 24% of CD4+ TEL cells that were 
differentiated in the absence of metformin and 38% in the presence of 1200μM metformin 
proliferated beyond their parent population. This corresponds to an overall increase in cell division 
by cells exposed to metformin by 14% (p=<0.0001) (Figure 3.16B-C). To determine whether 
metformin exposure also enhances TML proliferation, we performed the same experiments using 
TML differentiated cells. While approximately 53% of metformin unexposed CD4+ TML proliferated 
following secondary Ag85b peptide challenge, 79% of 1200uM exposed CD4+ TMLs proliferated 
beyond the parent population (Figure 13.16D-E). These data correspond to a 26% increase in 
cell division among metformin compared to unexposed CD4+ TML cells (p=0.0034) (Figure 13.14D-
E).   
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Figure 13.16. CD4+ TEL and TML, ± metformin, proliferation in response to Ag85b re-challenge. (A) 
Splenocytes were harvested from P25 mice and differentiated under TEL or TML conditions, ± metformin 
(0μM: black; 1200μM blue) for 120 hours, stained with CellTrace violet (CTV), rested for 24 hours, then 
re-stimulated with ± Ag85b peptide (1μg/ml). Percent proliferation was assessed by CTV dilution and 
quantified flow cytometry in (B-C) TEL and (D-E) TML cells. (C & D) Representative histograms of CTV 
staining 96 hours following (C) TEL or (E) TML re-challenge. (B & D) Data represents three independent 





To determine whether increased proliferation of metformin exposed cells corresponded to 
heightened production of the proliferation-inducing cytokine IL-2, supernatants of antigen re-
challenged TEL cells were collected and IL-2 was quantified using a LEGENDplex™ bead array. A 
modest, yet significant increase in IL-2 was found in the supernatants of 1200uM metformin 
exposed compared to unexposed TEL cells (p=0.0188) (Figure 13.17A). Furthermore, differences 
in CD4+ TEL viability were assessed and demonstrate that cells which were exposed to metformin 
during primary activation display three times greater survival compared to cells that did not receive 
metformin treatment (Figure 13.17B). Moreover, enhanced survival of metformin exposed CD4+ 








Figure 13.17. TEL Ag85b recall IL-2 production and survival, ± metformin. In vitro differentiated TEL 
cells, ± metformin (0μM: black; 1200μM blue), were re-challenged with Ag85b peptide as previously 
described. (A) Supernatants were collected 96 hours following re-challenge and IL-2 was quantified 
using a LEGENDplex™ bead array. Data represents four independent experiments (N=8). (B) Percent 
live CD4+ T cells were determined by flow cytometry 96 hours following re-challenge. Data represent 
the ratio between the percentage of live CD4+ cells from 1200μM metformin treatment compared to 




The goal of this study was to evaluate the impact of metformin on T cell differentiation and 
characterize the metabolic phenotypes associated with these cells. This study is in response to 
previous work performed by our laboratory, demonstrating metformin’s protective efficacy against 
TB disease in guinea pigs. In these studies, we showed that when initiated prior to or concurrent 
with Mtb infection, metformin dramatically reduced TB disease severity, as measured by 
decreased lung Mtb colony forming units and percent lesion burden. In association with enhanced 
disease protection, PBMC T cell metabolic phenotypes from metformin treated animals were 
similar to those from uninfected controls, while T cells from Mtb infected untreated guinea pigs 
displayed increased metabolic flux through glycolysis and OXPHOS as well as mitochondrial 
hyperpolarization. Given that immune cell metabolism is so tightly linked to cell function, these 
results led us to hypothesize that the protective effects by metformin are due to direct modulation 
of T cell metabolism, which results in the enhanced generation of memory-like T cells that are 
capable of self-renewal, multipotency, and persistence in response to Mtb infection. Our 
hypothesis is supported by several studies that show metformin’s beneficial effects against 
chronic inflammatory illnesses through regulation of pro-inflammatory potential by T cells as well 
as increased memory T cell formation in response to metformin 12, 19. In our current study, we 
define the generation of a non-terminally differentiated CD4+ effector T cell population in response 
to metformin treatment, which possesses a unique metabolic phenotype that supports enhanced 
cell survival and increased capacity to respond to secondary antigen challenge, in vitro. 
 In these studies, we used a model of in vitro T cell differentiation to directly evaluate the 
influence of metformin on T cell phenotypic marker expression, function, and corresponding 
metabolism. By varying the strength of the T cell receptor activating signal by using either soluble 
or plate bound anti-CD3, two distinct T cell populations were generated 34, 35. Surface marker 
expression and functional characterization revealed that cells activated with soluble antibody 
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expressed the typical memory T cell surface markers CD62L+CCR7+CD44+ and had a greater 
capacity to proliferate upon secondary antigen challenge in comparison to bound stimulated cells, 
which displayed a typical effector like phenotype, CD62L-CCR7-CD44+, and inability to robustly 
proliferate and survive. The controlled and predictable differentiation of these subsets were 
utilized to model T cell metabolism within effector-like (TEL) and memory-like (TML) T cell 
populations and thus compare the differential gradients of T cell differentiation in response to 
metformin treatment. 
 A recently defined metabolic feature of memory versus effector T cells is the differential 
polarization of the mitochondria. A recent study by Sukumar et al., demonstrated that 
mitochondrial membrane potential, the gradient of hydrogen ions between the inner mitochondrial 
membrane space and the lumen of the mitochondria, which is responsible for driving ATP 
production through ATP synthase, could effectively be used to distinguish memory T cells (low 
membrane potential) from highly differentiated effector T cell subsets (high membrane potential) 
30. Like the in vivo differentiated T cells described in Sukumar’s study, our in vitro differentiated 
TEL and TML phenotypes also displayed differential membrane potential following the same dogma. 
Following chronic Mtb infection in guinea pigs, mitochondrial hyperpolarization was a defining 
feature that distinguished T cells from untreated versus metformin treated animals, which 
maintained non-hyperpolarized mitochondrial membranes following infection. Considering 
metformin’s partial inhibition of complex I of the electron transport chain, abolished membrane 
potential was both expected and observed in a dose-dependent manner in TEL cells treated with 
metformin in vitro. Whether the decrease in membrane potential by metformin corresponded with 
increased memory generation, however, was unknown.  
 Previous work by Pearce et al. have shown that through modulating fatty acid metabolism, 
metformin enhances the production of antigen specific CD8+ memory T cells in response to 
vaccination 19. We, therefore, hypothesized that metformin would also enhance memory 
generation of CD4+ T cells in vitro, corresponding with reduced mitochondrial membrane potential. 
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The traditional memory surface markers, CD62L and CD44, were evaluated to assess the 
proportion of memory T cells generated following activation. Surprisingly, metformin did not 
change the proportion of memory T cells generated, for neither CD4+ nor CD8+ T cell populations. 
One explanation for the inconsistencies between these studies may be due to the short time 
course in which T cells were differentiated in our in vitro model system. Nonetheless, more in 
depth analysis of surface markers associated with T cell activation and differentiation revealed 
dramatic differences between metformin exposed and unexposed T cells. Specifically, dose 
dependent decreases in CD25 and increases in CD44 and CD69 were observed following 
metformin exposure. These findings indicate that although an increase of memory T cell 
populations did not result from metformin, altered cellular differentiation does, in fact, occur. Due 
to the roles that CD44 and CD69 play in cellular migration and tissue retention, we hypothesize 
that metformin may promote more efficient T cell trafficking to sites of infection, a known barrier 
in an effective T cell response against Mtb infection 36, 37, 38. Furthermore, reduced CD25, or the α 
chain of the IL-2 receptor, which serves as a marker of T cell activation and mediates signals for 
T cell activation in coordination with the β/γ chains, may correspond to a weaker primary activation 
response and reduced differentiation that is associated with enhanced self-renewal, survival, and 
plasticity.  
 Quantification of cytokine secretion also demonstrated the dramatic influence that 
metformin had on TEL function. Polyfunctionality of TEL cells were observed following in vitro 
activation as demonstrated by production of Th1, Th2, and Th17 cytokines and expression of the 
lineage associated transcription factors Tbet, GATA3, and RORγt. In response to metformin 
treatment, TEL cells displayed significantly decreased production of IL-6, IL-5, IL-4, IL-10, IL-21, 
and IL-22 as well as decreased IL-7 and IL-1β, but differences were not statistically different. 
Alternatively, IL-2 production was significantly increased in the supernatants from metformin 
treated TELs. These results are consistent with our previous in vivo findings and the literature 
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suggesting that metformin reduces T cell pro-inflammatory potential 14, 39. Interestingly, however, 
metformin did not reduce the levels of IFN-γ or IL-17A, two of the primary pro-inflammatory 
cytokines involved in the T cell response against Mtb 8, 40, 41, 42. The failure to decrease these 
cytokines was unexpected, but suggest that early following activation, T cells possess the 
capacity to mediate effective bacterial killing.  
In addition to pro-inflammatory cytokine characterization, we show that the regulatory 
cytokine TGF-β and Treg transcription factor FOXP3 were unchanged by metformin treatment, 
suggesting that decreased cytokine production is not due to the generation of regulatory T cells, 
but rather by direct influence on effector T cell function. It is important to note that supernatants 
were collected from heterogenous cell mixtures containing other populations capable of producing 
many of the measured cytokines, and therefore, may contribute to the observed differences. 
However, of the cells present in these samples, CD4+ T cells comprised the vast majority.  
 Altered surface marker expression and cytokine production next led us to hypothesize that 
metformin, rather than promoting memory T cell generation, modulates the extent of T cell 
differentiation along a broad, rather than narrowly defined, spectrum. Although the exact 
mechanism by which T cells differentiate into effector versus memory subsets is highly debated, 
evidence exists to suggest that T cells undergo progressive differentiation from less differentiated 
(i.e. naïve and memory T cells) to more highly differentiated subsets (i.e. effector and terminally 
differentiated T cells) 43, 44, 45. Less differentiated T cells are defined by the capacity to self-renew, 
survive for long periods of time, and maintain plasticity 24, 30, 46. In response to initial activation 
these cells produce low levels of cytokines and undergo limited numbers of cell division, but upon 
secondary antigen challenge display robust proliferative and cytokine responses. In contrast, 
highly differentiated T cells undergo robust proliferative expansion and produce large amounts of 
cytokines following primary antigen challenge, this however, is associated with pre-mature 
terminal differentiation resulting in rapid cell death 23. Recently developed single cell technologies 
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provide evidence that T cells undergo these functional and development changes throughout their 
lifespans, supporting the progressive differentiation model 43. To determine whether metformin 
impacts the extent of T cell differentiation in association with this model, the terminal differentiation 
marker KLRG1 as well as the ratio of expression between the antagonistic transcription factors 
Blimp-1, highly expressed in terminally differentiated T cells, and BCL-6, highly associated with 
memory T cells, were measured by flow cytometry 31. Using our in vitro model, we found that 
approximately 20% of CD4+ TEL cells expressed KLRG1 while TML cells completely lacked KLRG1 
expression. These results were expected and further supported by the increased ratios of Blimp-
1 to BCL6 expression in TEL compared TML cells, demonstrating the validity of these markers for 
characterizing progressive levels of T cell differentiation. In response to metformin treatment we 
found that like TML cells, metformin decreases the expression of both KLRG1 and the ratio of 
expression between Blimp-1 and BCL-6 in a dose-dependent response. These results are novel 
in that we describe a new mechanism by which metformin causes T cell immunomodulation by 
preventing CD4+ T cell terminal differentiation. Moreover, less differentiated T cells have been 
demonstrated to provide superior protection against Mtb infection, providing further evidence that 
it is through T cell targeting that metformin treatment improves TB disease outcome 24, 27, 36, 47. 
 To better understand the metabolic implications of metformin treatment on T cell 
metabolism and how this is linked to the generation of non-terminally differentiated CD4+ TELs, we 
characterized in vitro generated T cell metabolic profiles, with or without metformin. Previous 
studies have extensively characterized the metabolism of memory and effector T cells and it has 
become well appreciated that memory T cells predominantly rely on fatty acids to fuel oxidative 
metabolism for efficient energy production required for cellular maintenance and longevity 21. 
Alternatively, effector T cells predominantly rely on glycolysis, rather than OXPHOS, for rapid ATP 
production and the generation of biosynthetic intermediates that are needed for cell growth and 
proliferation 21. Likewise, we show that in vitro differentiated TML are highly dependent on 
OXPHOS in comparison to TEL, which engage in higher rates of glycolysis. Interestingly, once 
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treated with metformin, TELs engage in a unique metabolic phenotype that neither fully identifies 
with effector or memory T cells. Glycolytic rates are significantly increased while rates of OXPHOS 
are significantly reduced, corresponding to an overall glycolytic phenotype. These results were 
surprising given that decreased T cell differentiation is generally associated with greater reliance 
on OXPHOS. 
 The inverse relationship between glycolysis and OXPHOS made us question whether 
glycolytic increases were enough to maintain cellular energy demands. As expected, 
mitochondrial ATP production was found to be significantly reduced in metformin treated cells 
when measured by extracellular flux analysis. The ratio of ADP to ATP, which indicates cellular 
stress and energy insufficiencies when increased, remained constant, however, and suggest that 
glycolysis maintained cellular energy demands. This is complemented by increased extracellular 
glucose uptake, as measured by 2-NBDG staining, in TELs that were treated with metformin, 
representing the heightened demand for glucose to maintain high rates of glycolysis for ATP 
production. Decreased mitochondrial dependency for energy production by metformin treated 
cells may be linked to the shuttling of biosynthetic intermediates required for macromolecular 
synthesis that equip T cells to more efficiently respond to secondary, or persistent, antigen 
stimulation through increased proliferation and cytokine production, a feature of less differentiated 
T cells. One reasonable explanation is that while glycolysis maintains energy demands, the TCA 
cycle intermediate citrate may be utilized for de novo fatty acid synthesis and storage, a process 
that is known to contribute to cellular proliferation and survival 48, 49. However, further studies must 
be performed to validate this hypothesis. 
To determine whether dramatically decreased mitochondrial activity of non-terminally 
differentiated metformin treated TEL cells influenced other mitochondrial parameters associated 
with T cell function, we evaluated mitochondrial spare respiratory capacity (SRC) and proton leak. 
Spare respiratory capacity is a hallmark feature of memory T cells that is associated with T cell 
longevity and enhanced recall response to antigen re-challenge 50, 51. Consistent with the 
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literature, we show that in comparison to in vitro differentiated TELs, TML cells displayed 
significantly greater SRC. Interestingly, when treated with metformin, TEL were also able to 
maintain an SRC that was significantly greater than untreated cells. This was due to decreased 
use of OXPHOS following activation, thereby maintaining a respiratory reserve and function. In 
addition, these data correspond to decreased mitochondrial proton leak following metformin 
treatment, an indirect indicator of mitochondrial health and function. Proton leak measures 
uncoupled oxygen consumption and is often associated with high oxidative flux and the loss of 
electrons by the electron transport chain, yielding the production of reactive oxygen species 52. 
While in some cases mitochondrial derived reactive oxygen species (ROS) are necessary for cell 
signaling and cytokine production, they can also lead to mitochondrial damage and subsequent 
cell death 52, 53. However, whether ROS production was increased or decreased in TEL cells treated 
with or without metformin was not evaluated, therefore, proton leak can only be used to interpret 
mitochondrial activity. As such, we conclude that by decreasing mitochondrial oxidation, 
metformin preserves mitochondrial function of activated T cells by increasing SRC and decreasing 
proton leak. In comparison to highly differentiated T cells that engage in rapid rates of glycolysis 
and OXPHOS and die shortly following activation, it is logical to predict that this unique metabolic 
state endows long term T cell survival and responsiveness in the face of chronic infection. 
We next assessed fatty acid metabolism of CD4+ TEL cells to see whether decreased 
mitochondrial function was associated with the inability of non-terminally differentiated T cells to 
metabolize other fuel sources. Fatty acid metabolism is an essential component of memory T cell 
metabolism that has been directly linked to their formation and maintenance of SRC 19, 48. In 
response to metformin treatment, we show that fatty acid uptake is significantly increased by CD4+ 
TEL cells, as measured by staining of the palmitate analogue BODIPY FL C16. The capacity of 
metformin treated TEL cells to utilize fatty acids, however, was significantly decreased. We, 
therefore, hypothesize that rather than metabolizing fatty acids, metformin treated cells likely store 
them in lipid droplets for later retrieval and utilization. This is unique from memory T cells, which 
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endogenously create and metabolize fatty acids in a futile metabolic cycle, but is supported by 
the importance of fatty acids in maintaining survival of less differentiated cell phenotypes 48. 
To assert whether the phenotypic and metabolic characteristics of metformin derived non-
terminally differentiated CD4+ TEL cells are equipped with superior re-call functionality, we 
measured proliferative potential, quantified IL-2 production, and evaluated the survival of antigen 
re-challenged cells. Following re-stimulation, we show that 14% more TEL cells proliferated 
beyond the parent population from metformin treated compared to untreated cells, which 
corresponded to significantly greater IL-2 production, and significantly increased CD4+ T cell 
viability. Importantly, CD4+ TEL survival was significantly increased regardless of whether cells 
were re-challenged with peptide or not, demonstrating the survival advantage of non-terminally 
differentiated T cells over highly differentiated subsets. In addition, we show that when treated 
with metformin, TML cells also increase their proliferative capacity by 26% compared to untreated 
cells. Therefore, metformin may also have a desirable influence on memory T cell differentiation 
and function. These results are in support of our hypothesis and demonstrate that non-terminally 
differentiated metformin treated cells have an increased survival capacity and a superior recall 
response compared to untreated effector T cells. 
Finally, while the in vitro model system used in this study was essential for obtaining these 
results, it is important to note the differences in metformin concentration used in this study 
compared to those used in human and animal models. In general, in vivo metformin serum 
concentrations of human patients and those achieved in guinea pigs correspond to approximately 
10μM compared to the 1200uM dose used in these studies 12. Given differential cellular uptake 
and accumulation of metformin in in vitro versus in vivo settings, however, studies have 
demonstrated the requirement of high in vitro concentrations to achieve the same molecular 
effects that are observed in vivo 54, 55, 56. Therefore, while these concentrations appear high, they 
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are in line with concentrations used throughout the literature, which is backed by mechanistic 
evidence.  
Also, it is important to point out that we have taken into consideration the fact that 
metformin may also influence other immune populations responding to Mtb infection, including 
macrophages, the predominant cell type that is responsible for direct Mtb killing. Data from our 
previous studies reveal that the timing of treatment initiation in conjunction with Mtb infection 
dramatically influenced disease outcome, providing temporal insights into what branch of the 
immune response is most likely affected by metformin. While early treatment, beginning either 
prior to or concurrent with infection, yielded decreased disease burden, metformin initiated during 
chronic infection resulted in increased disease severity (unpublished data). These results infer 
that early modifications to the adaptive immune response are critical for beneficial treatment 
outcome and had macrophages been the direct target of metformin, we would have expected 
similar protection regardless of treatment timing due to macrophages continuous presence 
throughout infection. Therefore, these studies, which focus solely on T cells, likely address the 
immune mediated protection by metformin, in vivo. 
In conclusion, we show that while metformin does not enhance memory T cell generation 
in vitro, it prevents the terminal differentiation of effector T cells. Non-terminally differentiated T 
cells display overall decreased cytokine production, while maintaining their ability to produce IFN-
γ and IL-17A. These cells have a unique metabolic phenotype that is defined by high reliance on 
glycolytic metabolism for ATP production and maintenance of mitochondrial function and spare 
respiratory capacity that corresponds with enhanced survival and increased proliferation and IL-
2 production following secondary antigen challenge. With these results we have defined a novel 
cell phenotype with a metabolic advantage for survival and antigen recall. Current work is being  
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performed by our lab to address whether metformin treated non-terminally differentiated T cells 
do, in fact, elicit increased protection against Mtb infection and whether these cells can be used 
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CHAPTER 4 – IN VIVO RESPONSE OF METFORMIN TREATED NON-TERMINALLY 




In chapter 2, we demonstrated that the anti-diabetic drug metformin confers increased 
protection against Mycobacterium tuberculosis (Mtb) infection in guinea pigs. Characterization of 
T cell phenotype and metabolic profiles suggest that the beneficial effects of metformin are, in 
part, due to altered T cell function and phenotype. We show that in response to metformin 
treatment in vitro, anti-CD3/CD28 activated CD4+ T cells undergo reduced levels of differentiation 
compared to untreated cells, which is demonstrated by phenotypic, functional, and metabolic 
changes. Importantly, metformin treatment was associated with increased CD4+ T cell survival 
and enhanced recall response to secondary antigen challenge. The next logical step in our 
studies, and the goal of this chapter, was to then evaluate whether these less differentiated T 
cells directly correspond to increased protection against Mtb infection in vivo. Following adoptive 
transfer of untreated or metformin treated in vitro differentiated Mtb Ag85b specific CD4+ T cells, 
recipient mice were infected with the virulent H37Rv strain of Mtb. Disease burden was assessed 
at 15- and 30-days post infection and lung homing capacity and surface marker expression of 
adoptively transferred T cells were characterized. No significant differences in neither Mtb colony 
forming units nor lesion burden were discovered between groups, suggesting that T cell 
phenotypes associated with metformin treatment are not protective against early Mtb infection 
and acute TB disease. Furthermore, no significant differences in lung homing capacity nor surface 
marker expression were observed between metformin treated and untreated adoptively 
transferred cells. Despite these negative results, important observations have been made 
regarding the study design that may have impacted the overall outcome of this work. We propose 
that the timing of cell transfer in relation to infection likely has important implications on the 
outcome of the response, and that non-terminally differentiated T cells may be more beneficial 
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during chronic rather than acute stages of infection. Future studies will be performed to determine 
the kinetic relationship between cell differentiation and protection against Mtb. 
Introduction 
In Chapter 2, we showed that treatment of Mycobacterium tuberculosis (Mtb) infected 
guinea pigs with metformin resulted in significantly reduced lung disease burden during chronic 
stages of infection. This was associated with metabolic alterations of T cells from peripheral blood 
mononuclear cells (PBMCs), suggesting functional and phenotypic changes of Mtb antigen 
specific T cells. In chapter 3, we evaluated the mechanisms by which metformin influences T cell 
differentiation following primary activation and found that treatment resulted in a non-terminally 
differentiated CD4+ T effector cell phenotype compared to terminally differentiated T cells that 
were generated in the absence of metformin.  
Unlike previous work done by Pearce et al. we did not observe increased formation of 
memory T cell populations in response to metformin treatment, as defined by positive expression 
of the memory T cell identifying markers CD44 and CD62L 1. However, these cells displayed 
marked changes in surface marker expression, including an increase in the migration and 
adhesion markers CD44 and CD69, and a decrease in the T cell activation marker, CD25. 
Moreover, the terminal differentiation marker KLRG-1 was significantly decreased by metformin 
along with the ratio of expression between the transcription factors Blimp-1 and BCL-6, which 
define graded levels of differentiation based on their axis of expression 2, 3.  
In association with altered surface marker expression, these cells revealed a unique 
metabolic phenotype that displayed reliance on glycolytic metabolism whilst decreasing 
mitochondrial function. Interestingly, although these cells did not phenotypically or metabolically 
resemble memory T cells, they did possess memory-like properties. First, metformin treated 
effector T cells possessed a significantly increased spare respiratory capacity compared to 
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untreated cells, a hallmark characteristic of memory T cells that is attributed to their capacity to 
quickly respond to antigen re-stimulation 4, 5. Following secondary stimulation with the Mtb antigen 
Ag85b, we found that cells differentiated in the presence of metformin had an increased capacity 
to proliferate and produced higher levels of IL-2. Importantly, the percent of CD4+ T cells 
recovered from metformin treated compared to untreated samples was significantly higher, 
demonstrating their enhanced survival following primary differentiation. While our in vitro results 
are consistent with findings from our in vivo studies, the direct connection of whether these cells 
are responsible for enhanced host protection elicited by metformin treatment against Mtb are 
unknown and encompass the goal of this work. 
We hypothesized that non-terminally differentiated CD4+ effector T cells generated in vitro 
in the presence of metformin would confer increased protection against Mtb infection in mice. This 
hypothesis is supported by evidence showing that terminally differentiated T cells are unable to 
provide adequate protection against Mtb infection. Specifically, the expression of the terminal 
differentiation marker KLRG-1 has been associated with the inability of T cells to effectively 
migrate from the endothelial lined vasculature into the tissue parenchyma and these cells lack a 
protective immune response against Mtb 6, 7, 8. Furthermore, CD4+ T cells exhibiting decreased 
levels of differentiation have been found to provide superior protection against Mtb infection and 
other chronic inflammatory diseases in comparison to highly differentiated T cells in mice 9, 10. 
These observations are further supported by data from human studies showing that increased 
accumulation of highly differentiated T cells in the blood correspond to increased tissue 
destruction in the lung 11.  
To address this question, we performed an adoptive cell transfer experiment with in vitro 
differentiated CD4+ untreated effector-like (TEL), metformin treated effector-like (TEL + Met), 
untreated memory-like (TML), metformin treated memory-like (TML + Met), and naïve T cells (TN). 
Disease severity as well as adoptively transferred T cell homing and surface marker expression 
156 
were assessed 30 days following Mtb aerosol challenge. No significant increase in protection 
against TB disease was observed between animals that received either metformin treated or 
untreated cells. Review of these results in conjunction with study design raise the question as to 
whether these data reflect the true protective potential of these subsets or if using another 
experimental design will alter protection outcomes. Nonetheless, these results provide valuable 
information that will guide the development of new experiments and potentially reveal the 
importance of T cell differentiation in association with the kinetics of Mtb infection, which is critical 
for the development of an effective vaccines against TB disease.  
Materials and Methods 
Animals and sample collection 
Eight- week old male C57BL/6 mice were purchased from Jackson Laboratories and 
housed at the Colorado State University Laboratory Animal Resources facility in either a biosafety 
level 1 or 3 setting. At 30 days following Mtb aerosol infection, mice were euthanized by CO2 
overdose and blood was collected by heart stick using a 27-gauge EDTA-primed needle and 1ml 
syringe. The right cranial and middle lobes were collected following euthanasia and single cell 
suspensions were prepared by digestion with 0.5mg/ml Liberase TM (ThermoFisher Scientific 
Inc., Waltham, MA) + 0.25mg/ml DNase (2000units/mg) (Sigma-Aldrich, St. Louis, MO) in 
incomplete RPMI-1640. Suspensions were incubated in a rocking incubator held at 37℃ for 30 
minutes and tissues were pushed through a 70μM cell strainer followed by red blood cell lysis 
with 1x RBC lysis buffer until pellets were clear of RBC contamination (Biolegend Inc. San Diego, 
CA). The right caudal lung lobe, ½ of the spleen, and liver were collected for histopathology and 
fixed in 4% paraformaldehyde for 48 hours prior to processing. The left lung lobe and remaining 
spleen were suspended in 500ul 1x PBS and kept on ice until processed for Mtb colony forming 
unit quantification (same day). 
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Experiments were performed in accordance with the National Research Council's Guide 
for the Care and Use of Laboratory Animals and were approved by the Animal Care and Usage 
Committee at Colorado State University.  
Mtb aerosol exposure  
Culture stocks of Mtb strain H37Rv (TMC #102, Trudeau Institute) collected at mid-log 
phase of growth in Proskauer-Beck liquid medium containing 0.05% Tween-80 were diluted in 
water to 2×106 CFU/ml. Approximately 100 bacilli were delivered into the lungs of each 
mouse using a Glas-Col aerosol generation device. One day following aerosol infection, three 
mice were euthanized and the entire lungs were aseptically removed and plated to confirm Mtb 
delivery. 
In vitro T cell differentiation 
Spleens were aseptically removed from eight- to twelve-week, mixed gender, C57BL/6-Tg 
(H2-Kb-Tcra,-Tcrb)P25Ktk/J CD45.1 congenic (P25) mice (generously provided by Kevin Urdahl, 
Seattle Children’s Research Institute, Seattle, WA).  Splenocytes were isolated by pushing tissue 
through a 70μM cell strainer with the plunger of a 3ml syringe and suspended in T cell media 
(TCM) (RPMI-1640 with L-glutamine + 1x non-essential amino acids + 10mM HEPEs + 0.5μM 2-
mercaptoethanol). Live cells were counted using a hemocytometer and the dead cell exclusion 
dye trypan blue and suspended at a concentration of 2x106 cells/ml in TCM. 1, 1-
dimethylbiguanide hydrochloride (metformin) was added to cell suspensions at a final 
concentration of 1200μM for treated samples. 1ml of cell suspensions (2x106 cells) were plated 
into 48-well tissue culture treated plates and activated with either pre plate-bound anti-
CD3 (2μg/ml; clone 17A2) with soluble anti-CD28 (1μg/ml; clone 37.51) (TEL) or soluble anti-
CD3 (5μg/ml; clone 17A2) with soluble anti-CD28 (1μg/ml; clone 37.51) (TML). Cells were 
158 
incubated in a humidified incubator held at 37℃ + 5% CO2 for 120 hours. Cells were harvested 
for cell transfer and stained with the viability dye Zombie NIR (1:3,500) (Biolegend Inc., San Diego, 
CA), the fluorochrome-conjugated surface antibodies CD4-BV510 (clone RM4-5), CD8-BV570 
(clone 53-6.7), CD44-FITC (clone IM7), CD25-Alexa Fluor 700 (clone PC61), CD69-PECy7 
(clone H1.2F3), CD62L-Pacific Blue (clone MEL-14), CCR7-PE/Dazzle 594 (clone 4B12), and 
tetramethylrhodamine (TMRM; 25nM). All antibodies were purchased from Biolegend Inc, San 
Diego, CA. Samples were ran using a Cytek™ Aurora Spectral flow cytometer (Cytek Biosciences, 
Fremont, CA) and data was analyzed using FlowJo software (BD Biosciences, San Jose, CA).  
Adoptive Cell Transfer 
Live CD3+ T cells were purified using a CD3+ negative selection MojoSort kit (Biolegend 
Inc., San Diego, CA) and biotinylated annexin combined with streptavidin labeled MojoSort beads 
(Biolegend Inc., San Diego, CA). T cell purity was assessed by flow cytometry staining with the 
viability dye Zombie NIR, CD3-FITC (clone 17A2), CD4-PECy7 (clone RM4-5), and CD8-APC 
(clone 53-6.7). For cell transfer, cells were resuspended to a final concentration of 5x106 live CD3+ 
cells/ml in sterile 1x PBS. 1x106 cells in a 200ul volume were injected into the tail veins of eight-
week old C57BL/6 male mice using an insulin syringe with a 29-gauge needle.  
Flow Cytometry 
Lung  
Lung single cell suspensions were prepared in 1x PBS and seeded into 96 well round-
bottom plates for staining. Live/Dead staining was performed with Zombie NIR (1:3500) in 1x PBS 
for 15 minutes at room temperature. Antibody suspensions were prepared in 1x PBS + 1% BSA 
+ 5μg/ml anti-mouse CD16/32 (clone 93) blocking antibody and included CD4-Alexa Fluor 532 
(clone RM4-5; ThermoFisher Scientific, Waltham, MA), CD8-BV570 (clone 53.6-7), CD44-FITC 
(clone IM7), CD25-Alexa Fluor 700 (clone PC61), CD62L-BV785 (clone MEL-14), PD-1-BV421 
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(clone 29F.1A12), CD45.1- PerCP/Cy5.5 (clone A20), KLRG-1- BV605 (clone 2F1/KLRG1), 
CD127- PE Dazzle 594 (clone A7R34), and CXCR3- PE/Cy7 (clone CXCR3-173). Samples were 
incubated for 20 minutes at 4℃, washed with 1x PBS, and fixed with 4% paraformaldehyde for 
20 minutes. Cells were resuspended in 300μl total volume with 1x PBS + 1% BSA and ran on a 
Cytek™ Aurora Spectral flow cytometer (Cytek Biosciences, Fremont, CA). Sample collection 
volumes were recorded with SpectraFlo software (Cytek Biosciences, Fremont, CA) and used to 
calculate total cells/ lung. Data was analyzed using FlowJo software (BD Biosciences, San Jose, 
CA). All antibodies were purchased from Biolegend Inc, San Diego, CA, unless otherwise stated. 
Blood/ i.v.  
Prior to euthanasia, 1μg CD4- APC Fire 750 (clone GK1.5; Biolegend Inc, San Diego, CA) 
was suspended in 100ul 1x sterile PBS and administered to mice via tail vein injection. Mice were 
euthanized by CO2 overdose ten minutes following antibody administration and blood was 
collected by heart stick using an EDTA-primed 27-gauge 5/8” needle and a 1ml syringe. Red 
blood cells were lysed with 1X RBC lysis buffer (Biolegend Inc, San Diego, CA) until cell pellets 
were clear of RBC contamination. >95% CD4+ i.v. staining was confirmed by flow cytometry. 
Briefly, cell suspensions were stained, ex vivo, with CD4-AF532 (clone RM4-5) and evaluated by 
flow cytometry for dual staining of both i.v. and ex vivo CD4 antibodies using FlowJo analysis 
software (BD Biosciences, San Jose, CA). 
Mtb CFU Enumeration 
For day 0 counts, the entire lungs of three mice were aseptically collected following CO2 
euthanasia and homogenized in 1x PBS using a Bullet Blender Tissue Homogenizer set at speed 
8 for 4 minutes (Next Advance, Troy, NY). Lung homogenates were suspended at a final volume 
of 6mls in 1x PBS and plated onto three BD Difco™ 7H11 agar (Fisher Scientific, Pittsburgh, PA) 
bug plates per animal. At necropsy, left lung lobes and 1/2 of each spleen were added to 1x PBS 
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in bullet blender tubes, homogenized—as previously described—, and plated by serial dilution 
onto BD Difco™ 7H11 agar quad plates. After 3-6 weeks of incubation at 37℃, colony-forming 
units were counted, and CFU/ml was calculated per tissue. Data are expressed as log10.  
Histology  
Tissues were fixed in 4% paraformaldehyde, paraffin embedded, sectioned at 5μm, and 
stained with hematoxylin and eosin. Total and lesion area of lung and spleen were quantified 
using Stereo Investigator area fraction fractionator software (MBF Bioscience, Williston, VT) and 
the Nikon Eclipse 80i microscope. Lesion burden was calculated as ratio of tissue area to lesion 
area and expressed as a percentage of lesion to tissue. 
Data analysis   
Tukey’s IQR method was used to identify outliers in data sets. Based on data sets, One-
way ANOVA or T-tests were used to determine differences between groups. When necessary, 
data was log transformed to achieve normality and homoscedasticity of residuals or data. If 
normality or homoscedasticity could not be achieved, data was analyzed using non-parametric 
methods.  Post-hoc comparisons methods were Tukey, Sidak's, or Mann-Whitney multiple 
comparisons test, respectively. Data was analyzed with GraphPad Prism v.8 (GraphPad 
Software, San Diego, CA).   
Results 
Study Design 
In chapter 3, we described the impact that metformin has on T cell differentiation, which 
corresponds to the increased capacity of treated cells to respond to secondary antigen challenge, 
in vitro. To determine whether these cells also display an enhanced response against Mtb in vivo, 
and whether this corresponds to increased protection against TB disease, we performed an 
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adoptive transfer study using in vitro differentiated cells. Splenocytes from Mtb Ag85b TCR 
transgenic mice (C57BL/6-Tg(H2-Kb-Tcra,-Tcrb)P25Ktk/J), also known as P25 mice, were 
isolated and activated under effector-like (TEL) or memory-like (TML) generating conditions in the 
presence of either 1200μM metformin or left untreated, 0μM. Pre-differentiated T cells were 
phenotyped and transferred into wild type C57Bl/6 mice, followed by H37Rv Mtb aerosol 
challenge 24 hours following transfer. On days 15 and 30 of infection, necropsies were performed 
to assess cellular tissue localization, surface marker expression, and animal disease severity— 
assessed by quantification of bacterial and lesion burden in the lung and spleen. An intravascular 
(i.v.) staining technique was used to evaluate the localization of adoptively transferred cells to 
either the blood or the lung parenchyma 12 (Figure 4.1A-B). 
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TEL and TML phenotypes (Day -1) 
 To ensure that T cell phenotypes were generated consistent with our findings from chapter 
3, we evaluated surface marker expression by flow cytometry prior to cell transfer. At 120 hours 
following in vitro activation TEL expressed an effector phenotype (CD62L-CCR7-CD44-) while TML 
differentiated cells expressed memory T cell markers (CD62L+CCR7+CD44+). Exposure of TEL 
cells to 1200μM metformin during differentiation decreased CD25 expression and mitochondrial 
membrane potential and increased CD44 and CD69 expression, much like data from chapter 3. 
Moreover, we characterized surface marker expression of metformin treated and untreated CD4+ 
TML cells and show that in comparison to untreated (0μM) cells, metformin dramatically decreased 




CD25 and CD69 expression and increased the expression of CCR7. Due to the low number of 
samples used in this study; significance was not achieved.  
 T cell isolation efficacy 
Prior to adoptive transfer, live CD3+ T cells were isolated using magnetic bead separation. 
Following separation, viability, CD3 purity, and the percent of CD4+ versus CD8+ T cells were 
measured by flow cytometry. Percent viable cells ranged from 84.6% (TEL) to 99% (TN) and T cell 
purity (CD3+) >97% was achieved for all conditions (Figure 4.3A). All samples predominantly 
A. 
B. C. 
Figure 4.2. Differential surface marker expression and membrane potential TEL and TML cells, ± 
metformin. TEL or TML cells were differentiated in the presence of either 1200μM or 0μM metformin for 
cell transfer experiment. At 120 hours following differentiation surface marker expression and ΔΨm 
were measured by flow cytometry. (A) Differential expression of CD62L, CCR7, and CD44 between TEL 
and TML cells. MFIs are normalized to the mean MFI values of naïve CD4+ T cells (N=2). (B-C) 
Differential expression of CD25, CCR7, CD44, CD62L, CD69, and TMRM markers between (B) 0μM 
metformin and 1200μM metformin TEL cells and (C) 0μM metformin and 1200μM metformin TML cells. 
MFIs are normalized to the mean MFI values of (B) 0μM TELs or (C) 0μM TMLs (N=2). 
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contained CD4+ T cell populations, which ranged from 69.6%-80.5% of all viable CD3+ cells, while 
CD8+ cells only comprised 5.12%-10.9% of the population (Figure 4.3 B-C).  
 
 
Figure 4.3. T cell viability and purity. Magnetic bead cell selection for live CD3+ T cells was performed 
120 hours following in vitro differentiation. Isolated cells were stained with the viability dye zombie NIR 
and anti-CD3, anti-CD4, and anti-CD8 antibodies to assess purity. (A) Total percent viable cells. (B-C) 
% of live cells positively expressing CD3, CD3/CD4, or CD3/CD8. (C) Flow cytometry histograms of 




CFUs and Histology 
Bacterial burden was quantified by Mtb colony forming unit enumeration and lesion burden 
by histology to assess whether adoptively transferred T cells influenced the outcome of TB 
disease progression. On day 15 following infection, 3.13 (±0.078 SD; TML+ Met) to 3.59 (±0.191 
SD; TEL+ Met) logs of viable Mtb were recovered from the lungs of Mtb infected mice while no 
CFUs were recoverable from the spleens (Figure 4.4A-B). No significant differences in CFU 
counts were observed between treatment groups. Mean CFU counts from the lung increased 
roughly 1.6-fold by 30 days post-infection, with mean values ranging between 4.94 (±0.599 SD; 
TEL+ Met) and 5.92 (±0.167 SD; TML) logs, yet no significant differences were found between 
treatment groups (Figure 4.4A). In addition, CFUs were recovered from the spleens at day 30 
post-infection with mean log values ranging from 3.78 (±0.832 SD; TN) to 5.22 (±0.444 SD; TML) 
(Figure 4.4B). No significant differences were observed between groups. Lung and spleen lesion 
burden was quantified as the percent area of lesion to normal tissue at 30 days following Mtb 
infection. Percent lung lesion ranged from 2.943 (±2.313 SD; TEL) to 8.271 (±6.243 SD; TML) with 
no significant differences between groups, though mice that received TELs displayed a 1.8-fold 
reduction in lesion burden compared to naïve T cell controls (Figure 4.4C). Total percent spleen 
lesion burden ranged from 0.112 (± 0.120 SD; TN) to 0.494 (± 0.400 SD; TML) and no significant 
differences were observed between groups (Figure 4.4D). 
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Lung homing capacity of adoptively transferred T cells 
 The migration of adoptively transferred T cells from the vasculature into the lungs of Mtb 
infected mice was evaluated using an intravenous staining technique. On days 15 and 30 post-
infection, circulating CD4+ T cells were labeled with CD4-APC Fire 750 by tail vein antibody 
injection prior to euthanasia. Intravascular staining efficacy was verified by subsequent blood 
collection and ex vivo co-staining with CD4-Alexa Flour 532. Positive expression of both i.v. and 
Figure 4.4. Bacterial and lesion burden at days 15 and 30 post Mtb challenge of ACT mice. Lung 
and spleen tissues were collected from ACT Mtb challenged mice on days 15 and 30 post-infection. (A-
B) Mtb CFU quantification recovered from (A) lungs and (B) spleens. Data represents mean log10 values 
(N=2-5). (C-D) The ratio of lesion to normal tissue was quantified by histological analysis in the (C) 




ex vivo CD4 antibodies on >95% of all CD4 T cells was used to discriminate effective from 
ineffective i.v. staining (Figure 4.5A-B). 
Lung parenchyma versus blood homing of adoptively transferred CD4+ T cells was 
evaluated in Mtb infected mice on days 15 and 30 following infection. Following i.v. staining and 
euthanasia, single cell suspensions from the lung were prepared and stained ex vivo with CD4-
Alexa fluor 532 antibody and anti-CD45.1, the congenic marker used to differentiate between host 
derived (CD45.2+) and adoptively transferred (CD45.1+) CD4+ T cells. Flow cytometry analysis 
was used to identify marker expression, whereby CD45.1 gated cells that positively expressed 
both i.v. administered CD4-APC Fire 750 and ex vivo CD4-Alexa fluor 532 were considered blood-
homing, or i.v.+, while those that only expressed ex vivo CD4-Alexa fluor 532, i.v.-, were identified 
as lung parenchymal homing T cells. At both timepoints, small numbers of CD45.1+CD4+ T cells 
were positively identified in both the lungs and blood of Mtb infected mice. On day 15, the mean 
total numbers of lung homing cells ranged from 10.8±2.43 SD (TN) to 929.88±90.56 SD (TEL) and 
the number of blood residing cells ranged from 18.09±12.89 SD (TN) to 106.57±78.27 SD (TN+ 
Figure 4.5. Intravascular staining efficacy. Blood was collected at necropsy to evaluate i.v. staining 
efficacy of CD4+ T cells. (A) Total ex vivo stained CD4+ T cells. (B) Percent CD4+ T cells positively 
labeled by both ex vivo and i.v. staining. 
A. B. 
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Met) (Figure 4.6A). Significantly greater numbers of both TEL and TEL+ Met cells were found to 
home in the lungs of infected mice compared to TN cells at this timepoint (p=0.190 and p=0.388; 
Figure 4.6A). On day 30, 123.92±109.441 SD (TEL+ Met ) to 2,315±768.69 SD (TN) mean total 
cells were recovered from the lungs and 11.58±11.05 SD (TEL+ Met) to 446.67±515.07 SD (TN) 
from the blood of infected mice (Figure 4.6B). Contrary to day 15, significantly greater TN 
compared to TEL cells were recovered from the lungs of mice at this timepoint, which also 
corresponded to a greater recovery of blood homing TN compared to TEL cells (Figure 6B). 
Regardless of cell numbers, the ratio of lung (i.v.-) to blood (i.v.+) cells was calculated to assess 
the overall homing preference of each cell type. With the exception of TN and TEL+ Met, all cells 
displayed preference for lung homing on day 15 and by day 30, all cell types preferentially homed 
to the lung compared to the blood. Moreover, differential homing preference was observed 
between groups, where increased levels of differentiation positively impacted early lung homing 
capacity (Figure 4.6C).  
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In vivo adoptive transfer T cell marker characterization 
To determine whether the Mtb-specific response by adoptively transferred T cells 
corresponds to the adoption of unique phenotypes in vivo, we evaluated the expression of 
markers commonly associated with known functional properties, including CD44, CD62L, CD25, 
KLRG-1, CD127, CXCR3, and PD-1 on CD45.1+CD4+ T cells. By manual gating analysis, we 
evaluated the % positive cells and MFI values of positive expressing markers and found that 
A. B. 
C. 
Figure 4.6. Differential homing of adoptively transferred T cells in response to Mtb infection. The 
total numbers of lung (i.v.-) and blood (i.v.+) homing adoptively transferred T cells was quantified using 
an i.v. staining technique. Data represents the total CD45+CD4+ T cells recovered from the right cranial 
and middle lung lobes at (A) 15 and (B) 30 days following Mtb infection. (C) Proportion of lung 
parenchyma- (i.v.-) to vasculature-residing (i.v.+) CD45.1+CD4+ T cells at 15- and 30-days post-
infection. Data represents mean values (N=2-5). 
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among all markers, CD127 was the only one that displayed differential expression among groups. 
Approximately 30% more TELs and 28% more TELs+ metformin expressed CD127 in comparison 
to less differentiated subsets, TN and TML, 30 days following Mtb infection (p=0.0133, p=0.0169; 
Figure 4.7A). Interestingly, TML+ metformin did not follow the same trend as TN and TML cells, but 
rather showed a 10% increase in the percent of CD127 expressing CD45.1+CD4+ T cells in 
comparison to TNs and TMLs (Figure 4.7A). Furthermore, by evaluating MFIs, we show that CD127 
levels follow the same trends as percent measurements, indicating that not only is there an 
increase in the proportion of cells that express CD127, but also an increase on the level of CD127 
expression on a per cell basis (Figure 4.7B).   
  
FlowSOM analysis was explored as an unbiased gating technique to discover novel T cell 
populations among adoptively transferred T cells. Adequate samples sizes were obtained by 
combining, or concatenating, live CD45.1+CD4+ single cells from individual animals into one 
sample and running a consistent analysis on each respective group. Seven unique populations 
Figure 4.7. Differential CD127 expression on CD4+ adoptively transferred T cells. 30 days 
following Mtb infection T cell surface marker expression of CD127 was analyzed by flow cytometry. (A) 
The percent CD45.1+CD4+ CD127 expressing cells was quantified among groups by manual gating 
analysis. (B) MFIs were quantified using median fluorescence of CD127 on CD127+ cells. (A) 
Significance was determined using an ordinary one-way ANOVA (N=5). 
A. B. 
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were generated by FlowSOM by assigning cells into groups based on similar surface marker 
expression. The percent of cells within each population was calculated and visualization by 
heatmap representation demonstrates differential abundance of FlowSOM populations between 
groups (Figure 4.8A-B).  
Figure 4.8.  Differential abundance of FlowSOM-derived adoptively transferred T cell 
populations. Live CD45.1+CD4+ T cells from the lungs of Mtb infected mice 30 days following Mtb 
infection were analyzed by FlowSOM analysis. Seven populations were generated based on the 
expression of CD44, CD62L, CD25, KLRG-1, CD127, CXCR3, and PD-1. Heatmaps represent the 




 Surface marker expression of FlowSOM identified T cell populations were defined by 
manual gating analysis (Table 4.1). Manual gating was also used to confirm the relative 
abundance of each population in comparison to FlowSOM generated values (Figure 4.9A-H). 
Slight variations in the percentage of cells attributable to each population exist, however, trends 
in population distribution among groups using either FlowSOM or manual gating remain the same. 
Collectively, population 1 comprised the largest percentages of cells from each treatment group, 
with equal to or greater than 50% of those from TEL and TEL+ metformin groups (Figure 4.8B and 
4.9B). In comparison, only 27.6% of TN cells belonged to population 1, while most of these cells 
were more evenly spread amongst populations 1, 2, 3, and 7 (Figure 4.8B and 4.9B). The most 
notable differences among adoptively transferred cell populations were observed in populations 














Population Marker Expression 
0 PD-1- KLRG-1- CD62L+ CD44+ CD127+ CXCR3+ CD25+ 
1 KLRG-1- CD62L- CD44+ CD127+ CXCR3+ CD25+ 
2 PD-1- KLRG-1+ CD62L- CD44+ CXCR3+ CD25+ 
3 PD-1- KLRG-1- CD62L- CD44+ CD127- CXCR3+ CD25+ 
4 PD-1+ KLRG-1+ CD62L- CD44+ CD127- CXCR3- CD25- 
5 KLRG-1- CD62L- CD44+ CD127+ CD25- 
6 KLRG-1- CD62L- CD44+ CD127- CD25- 
7 PD-1+ KLRG-1- CD62L- CD44+ CD127- CXCR3+ CD25+ 
Table 4.1. Surface marker identification of FlowSOM derived T cell populations.  
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Figure 4.9. FlowSOM versus manual gating of adoptively transferred T cell populations. (A-H) 
Phenotypic characterization of ACT populations in the lung 30 days following Mtb infection. Graphs 
represent the % cells in each population identified by either FlowSOM (solid) or manual gating 











The aim of this study was to determine whether metformin treated in vitro differentiated 
CD4+ T cells elicit superior protection against Mtb infection in comparison to untreated cells, in 
vivo. Earlier studies performed by our lab showed that metformin treatment alone, when 
administered prior to or concurrent with Mtb infection, reduced TB disease severity of Mtb infected 
guinea pigs. These results were associated with differences in T cell metabolic phenotypes 
between metformin treated and untreated animals, suggesting metformin’s targeted effect on T 
cell metabolism, and potentially, T cell phenotype and function. In vitro analysis demonstrated 
that when differentiated in the presence of metformin, CD4+ T cells exhibited reduced properties 
of terminal differentiation compared to untreated cells. These non-terminally differentiated T cells 
displayed unique metabolic characteristics, which corresponded to improved survival and 
enhanced proliferation and IL-2 production in response to secondary antigen challenge.  
 To determine whether metformin treated in vitro differentiated CD4+ T cells also display 
enhanced function and protective properties against Mtb challenge in vivo, we adoptively 
transferred pre-differentiated Mtb Ag85b TCR transgenic p25 T cells into recipient mice. Mice 
were then subjected to Mtb aerosol infection and disease burden was assessed at acute 
timepoints following infection. In addition, properties of less differentiated T cells that typically 
correspond to increased protection against Mtb infection, including lung homing and surface 
marker expression were evaluated.  
Prior to adoptive transfer, in vitro differentiated CD4+ T cells were confirmed to resemble 
cell phenotypes produced in chapter 3. Effector like CD4+ T cells (TEL) were classified as CD62L-
CCR7-CD44+ and TMLs, CD62L+CCR7+CD44+. Consistent with previous findings, metformin 
resulted in reduced mitochondrial membrane potential and CD25 expression and increased 
expression of the migratory and tissue retention markers, CD44 and CD69, on TEL cells. Because 
metformin treatment also corresponded to enhanced proliferation by TML cells following antigen 
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re-challenge, both untreated and metformin treated TML cells were also assessed in this study. 
Like TELs, CD25 and mitochondrial membrane potential were both decreased by metformin 
treatment of TML cells. In contrast, however, CD69 was dramatically decreased rather than 
increased and expression of CCR7 and CD62L were increased on TML cells. Though further 
studies are needed to confirm the reproducibility of this phenotype, these data suggest that 
metformin also modulates TML differentiation, which appear to further resemble decreased 
activation and differentiation phenotypes. 
 Also prior to adoptive transfer, T cell purity and the proportion of CD4+ versus CD8+ T cells 
present in each sample was evaluated following negative selection of live CD3+ cells. Viability 
≥85% was confirmed for all samples and CD3 purity was confirmed to be >97%. Among these 
cells, most T lymphocytes were CD4+ (>70%) and only a small fraction (<11%) were CD8+; this 
was not significantly different between groups. These results were somewhat surprising since 
CD8+ T cells, in general, have a great propensity for survival and proliferation compared to their 
CD4+ counterparts 13. One explanation for this is due to the expression of the Ag85b transgenic 
TCR on CD4+ T cells, which like other TCR transgenic T cells, may confer a lower threshold for 
cellular expansion and survival signals. Nonetheless, these data support the fact that in vivo 
effects observed in this study are predominantly mediated by CD4+ T cell populations, which 
remain similar between groups. 
 On 30 days following infection with the H37Rv strain of Mtb, we show that adoptive transfer 
of any one pre-differentiated CD4+ T cell phenotype did not significantly enhance protection 
against TB disease— measured by lung and spleen bacterial and lesion burden. These results 
were surprising considering that previous studies have demonstrated that in vitro differentiated, 
Mtb antigen specific Th1 CD4+ effector T cells decrease Mtb bacterial load in the lungs by 
approximately one log 14, 15. Various explanations may explain these results. First, although our 
studies and others’ both utilize Mtb-antigen specific engineered T cells, our studies were the first 
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to use Ag85b TCR Tg T cells. Due to TCR specificity, differential antigen availability over the 
course of infection and variable responses to each different antigen may explain these differences 
16, 17. In addition, different methodologies used between experiments to derive Th1 polarized CD4 
T cells likely generates T cells with varying degrees of “effectorness”, which can ultimately impact 
cellular survival, recruitment, and response to antigen challenge 18.  
Other reasons that adoptively transferred T cells may have failed to reduce CFUs and 
lesion burden are due to the low numbers of transferred cells, cell survival, the timing of infection 
relative to cell transfer, and the relatively short infection period. Though studies demonstrate that 
1x106 T cells are sufficient to reduce lung CFUs, greater reductions in bacterial burden are 
achieved with higher cell numbers 6, 14. In addition, competition for survival niches and nutrients 
between transferred cells and host-derived populations may decrease their capacity to survive 
and expand over extended periods of time 6, 19. Lymphopenic hosts may be used in future 
experiments to facilitate the homing and survival of adoptively transferred cells. Furthermore, 
acute timepoints were evaluated in these studies to increase the likelihood of recovering 
transferred cells. This short time period, however, may not be adequate to observe disease 
reductions that occur as a consequence of resolution rather than immediate protection. Moreover, 
the timing of cell transfer relative to infection may not have yielded the appropriate response to 
assess the direct impact of T cell differentiation on protective efficacy. Recent literature suggests 
that while highly differentiated effector T cells produce higher levels of cytokines and respond well 
to early infection, they proliferate poorly, quickly die following antigen encounter, or become 
anergic and lose their ability to respond to infection 3, 11, 20, 21. Alternatively, less differentiated 
phenotypes, such as memory T cells, provide long term protection by continuously cycling through 
a pool of cells that migrate to the site of infection, proliferate, and produce cytokines 10, 21, 22, 23, 24. 
Reduced T cell differentiation by metformin leads us to believe that rather than providing an 
immediate and robust response, these cells may generate a pool of cells with high plasticity that 
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provide sustained response during chronic infection. This hypothesis is supported by our guinea 
pig data given that decreased disease burden was not observed until chronic stages of infection. 
Future studies will take this into account by transferring cells following the onset of infection rather 
than prior to it as well as assessing local lymphoid organs for the storage and maintenance of 
such populations.  
 In addition to resistance against TB disease, we measured the differential homing capacity 
of in vitro differentiated T cell subsets, treated with or without metformin, within the vasculature 
versus lung parenchyma on days 15 and 30 following Mtb infection. Previous studies show that 
the level of T cell differentiation is associated with their homing and migratory capacity, which in 
turn, corresponds to their protective efficacy against infection 7, 8. Highly differentiated CD4+ T 
cells, including those that express the terminal differentiation marker KLRG1, are more commonly 
found in the vasculature compared to non-terminally differentiated subsets and correspond to 
decreased protection against disease following adoptive transfer 6. Characterization of metformin 
exposed TEL and TML subsets found lower expression of the terminal differentiation markers 
KLRG1 and Blimp-1 and increased levels of the cell adhesion and migration marker, CD44, and 
the tissue retention molecule, CD69, in comparison to TEL cells. Based on these data we 
hypothesized that metformin treated TEL and TML cells would preferentially home to the lung 
parenchyma while terminally differentiated TEL would reside in the vasculature. Surprisingly, no 
significant differences in the proportion of lung tissue versus vasculature homing T cells were 
found among cellular phenotypes at neither 15 nor 30 days following infection. Although not 
significant, the greatest proportion of lung to vasculature homing cells were recovered from 
animals that received TEL cells, which contrasts with our hypothesis. It is unknown why this 
occurred but may be due to the preferential homing of less differentiated T cells to other organs, 
such as the spleen or lymph nodes. This would make sense given the sustained expression of 
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lymphoid homing receptors CCR7 and CD62L on TML cells but requires further investigation to 
draw definitive conclusions. 
 Surface marker expression of adoptively transferred T cells was evaluated on CD4+ cells 
isolated from the lungs of Mtb infected mice on day 30 post infection. Markers were specifically 
chosen based on their relationship to longevity, migration, and differentiation status and included 
PD-1, KLRG-1, CD62L, CD44, CD127, CXCR3, and CD25 6, 25, 26, 27. Interestingly, although 
surface marker expression was highly variable among phenotypes prior to their transfer, only 
subtle differences in marker expression were observed following infection. Metformin treatment 
did not significantly alter the expression of any one marker between either TEL or TML treated and 
untreated cells. The percent cells that positively expressed the IL-7 receptor CD127, most 
commonly expressed on naïve and memory T cell subsets and which promotes cell survival, was 
significantly increased on TEL subsets, with or without metformin, in comparison to TML and TN 
cells 28, 29. It is important to note that while TEL cells do in fact have increased expression of 
terminal differentiation features, the population as a whole is heterogenous and is likely comprised 
of both short-lived effectors, previously described as KLRG-1hiCD127lo, and long-lived effectors, 
KLRG-1loCD127hi 19. Therefore, selective survival and expansion of the latter may account for 
increased CD127 expression within TEL populations. 
 To expand our phenotypic analysis, we also applied an unbiased clustering algorithm, 
FlowSOM, to all samples 30. Eight unique populations were identified based on their similar 
expression of surface markers, which comprised anywhere from <1% to >60% of all CD4+ T cells. 
Most notably, FlowSOM identified populations are more evenly distributed among less 
differentiated phenotypes while TEL cells preferentially clustered into one population of KLRG-1- 
CD62L- CD44+ CD127+ CD25- expressing cells—accounting for greater than 50% of all CD4+ T 
cells. Without observed differences in the response to infection it is difficult to decipher the 
relevance of differential surface marker expression between populations. The adoption of similar 
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profiles in response to Mtb infection in vivo, however, may help explain the lack of variable 
protection among cell phenotypes.  
Finally, it is difficult to make definitive conclusions from these data without reproducing 
this experiment; however, our data suggest that reduced levels of CD4+ T cell differentiation by 
metformin do not enhance protection against early Mtb infection and acute TB disease. Our 
thorough assessment of the potential pitfalls of this experiment will aide in the design of future 
experiments to more accurately assess the impact that these cells have on chronic Mtb infection. 
Importantly, regardless of the outcome, these results contribute to our current understanding of 
the immune response against Mtb and bring to light the importance of the kinetics of TB disease 
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The goals of these studies were to 1. evaluate whether treatment with the anti-diabetic 
drug metformin improves the clinical outcome of tuberculosis (TB) disease and 2. determine the 
mechanisms by which metformin modulates the host response to disease. The outcomes of these 
studies were intended to increase our understanding of the pathogenesis of TB as well as identify 
novel markers that are predictive of host resistance against disease. The use of a metformin 
allowed us to evaluate the impact of both systemic and cellular metabolism on TB pathogenesis, 
and importantly, was used as a tool to better understand how immunomodulation through 
metabolic targeting could lead to a more desirable immune response against Mycobacterium 
tuberculosis (Mtb). 
Metformin enhances host-mediated protection against Mtb infection. 
The first aim of this study was to evaluate whether metformin treatment of Mtb infected 
guinea pigs could improve clinical TB disease outcome. We conclude that, when initiated prior to 
or concurrent with Mtb infection, metformin does indeed improve TB disease severity during the 
chronic stages of infection. This was demonstrated by a significant reduction in lung CFUs and 
percent lesion burden in metformin treated compared to untreated animals. Of note, improved 
disease outcome in the lungs did not translate to increased survival of metformin treated animals. 
Assessment of disease in secondary organs, including the spleen and liver, showed that despite 
decreased disease in the lungs, CFUs and lesion burden were unchanged between treated and 
untreated animals, which may explain the lack of improved survival by metformin. 
The outcome from this aim suggests that while metformin may not be a practical 
therapeutic for the treatment of TB, it is a useful tool for studying host-derived protective 
responses against disease. In addition, metformin treatment may have added therapeutic value 




In vivo systemic and cellular metabolism are altered in response to Mtb infection and 
metformin treatment. 
In aim 1, we hypothesized that reduced TB disease by metformin treatment would be due 
to the maintenance of hemostatic blood glucose concentrations through normalization of insulin 
sensitivity and glucose tolerance, both of which are altered over the course of Mtb infection. 
Consistent with previous results, we found that guinea pigs in our study developed insulin 
resistance and glucose intolerance in response to Mtb infection. Treatment of Mtb infected 
animals with metformin resulted in restoration of insulin sensitivity compared to uninfected 
animals, yet despite these results, it was unable to restore homeostatic glucose tolerance. From 
these results we concluded that the protective effects of metformin were not due to the 
maintenance of systemic metabolism, but rather due to other host-directed mechanisms. 
Because metformin is also known to directly target cellular metabolism, we hypothesized 
that by modulating immune cell metabolism, metformin could influence immune response to Mtb 
infection that result in a more favorable disease outcome. Immunometabolism, or the link between 
cell metabolism and function, has recently emerged as a novel area of research to help explain 
the implications of disease on immune function as well as identify unique targets for the 
development of immune-mediated therapeutics. Evaluating immune cell metabolism was 
therefore, not only logical approach to identify the underlying mechanisms of metformin’s 
protection against TB, but also a widely unexplored area in TB research that could be used to 
aide in our current understanding of the immune response to disease. 
In our studies, we found that infection with Mtb alone increases PBMC metabolic rates, 
which correspond to heightened levels of inflammation over the course of disease and ultimately, 
disease progression. Treatment with metformin, however, maintained metabolic homeostasis that 
was associated with reduced lesion burden and CFUs during chronic infection. Additionally, 
significantly reduced levels of pro-inflammatory cytokines were measured in the lungs of 
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metformin treated compared to untreated Mtb infected animals, further supporting reduced 
inflammation by metformin. We concluded that metformin elicits host-mediated protection against 
Mtb by directly modulating immune cell metabolism resulting in decreased inflammation. 
From this study it was not clear exactly what cell type was responsible for this increased 
protection, however, evidence of altered T cell metabolism highly suggested that T cells are likely 
responsible for these results. Furthermore, it is not well understood whether normalized 
metabolism of T cell derived PBMCs is a result of disease resolution from some other mechanism 
or if altered T cell function is directly responsible for the observed disease reduction. In support 
of the latter, data from our study show that T cell metabolism, specifically mitochondrial membrane 
potential, was significantly impacted by metformin treatment prior to chronic infection, which 
suggests the direct effect of metformin on cellular metabolism prior to disease resolution. 
Metformin prevents premature CD4+ T cell terminal differentiation. 
The results from the first aim of this dissertation led us to hypothesize that metabolic 
targeting of T cells by metformin promotes the formation of memory T cells. Using an in vitro 
model of T cell differentiation, we showed that while metformin does not result in the increased 
generation of CD4+ memory T cells, it does dramatically modulate the expression of surface 
markers associated with activation, migration, and tissue homing. Furthermore, metformin 
significantly reduced expression of the terminal differentiation marker KLRG1 and transcription 
factor Blimp-1. Like the results observed in our in vivo studies in aim 1, we found that T cells 
differentiated in the presence of metformin in vitro had significantly lower mitochondrial membrane 
potential and produced significantly less pro-inflammatory cytokines in comparison to untreated 
T cells. Furthermore, antigen re-stimulation of CD4+ T cells differentiated in the presence of 
metformin resulted in more robust cell proliferation, increased survival, and increased IL-2 
production. 
The overall conclusion from this portion of the dissertation is that metformin impacts T cell 
function by preventing terminal differentiation of effector T cells. Consequently, the reduced level 
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of differentiation yields antigen-specific T cells that have  enhanced survival and recall to 
secondary antigen challenge. Based off these findings, we hypothesize that metformin also 
prevents T cell terminal differentiation of T cells responding to Mtb infection, resulting in a pool of 
antigen-specific T cells that maintain plasticity, have increased survival and proliferative potential, 
and effectively migrate to the site of infection throughout the course of disease. While aim 3 was 
performed to address whether T cells that were exposed to metformin during differentiation do in 
fact have these properties and provide increased protection against TB disease, limited 
conclusions can be drawn from this study. As previously discussed, nutrient competition by other 
T cells of an immunocompetent host, the timing of transfer relative to infection, and the duration 
of infection may all impact the outcome of adoptive transfer experiments. 
Future studies will need to evaluate whether in vivo treatment with metformin yields similar 
alterations to T cell development and function in response to Mtb infection. Furthermore, future 
studies will address concerns about the study design for aim 3 and thereby, provide more 
conclusive evidence as to whether T cell immune phenotypes elicited by metformin improve T cell 
mediated protection against Mtb infection. 
Metformin modulates T cell metabolism. 
Finally, one of the last goals of this dissertation was to evaluate the mechanisms by which 
metformin modulates T cell metabolism to identify and describe metabolic properties of T cell 
function and phenotype. Major findings from this portion of ours studies show that metformin 
preserves mitochondrial function by increasing glycolysis to maintain energy demands and 
induces properties of memory T cell metabolism including increased mitochondrial spare 
respiratory capacity and decreased mitochondrial membrane potential. 
Increased glycolytic dependency was surprising in that T cells with less-differentiated 
phenotypes generally display upregulated reliance on oxidative rather than glycolytic metabolism. 
However, the reduction in mitochondrial membrane potential and corresponding decrease in the 
ratio of NAD to NADH provides strong evidence that metformin promotes glycolysis by inhibiting 
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the electron transport chain. Increased glucose uptake and fulfillment of cellular energy demands, 
as demonstrated by maintenance of ADP ATP ratios, further demonstrate that glycolysis is 
sufficient to maintain energy production for survival and maintenance of metformin treated cells. 
Therefore, we conclude that by increasing glycolysis through electron transport chain inhibition, 
glycolysis is utilized as the primary pathway for energy production by metformin treated TEL cells. 
In addition, metabolic characterization revealed that although metformin reduces 
mitochondrial metabolism, it increases mitochondrial spare respiratory capacity, a hallmark 
feature of memory T cells. While we did not find that metformin promoted the differentiation of 
memory T cells, these results describe a unique metabolic phenotype that may equip these cells 
to better respond to secondary challenge, which is observed in our recall experiments. 
Additionally, though our studies did not directly assess the cause of increased spare respiratory 
capacity by metformin, increased fatty acid uptake along with decreased capacity to perform fatty 
acid oxidization suggest that metformin may promote fatty acid storage, which has been 
previously demonstrated to be linked to SRC. Moreover, endogenous fatty acid synthesis and 
storage are shown to be upregulated among T cells that possess memory like characteristics, 
including long term survival and increased proliferative capacity. It is, therefore, possible that 
metformin “primes” T cell metabolism to enhance the recall response by diverting biosynthetic 
intermediates away from mitochondrial metabolism and into anabolic pathways in which 
intermediates are synthesized and stored for future cell growth and proliferation.  
Concluding remarks. 
Taken together, we describe a non-terminally differentiated CD4+ effector T cell phenotype 
with unique metabolic properties that are associated with enhanced survival and recall capacity 
in response to metformin treatment. While we were unable to determine whether these cells play 
a direct role in the enhanced response to chronic Mtb infection— that is observed in vivo by 
metformin— we have defined a novel cell subset that will aide in the understanding of 
pathogenesis and immune-mediated protection against multiple diseases that benefit from 
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metformin treatment. In the future, our goal is to translate these findings into immune protection 
against Mtb in order to describe biomarkers of protection and help guide the development of novel 
vaccines and immunotherapeutics. 
 
 
 
 
 
